Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  1 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS  A Randomized, Placebo- controlled, Double- blind, Multicenter Phase 2 Study of 
Atezolizumab With  or Without  Entinostat  in Patients with Advanced  Triple  Negative 
Breast Cancer, with a Phase 1b Lead in Phase [SNDX -275-0602]  
Syndax  Protocol  SNDX -275-0602 
TRIO  Study  Number:  TRIO025  
Clinical Study  S ponsor:  Syndax  Pharmaceuticals,  Inc. 
35 Gatehouse Drive, 
Building D, Floor 3  
Waltham,  MA 02451  
Key Sponsor  Contacts:   
 
Telephone:   
 
T
elephone:   
Contract  Research 
O
rganization Translational  Research in Oncology  (TRIO) 
Suite 1100  
9925 – 109th Street 
Edmonton,  Alberta T5K 2J8 
Canada  
Date,  Version:  11 Sep 2018,  Version  3.0 
Amendment: 
IND Number:  2 64,722  
Confidentiality  Notice  
This document contains confidential information of Syndax  Pharmaceuticals, the contents of 
which  must  not be disclosed to anyone other  than the study  staff and members  of the respective 
Institutional Review Board/Ethics Committee.  NCT #[STUDY_ID_REMOVED]

Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  2 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 The information in this document cannot be used for any purpose other than the evaluation or 
conduct  of the clinical investigation without  the prior written  consent  of Syndax  Pharmaceuticals.  
Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  3 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
 Investigator’s  Agreement  
 
I have read the attached  protocol  entitled  “A Randomized,  Placebo -controlled,  Double -blind, 
Multicenter Phase 2 Study of Atezolizumab With or Without Entinostat in Patients with 
Advanced Triple Negative Breast Cancer, with a Phase 1b Lead in Phase [SNDX- 275- 
0602] ”, dated 11 Sep 2018 and agree to abide by all provisions set forth th erein.  
I agree  to comply  with the International  Conference on Harmonisation Tripartite  Guideline on 
Good Clinical Practice applicable regulations of the Food and Drug Administration and other 
applicable regulations. 
I agree to ensure that Financial  Disclos ure Statements  will be completed by: 
 
• me 
• my sub-investigators  
at the start of the study, at study  completion,  and for up to 1 year after the study  is completed,  if 
there are changes that affect my financial disclosure status. 
I agree  to ensure that the confidential information contained in this document  will not be used  for 
any purpose other than the evaluation or conduct of the clinical investigation without the prior 
written consent of Syndax . 
 
  
 
Signature  
   
 
Name  of Principal  Investigator  Date 
Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  4 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
 Table  of Contents  
1. PROTOCOL  SYNOPSIS  SNDX -275-0602  (TRIO -025) .................................................. 9 
2. STUDY  GLOSSARY  ......................................................................................................... 23 
3. OBJECTIVES  ..................................................................................................................... 28 
3.1 Primary  ................................................................................................................... 28 
3.2 Secondary  .............................................................................................................. 28 
3.3 Exploratory  ............................................................................................................. 29 
4. ENDPOINTS  ....................................................................................................................... 30 
4.1 Efficacy ................................................................................................................... 30 
4.2 Safety  ...................................................................................................................... 30 
4.3 Exploratory  ............................................................................................................. 30 
5. BACKGROUND AND RATIONALE  ................................................................................ 31 
5.1 Study  Treatment  .................................................................................................... 36 
5.1.1  Entinostat  (SNDX -275) ....................................................................... 36 
5.1.2  Atezolizumab  ....................................................................................... 38 
5.2 Study  Rationale  ..................................................................................................... 41 
5.3 Rationale for the Dose  Selection  ......................................................................... 41 
5.3.1  Entinostat  ............................................................................................. 41 
5.3.2  Atezolizumab  ....................................................................................... 42 
5.4 Hypothesis  ............................................................................................................. 43 
6. EXPERIMENTAL  PLAN  .................................................................................................... 45 
6.1 Study  Design  ......................................................................................................... 45 
6.2 Number  of Centers  ................................................................................................ 49 
6.3 Number  of Patients  ................................................................................................ 49 
6.4 Estimated  Study  Duration .................................................................................... 50 
7. PATIENT  ELIGIBILITY  ...................................................................................................... 51 
7.1 Inclusion Criteria  ................................................................................................... 51 
7.2 Exclusion Criteria  .................................................................................................. 53 
8. PATIENT  ENROLLMENT  ................................................................................................. 55 
9. TREATMENT  PROCEDURES  ......................................................................................... 56 
9.1 Study  Drugs  ........................................................................................................... 56 
9.2 Entinostat  ............................................................................................................... 56 
9.2.1  Supply  and Storage ............................................................................ 56 
9.2.2  Dosing  and Administration  ................................................................ . 57 
9.3 Atezolizumab  ......................................................................................................... 58 
9.3.1  Supply  and Storage ............................................................................ 58 

Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  5 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
 9.3.2  Dosing  and Administration  ................................................................. 58 
9.4 Study  Drug(s) Accountability  ............................................................................... 59 
9.5 Entinostat  Compliance  ......................................................................................... 59 
9.6 Dose -limiting  Toxicity ............................................................................................ 59 
9.7 Maximum Tolerated  Dose  .................................................................................... 61 
9.8 Recommended  Phase  2 Dose  ............................................................................ 61 
9.9 Treatment  Duration  ............................................................................................... 62 
9.10 Dose  Interruptions  and Modifications  ................................................................. 62 
9.10.1  Entinostat  ............................................................................................. 63 
9.10.2  Atezolizumab  ....................................................................................... 65 
9.11 Concomitant  Therapy  ........................................................................................... 66 
9.12 Prohibited Medication  ........................................................................................... 67 
9.13 Medications  to be Avoided During  the Study  .................................................... 68 
9.14 Management  for Atezolizumab- Specific  Adverse Events  ............................... 68 
9.14.1  Pulmonary  Events  ............................................................................... 69 
9.14.2  Hepatic  Events  .................................................................................... 71 
9.14.3  Gastrointestinal  Events  ...................................................................... 72 
9.14.4  .Endocrine Events  ............................................................................... 75 
9.14.5  Ocular  Events  ...................................................................................... 77  
9.14.6  Immune-Related  Myocarditis  .............................................................. 78 
9.14.7  Pancreatic  Events  ............................................................................... 81 
9.14.8  Infusion-Related  Events ...................................................................... 84 
9.14.9  Dermatologic  Events  .......................................................................... 86 
9.14.10  Neurological Disorders  ....................................................................... 86 
9.14.11  Immune-Related  Meningoencephalitis  ............................................... 88 
9.14.12  Systemic Immune  Activation  ............................................................. 89 
9.15 Diet/Activity/Other  Considerations  ...................................................................... 90 
9.15.1  Diet ........................................................................................................ 90 
9.15.2  Contraception  ...................................................................................... 90 
9.15.3  Study  Drug  Use in Pregnancy  ........................................................... 90 
9.15.4  Study  Drug  Use in Nursing  Women  ................................................. 91 
10. STUDY  TESTS AND OBSERVATIONS  ......................................................................... 92 
10.1 Screening Assessments  ...................................................................................... 93 
10.1.1  Demographics  ..................................................................................... 93 
10.1.2  Medical  History  .................................................................................... 93 
10.1.3  Pregnancy  Testing .............................................................................. 93 
10.2 Safety  Assessments  ............................................................................................. 93 
10.2.1  Physical Examination  ......................................................................... 93 
10.2.2  Electrocardiograms  ............................................................................. 94 
10.2.3  Vital Signs  ............................................................................................ 94 

Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  6 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
 10.2.4  Weight ................................................................................................... 94 
10.2.5  ECOG  Performance Status  ............................................................... 94 
10.2.6  Clinical Laboratory  Tests  ................................................................... 95 
10.2.7  Adverse Events  ................................................................................... 96 
10.3 Efficacy Assessments  .......................................................................................... 97 
10.3.1  Tumor  Measurements  and Disease  Response Assessment  ........ 97 
10.3.2  Treatment  after Initial Radiologic  Progression  ............................. 102 
10.4 Protein Lysine Acetylation and Immune Correlates  ...................................... 103 
10.4.1  Blood  ...................................................................................................103 
10.4.2  Tumor  Tissue .....................................................................................104 
10.5 Pharmacokinetics  ................................................................................................105 
10.5.1  Entinostat  ...........................................................................................105 
10.5.2  Atezolizumab  .....................................................................................106 
10.6 TRegs  and Ki67  .................................................................................................. 106 
10.7 Atezolizumab Plasma  Biomarker  ......................................................................106 
10.8 Atezolizumab Serum  Biomarker  .......................................................................106 
11. DISCONTINUATION AND  REPLACEMENT  OF PATIENTS  ....................................107 
12. ADVERSE EVENTS,  DATA  REPORTING,  AND RECORDING  .............................. 108 
12.1 Study  Drugs  .........................................................................................................108 
12.1.1  Entinostat  ...........................................................................................108 
12.1.2  Atezolizumab  .....................................................................................108 
12.2 Adverse Event  Definitions  ..................................................................................108 
12.2.1  Adverse Events  ................................................................................ 108 
12.2.2  Suspected Adverse Reaction ......................................................... 109 
12.2.3  Unexpected Adverse Event  ............................................................ 109 
12.2.4  Serious  Adverse Events  .................................................................. 110 
12.3 Reporting Procedures  for All Adverse Events  ............................................... 110 
12.4 Serious  Adverse Event  Reporting Procedures  .............................................. 112 
12.4.1  Pregnancy  and Lactation  Reporting  Procedures  ......................... 113 
12.4.2  Definition of an Overdose and Reporting of Overdose to the  
Sponsor  ..............................................................................................113 
12.4.3  Adverse Events  of Special  Interest  with Atezolizumab ............... 113 
12.4.4  Follow -Up of Adverse Events  ......................................................... 115 
12.4.5  Reporting Safety  Information ..........................................................  116 
12.4.6  Protocol  Deviations  Due to an Emergency  or Adverse Event  ... 116 
12.5 Safety  Monitoring ................................................................................................117 
13. STATISTICAL  CONSIDERATIONS  ............................................................................. 118 
13.1 Sample Size Estimation  ..................................................................................... 118 
13.1.1  Dose  Determination Phase  ............................................................. 118 

Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  7 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
 13.1.2  Expansion Phase  ............................................................................. 118 
13.2 Phase 2 Interim  Efficacy Analyses  ...................................................................119 
13.3 Populations  for Analysis  .....................................................................................120 
13.4 Study  Endpoints  ..................................................................................................120 
13.5 Statistical  Methods  ..............................................................................................121 
13.5.1  General  ...............................................................................................121 
13.5.2  Patient  Disposition  ........................................................................... 122 
13.5.3  Demographics  and Characteristics  ................................................ 122 
13.5.4  Extent  of Exposure  .......................................................................... 122 
13.5.5  Efficacy Analyses  ............................................................................. 122 
13.5.6  Safety  Analyses ................................................................................ 124 
13.5.7  Pharmacokinetic  and Antidrug Antibody  Analyses  ...................... 126 
13.5.8  Correlative  Analyses  ........................................................................ 126 
14. REGULATORY  OBLIGATIONS  .....................................................................................127 
14.1 Informed  Consent  ...............................................................................................127 
14.2 Institutional  Review Board (IRB)/Ethics  Committee  (EC)  ............................. 127 
14.3 Pre-study  Documentation Requirements  ........................................................ 128 
14.4 Patient  Confidentiality  .........................................................................................128 
15. ADMINISTRATIVE  AND LEGAL  OBLIGATIONS  ...................................................... 130 
15.1 Protocol  Amendments  and Study  Termination .............................................. 130 
15.2 Study  Documentation and Archive  .................................................................. 130 
15.3 Study  Monitoring and Data  Collection  ............................................................. 131 
16. REFERENCES  .................................................................................................................132 
17. APPENDICES  ..................................................................................................................132 
17.1 Appendix 1 New York Heart Association (NYHA) Classification of Heart  
Failure ...................................................................................................................137 
17.2 Appendix  2 Concomitant  Medications  to be Avoided ................................... 138 
17.3 Appendix  3: Pre-existing  Autoimmune Diseases  ......................................... 139 
17.4 Appendix  4: Immune- related Response Criteria  Derived  from RECIST  
1.1 (irRECIST)  .....................................................................................................140 
Table 1-1 Schedule of Study  Assessments  ..................................................................... 19 
Table 9-1 Non-hematologic  Toxicity: Dose  Modifications  for Entinostat  ..................... 64 
Table 9-2 Hematologic  Toxicity:  Dose  Modification  for Entinostat  .............................. 65 
Table 9-3 Management  Guidelines  for Pulmonary  Events,  Including Pneumonitis  ... 70 
Table 9-4 Management  Guidelines  for Hepatic  Events  ..................................................
 72 
Table 9-5 Management  Guidelines  for Gastrointestinal  Events  (Diarrhea/Colitis)  ..... 74  
Table 9-6 Management  Guidelines  for Endocrine Events  ............................................. 76 

Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  8 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
 Table 9-7 Management  Guidelines  for Ocular  Events  ................................................... 78 
Table 9-8 Management  Guidelines  for Immune- Related Myocarditis  .......................... 80 
Table 9-9 Management  Guidelines  for Pancreatitis  ........................................................ 82 
Table  9-10 Management  Guidelines  for Infusion -Related Reactions  ............................. 84 
Table 9- 11 Management  Guidelines  for Pancreatitis  ........................................................ 84 
Table 9- 12 Management  Guidelines  for Immune -Mediated Dermatologic  Events  ....... 86 
Table 9- 13 Management  Guidelines  for Neurologic  Disorders  ....................................... 87 
Table 9- 14 Management  Guidelines  for Immune- Related  Meningoencephalitis  .......... 89 
Table 10-1 Eastern Cooperative Oncology Group Performance Status Scale, with  
Equivalent  Karnofsky  Performance  Status  Scores  ....................................... 95 
Table 10-2 Imaging and Treatment  After  1st Radiologic  Evidence of PD ................... 103 
Table 12-1 Standard Severity  Grading Scale  .................................................................. 112 
Table 17-1: Examples  of substrates  that may be affected  by entinostat  ...................... 138 
Table 17-2 P- gp Inhibitors  and Inducers  .......................................................................... 138 

Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  9 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
1.PROTOCOL  SYNOPSIS  SNDX -275-0602  (TRIO -025) 
 
Title:  A Randomized,  Placebo- controlled,  Double- blind,  Multicenter  Phase 2 Study  of Atezolizumab  With 
or Without Entinostat in Patients with Advanced Triple Negative Breast Cancer, with a Phase 1b Lead in 
Phase [SNDX -275-0602 (TRIO025)]  
Study  Phase: Phase  1b/2 
Indication: Advanced  Triple  Negative Breast  Cancer  (aTNBC)  
Primary  Objective:  
Phase 1b: (D ose Determination Cohort) : To determine  the dose- limiting  toxicities  (DLT) and maximum 
tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of entinostat (SNDX -275) given in 
combination with atezolizumab.  
Phase 2 (Expansion Cohort):  To per f orm an evaluation of the efficacy of entinostat at the RP2D in 
combination with atezolizumab in  patients  with aTNBC,  as determined by the duration of progression- free 
survival  (PFS)  based on the local investigator’s  assessment  of progressive disease  Response Eval uation 
Criteria in Solid Tumors version 1.1 (RECIST 1.1).  
Secondary  Ob jectives:  
Efficacy : T o  evaluate the efficacy  of entinostat  in combination  with atezolizumab in patients  with aTNBC, 
as determined by:  
• PFS bas ed on immune response RECIST  (irRECIST)  
• Overall  response rate (ORR)  (i.e., complete response [CR] or partial  response  [PR])  based on 
RECIST 1.1  
• Overall  response rate (ORR)  (i.e., complete response [CR] or partial  response  [PR])  based on 
irRECIST  
• Clinical benefit  rate (CBR)  (i.e. CR or PR or stable disease  [SD] for at least  24 weeks)  based on 
RECIST 1.1 and irRECIST  
• Overall  survival  (OS) 
In patients  with best overall  response of CR or PR: 
• Duration  of response (DOR)  
• Time  to response (TTR)  
Safety: To ev aluate safety  and the tolerability  of entinostat  in combination  with atezolizumab,  as 
measured by clinical adverse events (AEs) and laboratory parameters.  
Exploratory  Ob jectives:  
•  
 
•  
•  
 
•  
•  

Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  10 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
 Exploratory  Objectives cont’d 
•  
 
•  
•  
•  
•  
•  
Hypothesis: 
Phase  1b: The combination  of atezolizumab  and entinostat  at a biologically  active  dose will be sufficiently 
safe and well tolerated to warrant further investigation.  
Phase 2: Entinostat  at the dose determined in Phase  1b combined with  atezolizumab will result  in an 
improved progression free survival compared to atezolizumab alone.  
Study  Design : 
This is a Phase 1b/2 study evaluating the combination of entinostat plus atezolizumab in patients with 
aTNBC. The study has 2 phases:  an open- label Dose Determination Phase (Phase 1b) followed by an 
Expansion Phase (Phase 2). The Expansion Phase will evaluate the efficacy and safety of entinostat when administered at  the RP2D  with atezolizumab in patients  with aTNBC  in a randomized,  double- blind, 
placebo- controlled setting.  Following the enrollment and completion of Cycle 1 of the first 20 patients in 
the Expansion Phase, cumulative study safety data will be reviewed by an independent safety review board.  Up to 88 evaluable patients are anticipated if the study completes all phases of evaluation (up to 
18 patients for Phase 1b,  up to 70 patients for Phase 2). Up to 50 international study centers may 
participate.  
Regardless of phase, patients will be screened for study eligibility within 21 days before enrollment into the study.  Patients  who are determined to be eligible  based on screening assessments  will be enrolled  in 
the study within 3 business days of starting study treatment Cycle 1, Day 1 (C1D1).  
A treatment  cycle  is 3 weeks  (21 days)  in length.  The dose of atezolizumab will be fixed  at 1200 mg IV 
q 3 weeks (day 1 of each cycle) for all patients. Entinostat (during the Phase 1b Dose Determination  
Phase)  and e
 ntinostat  / placebo (during Phase 2,  Expansion Phase)  will be administered orally  on days  1, 
8 and 15 of each 21 day  cycle. The Dose Determination Phase will begin with a starting dose (dose level 
1) of entinostat 5 mg po weekly.  If dose level 1 exceeds the MTD, then entinostat 3 mg po weekly (dose 
level -1) will be investigated. If dose level - 1 exceeds the MTD, then entinostat 2 mg po weekly (dose 
level -2) will be investigated.  Dosing is  planned  to be continuous  unless  interrupted for management  of an 
adverse event.  The entinostat dose determined appropriate for combination with atezolizumab will then 
be taken forward into the Phase 2 Expansion Phase of the study as the RP2D.  
During  treatment,  patients  will attend  study  center  visits and have study  evaluations  performed on C1D1, 
C1D8,  and C1D15;  D1 and D15 of C2; and on  D1 of each cycle  thereafter.  Patients  will have radiological 
disease assessments performed within 28 days prior to the first dose of study drug, and then every 6 weeks  (+/-3 days)  through week  36 (Weeks  6, 12, 18, 24, 30, 36) until unequivocal  progressive disease. 
Patients  remaining  on study  after week  36 will undergo radiological disease assessments  every  9 weeks 
(+/- 3 days) until unequivocal progressive disease occurs. Disease will be assessed by computed 
tomography (CT), magnetic resonance imaging (MRI), and bone scans, as appropriate using the same 
method as used for the screening evaluation, and response will be assessed by the Investigator using 
RECIST 1.1.  

Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  11 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
 Safety will be assessed during the study by documentation of AEs using United States (US) National 
Cancer  Institute  (NCI) Common  Terminology  Criteria  for Adverse Events  (CTCAE),  version 4.03,  clinical 
laboratory tests, physical examinations, vital sign measurements, electrocardiograms (ECGs), and 
Eastern Cooperative Oncology Group (ECOG) performance status. Adverse events of special interest 
(AESI) will be collected and reviewed in a manner consistent with serious adverse event reporting procedures.  
Fresh  tumor  tissue  core biopsy  samples  will be collected during  the study  as follows:  
• During  screening  from all patients  on a mandatory  basis.  Archival  biopsies  when available  will 
also be collected for comparison.  
• On C
2D15 (+3 days)  on an optional  basis  from patients  in the Dose  Determination Phase.  All 
patients will be encouraged to provide an optional biopsy in order to help understand dose- 
immune correlate effects.  
• On C2D15 (+ 3 days)  on a mandatory  basis  until 20 samples  are obtained in  the Phase 2 portion 
and on an optional basis for subsequent patients in this phase 2 expansion.  
• At the end  of study  treatment  prior to the start of another  systemic therapy,  on an optional  basis.  
• At the time of disease progression on an optional  basis.  
• If, based on an interim review of tumor tissue data from the initial patients in the Phase 2 portion 
such data are considered informative, then tumor tissue samples may be collected on a mandatory  basis  from all subsequent  patients  on C2D15 (+3 days).  Alternatively,  if such  data are 
not considered informative, these samples will not be collected from subsequent patients.  
Blood for immune correlates is to be collected pre- dose on C1D1, C2D1, C2D15 and C3D1 and at the 
end of treatment  visit. Blood  for protein lysine  acetylation testing  will be collect ed pre-dose on C1D1  and 
C1D15.  
Blood samples for determination of entinostat levels will be collected pre- dose on C1D1 and 2- 4 hours  
post dose; anytime post dose on C1D8 and D15, and pre- dose on C2D1.  
Blood  samples  for determination of atezolizumab levels  and anti-atezolizumab antibodies  will be collected 
pre-dose on C1D1 and again 30 minutes (+/ - 10 minutes)  following  infusion completion (this sample is for 
PK only), and pre- dose on C2D1, C4D1 and at the end of treatment visit. A PK sample will also be 
collected from any patient who continues to be followed per protocol for PFS, 120 days after the end of treatment visit.  
Patients will remain on study treatment until unequivocal progression of disease (PD), intolerable toxicity, or one of the other study withdrawal criteria is met (Protocol Section 11). Patients with radiographic 
progression only, as defined by RECIST 1.1 should continue on study treatment until unequivocal 
progressive disease is determined as defined by irRECIST, at the discretion of the investigator.  After 
study  treatment  discontinuation, patients will complete an End of Treatment  (EOT) visit  within  7 days  after 
the last study drug dose and a Safety Follow -up (F/U) visit 30 d ays (+/ -3 days) later.  After completion of 
the 30-day (+/- 3 days)  Safety  F/U visit, patients  who have not experienced PD, are to be followed every  6 
weeks for a clinic visit and radiological imaging until unequivocal progressive disease or until study week 36, whichever occurs first. If PD has not been documented at that time, patients will be followed every 9 
weeks  for radiological imaging until  unequivocal  progressive disease,  death or  end of the study  whichever 
occurs first.  Patients who discon tinue  study  treatment  for PD will be contacted every  3 months  for survival 
status and post study therapies until death or closure of the study by the Sponsor.  
Phase 1b / Dose Determination Phase: U
 p to 18 patients are expected to be enrolled in the Dose 
Determination Phase of the study which employs a classical 3+3 design, with the determination of DLT 
and the MTD and/or RP2D based on entinostat in combination with atezolizumab in C1. All dose cohorts will receive entinostat orally at the assigned dose on Days 1, 8 and 15 along with atezolizumab 1200 mg on Day 1 of a 21 day  cycle.  Dose group 1 will include  3-6 patients  who will receive entinostat  at a starting 
dose of 5 mg. If the entinostat  5 mg dose exceeds the MTD, then a 3 mg dose of entinostat (Dose Group  

Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  12 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
 -1) will be evaluated in the same manner.  If the entinostat  3 mg dose exceeds  the MTD,  then a 2 mg dose 
of entinostat  (Dose Group - 2) will be evaluated in the same manner. All patients within a cohort are to 
complete C1, have safety assessments performed through C2D1, and be assessed for DLT before 
enrollment of additional patients may commence. If <33% patients within a cohort have a DLT (i.e., <2 of 
6), then enrollment of the Phase 2 Expansion cohort may commence with approval from the Syndax 
Study Physician.  
If the - 2 dose level exceeds the MTD, then the study will discontinue or additional doses or dosing 
schedules may be investigated via a protocol amendment.  Also, based on evaluation of the safety and 
tolerability  data gathered during the dose determination  phase  together  with data from other  clinical trials, 
it may also be decided that accrual will take place at an alternate dose level or dosing schedule via a protocol amendment.  
Toxicities will be assessed by the Investigator using the United States (US) National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. Although  decisions 
regarding subsequent patient dosing will be made based on review of data from C1, safety data will also be collected from  all patients  continuing treatment  and these data will be reviewed in  an ongoing  manner 
by the Syndax Study Physician in consultation with the Investigators. Any detected cumulative toxicity may require later dose reductions  and/or  other  changes  to the dosing schedule,  as appropriate,  including 
further refinement of the RP2D.  
Phase 2 / Expansion :
  In the Expansion Phase, the efficacy and safety of entinostat (compared to 
placebo) in combination with atezolizumab will be evaluated using the RP2D identified in the Dose 
Determination Phase.  Following the enrollment  and completion through Cycle  1 of the first 20 patients  in 
the Expansion Phase, cumulative study safety data will be reviewed by a Data Safety Monitoring Board. 
Up to 70 patients  with aTNBC  will be randomized to receive  atezolizumab + entinostat  or atezolizumab + 
placebo in a 1:1 ratio.  
Sam p le  Size Considerations  
Dose D etermination  Phase  
Three to 6 patients  will be enrolled in  each dose  cohort  based on  a standard Phase  1 dose  scheme.  Each 
patient  will be counted  in only 1 dose cohort.  Six patients  will need to be treated in a dose  level for it to be 
considered MTD or the RP2D. The total number of patients to be enrolled in the Dose Determination Phase will be determined by the number of necessary dose cohorts required to achieve the MTD or RP2D.  
A starting sample size of at least 3 patients per dose cohort, expanding to 6 patients in the event of a marginal  DLT rate (33%)  was deemed to be a safe and conventional  approach in the dose confirmation of 
a novel oncologic agent. Assuming a true DLT rate of 5% or less, there would be a 3% chance that dose escalation would be halted in a given cohort (i.e., observing 2 or more patients with DLT). If a true DLT 
rate of 50% is assumed, then there would be an 83% chance that dose escalation would be halted in a 
given cohort.  
Note:  Patients  who discontinued  the study  for reasons  other  than study  drug related  toxicities  before 
completing C1 may be replaced.  
Expansion P
 hase:  Phase 2 aTNBC Cohort  
The Expansion Phase will evaluate the efficacy and safety of entinostat  (compared to placebo) when 
administered at the RP2D with atezolizumab in a randomized, double- blind, placebo- controlled setting. 
PFS will be the primary measure of efficacy; secondary measures of efficacy include ORR, CBR, DOR, TTR, and OS.  Up to 70 eligible patients with aTNBC will be randomized to receive atezolizumab with 
entinostat or placebo in a 1:1 allocation.  The sample size was determined based on the following 
considerations:  True median PFS for patients with a TNBC receiving atezolizumab monotherapy is 
expected to be approximately 4 months when measured from randomization.  It is hypothesized the 
combination of entinostat  and atezolizumab will improve true median PFS by 3 months (i.e., median PFS 
of 4 vs. 7 months).  Under  the exponential  distribution,  such  an improvement  in median  PFS represents  a 
reduction of 43% for the true PFS failure hazard rate or equivalently, a hazard ratio of 0.57.  The primary  
Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  13 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
 analysis of PFS will be performed using a stratified log -rank test, stratifying on the randomization 
stratification factor of geographic location.  Total information of 60 PFS failures, defined as documented 
progressive disease by RECIST 1.1 or death due to any cause without documented progressive disease 
beforehand, is estimated to provide 80% power to detect the aforementioned 43% reduction in the PFS 
failure hazard rate with one -sided significance level of 0.1.  Assuming approximately 9 months of accrual 
and an additional  9 months  of follow -up, total accrual  of 70 patients  (approximately  35 per treatment  arm) 
is projected to result in 60 PFS failures within approximately 18 months of the date the first patient is randomized.  Patients who discontinue study treatment for reasons not due to documented progressive 
disease by RECIST 1.1 will continue to undergo disease assessments until the earlier of documented 
progressive disease,  death,  or withdrawal  of consent/lost  to follow -up. It is anticipated that the number  of 
patients  who will drop out of the study  without  PFS failure  beforehand will be low (expected to not exceed 
2–3%). Depending on the actual number of such dropouts, the number of patients accrued may be 
increased by 6– 10 additional patients to accommodate for a higher -than- expected number of dropouts.  
The sample size and number of PFS failures was adjusted using the O’Brien- Fleming group sequential 
procedure to account for one planned interim analysis of PFS after 45 events (75% information).  It is 
projected 75% and 100% of total information will be reported at approximately 12 and 18 months, 
respectively.  The interim  analysis  will be performed to support  the Sponsor’s  product  development  plans 
and ongoing resourcing activities.  Although there are no plans to terminate the study early because of 
early evidence of superior efficacy for the combination treatment, the significance levels at the interim analysis and final analysis will be adjusted to maintain control of the overall type I error rate for multiple 
testing of PFS ( O’Brie n 1979).  
Endpoints  
Primary  Efficacy Endpoint: 
• PFS,  as determined by the local investigator  using RECIST  1.1 
Secondary  Endpoints: (analyzed  in the same populations  as the primary  endpoint): 
• PFS by immune response RECIST  (irRECIST)  
• ORR (CR or PR) by RECIST  1.1 and irRECIST  
• CBR  (CR, PR, or SD for at least  24 weeks)  
• OS 
In patients  who experience  best overall  response of CR or PR: 
• DOR 
• TTR 
Safety:  
• Determination of DLT,  MTD  and RP2D  
• AEs 
• Clinical laboratory  parameters,  vital signs,  physical  exam  
Exploratory:  
•  
 
•  
•  
 
•  

Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  14 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
 •  
•  
•  
•  
•  
•  
•  
S
ummary  of Patient  Eligibility Criteria:  
Inclusion  Criteria  
Patients  meeting  all of the following criteria  are considered eligible  to participate  in the study:  
1. Females  aged 18 years  or older  on the day written informed consent  is given.  
2. Has histologically or cytologically confirmed triple negative breast adenocarcinomathat is either 
metastatic (stage IV of the TNM classification) or locally recurrent and not amenable to local curative 
treatment. TNBC diagnosis should be based on local ER/ PgR/HER -2 laboratory results and will be 
defined  as HER2  negativity  (IHC 0-1 and/or  ISH non-amplification)  and ER and PgR negativity  (<1%). 
Disease must also be amenable to a core biopsy (image- guided if applicable) at screening and for 
certain cohorts as described in the protocol, at least once during study treatment.  
3. Evidence of measurable  (according to RECIST  version  1.1) locally  recurrent  or metastatic  disease 
based on imaging studies (e.g., CT, MRI) within 28 days before the first dose of study drug.  
4. Has received at least  1, but no more than 2,  prior lines of systemic  therapy  for locally  recurrent  and/or 
metastatic disease.  
5. If pat ient  has a history  of treated asymptomatic  CNS  metastases  they are eligible,  provided they meet 
all of the following c riteria:  
• Patient  has measurable disease outside CNS;  
• Patient  does  not have  metastases  to midbrain,  pons,  medulla  or spinal  cord;  
• Patient  is not on corticosteroids  as therapy  for CNS  disease (anticonvulsants  at a 
stable dose are allowed);  
• Patient  has not had whole -brain radiation  within  6 weeks  prior to study  enrollment;  
• Patient  has stable  CNS  disease as demonstrated by at least  4 weeks  of stability 
between the last intervention scan and the study screening scan  
6. ECOG  performance status  of 0 or 1. 
7. Has the following  laboratory  parameters  within  21 days  before enrollment  
 
System  Laboratory  Value  
Hematological   
Absolute  neutrophil  count  (ANC)  ≥1.5×109/L 
Platelets  ≥100×109/L 
Hemoglobin  ≥9 g/dL or ≥5.6 mmol/L  

Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  15 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
System  Laboratory  Value  
Renal  
Creatinine OR 
Measured or calculated1 creatinine clearance (CrCl)  
(glomerular  filtration  rate [GFR]  can also be used  in 
place of creatinine or CrCl)   
≤1.5×  the upper  limit of normal  (ULN)  OR 
≥60 mL/min  for patient  with creatinine levels  >1.5× 
institutional ULN  
Hepatic   
 ≤1.5×ULN  OR 
Total  bilirubin  Direct  bilirubin  ≤ULN  for patients  with total bilirubin  
 levels  >1.5×ULN  
Aspartate  aminotransferase  (AST)  and alanine  ≤2.5×ULN  OR 
aminotransferase  (ALT)  ≤5×ULN  for patients  with liver metastases  
Coagulation   
International  Normalized  Ratio  (INR)  or Prothrombin  ≤1.5×ULN  unless  patient  is receiving  anticoagulant  
Time  (PT) therapy  as long as PT or PTT is within  therapeutic  range  
 of intended  use of anticoagulants  
Activated  Partial  Thromboplastin  Time  (aPTT)  ≤1.5×ULN  unless  patient  is receiving  anticoagulant  
 therapy  as long as PT or PTT is within  therapeutic  range  
 of intended  use of anticoagulants  
1 Creatinine  clearance should be calculated  per institutional  standard.  
 
8. If a female  of childbearing  potential,  has a negative serum blood  pregnancy  test during  screening and 
a negative urine pregnancy test within 3 days prior to receiving the first dose of study drug. If the 
screening serum test is done within 3 days prior to receiving the first dose of study drug, a urine test 
is not required. Note: Women of childbearing potential (WoCP) are any women between menarche and menopause who have not been permanently or surgically sterilized and are capable of procreation.  Menopause is  defined  as at least  12 consecutive  months  since  date of  last menstruation, 
FSH and estradiol in postmenopausal ranges. Permanent sterilization includes hysterectomy and/or bilateral oophorectomy and/or bilateral salpingectomy but excludes bilateral tubal occlusion. WoCP 
include women who have experienced menopause onset < 12 months prior to enrollment.  
9. If a female of childbearing potential,  willing  to use 2 methods  of birth control  or willing  to abstain from 
heterosexual activity for the course of the study through 120 days after the last dose of study drug.  
10. E
xperienced resolution of toxic effect(s) of the most recent prior anti -cancer therapy to Grade < 1 
(except  alopecia or neuropathy).  If patient  underwent  major  surgery  or radiation therapy  of >30 Gy, 
they must have recovered from the toxicity and/or complic ations from the intervention.  
11. Ab le  to understand  and give written  informed  consent  and comply  with study  procedures.  
EXCLUSION  CRITERIA:  
Patients  meeting  any of the following  criteria  are not eligible  for study  participation:  
1. Diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of 
immunosuppressive therapy  within  7 days  prior to the first dose of study  drug.  The use of physiologic 
doses of corticosteroids may be approved after consultation with the Medical Monitor.  
2. Active  autoimmune disease  including active  diverticulitis,  symptomatic  peptic  ulcer  disease,  colitis,  or 
inflammatory bowel disease that has required systemic treatment in past 2 years (i.e., with disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment.  
3. Previously treated with a PD -1/PD -L1-blocking antibody (e.g., atezolizumab, nivolumab, 
pembrolizumab)  or a histone  deacetylase inhibitor  (e.g..,  vorinostat,  belinostat,  romidepsin, 
panobinostat)  
Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  16 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
 4. History or current evidence of any condition, therapy, or laboratory abnormality that might confound 
the results  of the study,  interfere with the patient’s  participation for the full duration of  the study,  or is 
not in the best interest of the patient to participate, in the opinion of the treating Investigator, 
including, but not limited to:  
• History  of immune  deficiencies  or autoimmune  disease  (refer  to Appendix  3 for complete list) 
• Myocardial infarction or arterial thromboembolic events within 6 months prior to screening or 
severe or unstable angina,  New York Heart  Association  (NYHA)  Class  III or IV disease,  or a QTc 
interval > 470 msec.  
• Uncontrolled hypertension or diabetes  mellitus.  
• Another known malignancy that is progressing or requires active treatment (excluding adequately 
treated basal  cell carcinoma or cervical  intraepithelial  neoplasia [CIN]/cervical  carcinoma in situ or 
melanoma in situ ). Prior history of other cancer is allowed, as long as there is no active disease 
within the prior 5 years.  
• Active  infection  requiring systemic therapy.  
• Known active  central  nervous  system  (CNS)  metastases  and/or  carcinomatous  meningitis.  (see 
inclusion criterion 5)  
5. Any contraindication to oral agents  or significant  nausea and vomiting,  malabsorption,  or significant 
small bowel resection that, in the opinion of the investigator, would preclude adequate absorption.  
6. Received a live vaccine  within 30 days  of the first dose  of treatment.  (Inactivated  forms  of influenza 
vaccinations can be given during influenza season only (approximately October to March in the 
Northern hemisphere and April to September in the Southern Hemisphere)).  
7. Prior anti -cancer monoclonal antibody (mAb) within 4 weeks prior to enrollment or who has not 
recovered (i.e., ≤Grade 1 at enrollment)  from AEs due to mAb agents  administered  more  than 4 
weeks earlier.  
8. Prior  chemotherapy  within  3 weeks,  targeted  small  molecule  therapy  or radiation  therapy  within  
2 weeks  prior to enrollment,  or who has not recovered (i.e., ≤Grade  1 at enrollment)  from AEs due to 
a previously administered agent.  
Note:  P atients  with ≤Grade  2 neuropathy  or ≤Grade 2 alopecia are an exception to this criterion  and 
may qualify for the study.  
9. Received transfusion of blood products (including platelets or red blood cells) or administration of colony stimulating factors (including granulocyte- colony stimulating factor [G -CSF], granulocyte 
macrophage-c olony  stimulating  factor  [GM- CSF],  or recombinant  erythropoietin)  within  4 weeks  prior 
to the first dose of treatment.  
10. Currently participating and receiving study therapy or  has participated in a study  of an investigational 
agent  and received study  therapy  or used  an investigational  device  within  4 weeks  of the first  dose of 
study drug.  
11. Currently  receiving  treatment  with any other  agent  listed  on the prohibited medication list (protocol 
section 9.12 
12. If female,  is pregnant,  breastfeeding,  or expecting to conceive starting  with the screening visit through 
120 days after the last dose of study drug.  
13. Known history  of human immunodeficiency  virus  (HIV)  (HIV 1/2 antibodies).  
14. Known active hepatitis B (e.g., hepatitis B surface antigen- reactive) or hepatitis C (e.g., hepatitis C 
virus ribonucleic acid [qualitative]). Patients with past hepatitis B virus (HBV) infection or resolved HBV infection  (defined  as the presence of hepatitis  B core antibody  [HBc  Ab] and absence of  HBsAg) 
are eligible. HBV DNA test must be performed in these patients prior to randomization. Patients  

Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  17 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
 positive  for hepatitis  C virus  (HCV)  antibody  are eligible  only if polymerase  chain  reaction  is negative 
for HCV RNA.  
15. Allergy  to benzamide or inactive  components  of entinostat.  
16. History  of allergies  to any active  or inactive ingredients  of atezolizumab.  
17. Known psychiatric  or substance abuse disorders  that would interfere  with cooperation with the 
requirements of the study.  
Investigational  Product:  
Entinostat  
Entinostat  is a synthetic small molecule bearing the chemical name 3- pyridylmethyl -N-{4-[(2- 
aminophenyl)carbonyl]  benzyl}carbamate  and the molecular  formula C 21H20N4O3, with a molecular  weight 
of 376.41. Entinostat is classified as an antineoplastic agent, specifically functioning as an inhibitor of 
histone deacetylases by promoting hyperacetylation of nucleosomal histones, allowing transcriptional 
activation of a distinct set of genes that leads to the inhibition of cell proliferation, induction of terminal 
differentiation, and/or apoptosis. Entinostat is given orally and is supplied in two strengths of film- coated 
tablets containing 1.0 mg (pink to light red) or 5.0 mg (yellow).  
Entinostat  should  be stored  at a controlled  room temperature of 15°C –25°C  (59°F –77°F).  
Atezolizumab  
Atezolizumab is a humanized monoclonal antibody designed to target PD -L1 expressed on tumor cells 
and tumor -infiltrating  immune cells,  and prevent  binding  to PD-1 and B7.1  on the surface of T cells.  This 
may enable the activation of effector T cells as well as recruitment of other T cells to attack the tumor, thus empowering the body's own immune system to fight multiple types of cancer.  
Atezolizumab drug product is provided in a single- use, 20- mL USP/PH. Eur. Type 1 glass vial as a 
colorless -to-slightly -yellow, sterile, preservative- free clear liquid solution intended for IV administration. 
The vial is designed to deliver 20 mL (1200 mg) of atezolizumab solution but may contain more than the stated volume to enable delivery of the entire 20- mL volume.  The atezolizumab drug product is 
formulated as 60 mg/mL of atezolizumab  in 20 mM histidine  acetate,  120 mM sucrose,  0.04%  polysorbate 
20, pH 5.8.  
Atezolizumab must be refrigerated at 2°C−8°C (36°F−46°F) upon receipt until use. Atezolizumab vials 
should not be used beyond the expiration date provided by the manufacturer.  No preservative is used in 
the atezolizumab drug product; therefore, each vial is intended for single use only. Vial contents should not be frozen or shaken and should be protected from direct sunlight.  
Statistical  Considerations: 
The safety and efficacy analyses will be presented by study phase.  For the Dose Determination Phase, 
tabulations  will be provided  by dose cohort  and overall.  Some  analyses  may be performed based  on the 
Dose Determination and Expansion Phases combined.  
Safety A
nalyses  
Safety  analyses  will be conducted using  the Safety  Analysis  Set. 
An interim  safety  analysis  is planned following  the completion of Cycle  1 for the first 20 patients  enrolled 
in the Phase 2 expansion phase and will utilize a Data Safety Monitoring Board.  
Treatment -emergent AEs reported during the study will be tabulated and listed by Medical Dictionary for 
Regulatory Activities (MedDRA) System Organ Class  (SOC ) and Preferred Term (PT). Tables  will display 
number and percentage of patients experiencing the event for the following categories: all AEs; AEs considered related to study  treatment;  AEs by severity;  DLTs;  AEs occasioning treatment  delay,  reduction 
or discontinuation; and serious adverse events (SAEs). For the Dose Determination Phase, the observed DLT rate in each dose cohort will be calculated by the crude proportion of patients who experienced DLT with a 2- sided 95% exact binomial confidence interval (CI).  
Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  18 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
 Hematology and serum chemistries will be summarized using conventional summary statistics (mean, 
standard deviation, median, and range) for the following: enrollment value, minimum and maximum post enrollment values, average post enrollment value, and last post enrollment value. Standard shift tables 
will also be prepared presenting worst  post enrollment  toxicity  grade versus  enrollment.  Vital signs  will be 
summarized in a descriptive manner by calculating the mean, standard deviation, median, and range in 
the same manner described for laboratory values.  
Efficacy Analyses  
Efficacy  analyses  will be conducted using  the Full Analysis Set and, where appropriate,  the Per -protocol 
Set. An interim efficacy analysis is planned after 45 PFS events have occurred in the Phase 2 study 
portion.  
PFS is the primary endpoint for the Expansion Phase of this study.  PFS is defined in the conventional 
manner as the number of months from the randomization date to the earlier of documented progressive 
disease or death due to any cause.  Progressive disease will be assessed by the local investigator using 
RECIST 1.1.  The disease progression date and censoring date will be based on published conventions ( 
FDA 2007).  Sensitivity analyses will be performed to identify asymmetry between treatment arms for the 
frequency of missed disease assessments, deviations of the actual disease assessment times from the planned assessment times.  Alternative censoring conventions will also be used to assess among other 
concerns,  dropouts  with undocumented progressive disease.  PFS will be summarized descriptively  using 
the Kaplan- Meier method.  The primary inferential  comparison between treatment arms  will be performed 
using the log- rank test stratified by the randomization stratification factor of geographic location.  
Estimation of the hazard ratio for treatment arm will be determined using a stratified Cox proportiona l 
hazards  model,  without  any other  covariate.  The corresponding results  from the log-rank test and Cox 
model without stratification will be reported as supplemental analyses.  
The statistical  methods  to be used  for the analysis  and reporting of  the secondar y efficacy  endpoints  are 
described in Section 13.5 of the protocol.  
Procedures:  The Schedule of Study  Assessments is included in Table  1-1 below.  

Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  19 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
Table  1-1 Schedule of Study Assessments 
 
 
 
 
Procedure   
 
Screening  
(D -21 to - 1) Combination  Therapy  EOT 
(≤7 days  of 
last study  
drug dose)  Safety 
F/U 
(≤30 days  of 
EOT)   
Post - 
Study 
F/U 1 C1 C2 ≥C3 
D1 D8 D15 D1 D15 Day 1 
Visit  Window  - - ±1D ±1D ±3D ±3D ±3D ±3D ±3D ±5D 
Provision  of written  informed consent  X          
Demographics  X          
Medical  and disease  history  X X         
Complete physical  examination X2 X2      X X  
Symptom -directed  physical  examination   X X X X X X    
ECG X      X3 X   
Vital signs,  weight  (height  at screening only) X X   X  X X X  
ECOG  performance status4 X X   X  X X X  
Radiological  Imaging,  Disease  assessment  X5      X6 X7  X7 
Pregnancy  testing  X X8         
Hematology,  coagulation studies9, and 
clinical chemistries10, 11 X X11 X X X X X X   
Blood sample  for immune  correlates12  X12   X12 X12 X12 X12   
Blood sample for TRegs/KI67   X13   X13  X13 X13   
Blood sample  for atezolizumab  serum 
biomarker   X13   X13 X13 X13 X13   
Blood sample  for atezolizumab  plasma 
biomarker   X13   X13 X13 X13 X13   
Blood sample  for protein lysine acetylation13  X14  X14       
Tissue  sample  biopsy  for immune  correlates 
(also archival tissue when available)  X15     X15  X15   
Entinostat self -administration   Self-administered weekly  starting on C1D1;  C1D1  ≤3 business  days  of    
Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  20 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
 
 
Procedure   
 
Screening  
(D -21 to - 1) Combination  Therapy  EOT 
(≤7 days  of 
last study  
drug dose)  Safety 
F/U 
(≤30 days  of 
EOT)   
Post - 
Study 
F/U 1 C1 C2 ≥C3 
D1 D8 D15 D1 D15 Day 1 
Visit  Window  - - ±1D ±1D ±3D ±3D ±3D ±3D ±3D ±5D 
  enrollment     
Atezolizumab  administration16  X   X  X    
Blood  sample  for entinostat 
pharmacokinetics17  X17 X17 X17 X17      
Blood sample for atezolizumab 
pharmacokinetics  and anti-therapeutic 
antibodies18  X18   X18   X18  X18 
Pre-treatment/concomitant  medications  X X X X X X X X X  
Adverse events  X X X X X X X X X  
Study  drug compliance  assessment   X X X X X X X   
1 After the Safety F/U visit, patients who have not experienced PD are followed (including radiological assessments) q6 weeks (+/ - 3 d) through study week 36 and 
then every  9 weeks  (+/- 3 d) thereafter  until unequivocal  PD. Thereafter,  they are contacted  q3 months  until death or study  closure  for information on PD, alternate 
treatments and survi val status.  
2 If the screening complete PE was performed within  7 days  before C1D1,  then a symptom -directed examination  may be performed at enrollment.  
3 An ECG  is to be performed  pre-dose  on C3D1  (- 3d) and then every  3 cycles (- 3d) thereafter.  An ECG  may be repeated anytime,  as clinically  indicated.  
4 Also performed if fluid retention occurs  
5 Performed  only if last scan  was performed  >28 days  before C1D1  
6Patients  will have  radiological  disease assessments  performed every  6 weeks  (+/-3 d) through week  36 (Week  6, 12, 18, etc.) and then q9 weeks (+/- 3 d) hereafter  
during treatment and for patients who have not yet progressed when discontinuing study treatment, until progression based on this schedule.  
-  Partial  or complete response  should be confirmed by a repeat  tumor  imaging assessment  at the earliest 4  weeks  after the first indication of response,  or at 
the next scheduled scan if on a 6 week schedule, whichever is clinically indicated.  
- If radiologic  imaging demonstrates  initial evidence for PD, tumor  assessment  should  be repeated at the earliest  of 4 weeks,  or preferably  on the study 
schedule of 6 weeks, in order to confirm PD.  
7 Performed  only if radiological  progression was not previously  observed on study.  
8 For female patients  of child-bearing potential, a  required serum  pregnancy  test is to be performed during  screening  and a urine  test within  3 days  before  the first 
study drug dose. Pregnancy testing is to be repeated during the study any time pregnancy is suspected.  
9 Analytes tested: RBC, WBC with absolute counts of individual  cell types, platelet count, HGB and HCT. Screening only also includes: prothrombin time (PT) or 
international normalized ratio (INR) and activated partial thromboplastin time (aPTT). 10Analytes tested: ALT, AST, albumin, alkaline phosphatase, total bilirubin, 
BUN,  calcium,  creatinine,  sodium,  potassium,  chloride,  bicarbonate,  glucose,  LDH,  phosphorus,  total protein and uric acid.  Magnesium  and TSH at enrollment  only, 
unless clinically indicated.  
Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  21 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
11 Performed  only if screening  laboratory  tests performed >7 days  prior to enrollment;  screening laboratory  results  remain as the baseline  entry  criteria  and 
abnormalities thereafter are to be noted as, and treated as, adverse events  
12 Samples  collected pre-dose;  not collected  after C3 D1 except  at EOT.  
13 Samples  collected  pre-dose.  
14 Sample  taken  before any study  drug administration.  
15 Fresh  tumor  core biopsy  during screening  from all patients  on a mandatory  basis;  required  on C2D15 (+/-3 days)  funtil  20 samples  are obtained in the Phase 2, but 
optional for everyone else; optional for all patients at disease progression and end of study treatment. Archival tissue is collected at screening when available.  
16The initial  dose  of atezolizumab will be delivered  over 60 (± 15) minutes.  If tolerated without  infusion -associated  adverse  events,  the second  infusion  may be 
delivered over 30 (± 10) minutes  and if well tolerated,  all subsequent  infusions  as well. Vital signs  should be determined up to 60 minutes  before  each  infusion 
as well as during  and after infusion  if clinically  indicated.  
17C1D1  samples  are taken pre-dose  and 2-4 h post entinostat  dosing;  C1D8  and C1D15 taken any time after entinostat  dosing;  C2D1  taken  pre-dose  
18C1D1  samples  for PK and ADA are taken pre-dose  and again 30 minutes  (+/- 10 minutes)  post infusion  (PK only);  C2D1,  C4D1  are taken  pre-dose;  EOT and, if 
patient is still being following per protocol on day 120 after coming off study treatment, a PK sample should be collected  
Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  22 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
Page Intentionally Left Blank 
Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  23 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
2.STUDY  GLOSSARY   
Abbreviation/Acronym  Definition  
ADaM  Analysis  Dataset  Model  
AE Adverse event  
AESI  Adverse Event  of Special  Interest  
ALK Anaplastic  lymphoma  kinase  
ALP Alkaline  phosphatase  
ALT Alanine aminotransferase  
ANC Absolute neutrophil  count  
aPTT  Activated  partial  thromboplastin time 
ATA Anti-tumor  activity 
aTNBC  Advanced Triple  Negative Breast  Cancer  
AZA 5-Azacitadine  
BSA Body  surface  area 
BUN Blood  urea nitrogen 
C Cycle  
CBC Complete blood count  
CBR Clinical benefit  rate 
CI Confidence interval  
CIN Cervical  intraepithelial  neoplasia  
CNS Central  nervous  system  
CR Complete response  
CrCl Creatinine clearance  
CSC Cancer  stem cell 
CT Computed tomography  
CTCAE  Common  Terminology  Criteria  for Adverse  Events  
Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  24 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
Abbreviation/Acronym  Definition  
CTLA -4 Cytotoxic  T-lymphocyte -associated antigen-4 
D Day 
DKA Diabetic  ketoacidosis  
DLT Dose- limiting  toxicity  
DNA Deoxyribonucleic  acid 
DOR Duration of response  
EC Ethics  Committee  
ECG  Electrocardiogram  
ECOG  Eastern Cooperative Oncology  Group  
eCRF  Electronic  case  report  form 
EDC Electronic  data capture  
EGFR  Epidermal  growth factor  receptor  
EOT End of Treatment  
F/U Follow -up 
FAS Full Analysis  Set 
FDG 18F-deoxyglucose  
FoxP3  Forkhead box P3 
G-CSF Granulocyte- colony  stimulating factor  
GFR Glomerular  filtration rate 
GI Gastrointestinal  
GM-CSF Granulocyte  macrophage- colony  stimulating  factor  
G-MDSCs  Granulocytic  myeloid- derived suppressor  cells 
HDAC  Histone  deacetylase  
HIV Human immunodeficiency  virus 
IB Investigator’s  Brochure  
Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  25 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
Abbreviation/Acronym  Definition  
ICH International  Council  for Harmonisation  
ID Identification  
IFN-γ Interferon- gamma  
Ig Immunoglobulin  
ILD Interstitial  lung disease  
IND Investigational  New Drug  Application  
INR International  normalized  ratio 
irAE Immune- related adverse events  
IRB Institutional  Review  Board  
irRECIST  Immune- related Response Evaluation  Criteria  in Solid  Tumors  
ITIM Immunoreceptor  tyrosine- based inhibition  motif  
ITSM  Immunoreceptor  tyrosine -based switch  motif  
IV Intravenous(ly)  
LDH Lactic  dehydrogenase  
mAb Monoclonal  antibody  
MDSC  Myeloid -derived suppressor  cells 
MedDRA  Medical  Dictionary  for Regulatory  Activities  
MRI Magnetic  resonance imaging 
MTD  Maximum tolerated dose  
NCI National  Cancer  Institute 
NE Inevaluable  
NSCLC  Non- small  cell lung cancer  
NYHA  New York Heart  Association  
ORR Overall  response rate 
OS Overall  survival  
Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  26 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
Abbreviation/Acronym  Definition  
PD Progressive disease  
PD-1 Programmed death  receptor -1 
PD-L1 Programmed death ligand-1 
PD-L2 Programmed death ligand-2 
PET Positron  emission tomography  
PFS Progression- free survival 
PK Pharmacokinetic  
PO By mouth 
PP Per-protocol  
PR Partial  response  
PT Prothrombin  time 
Q2W  Every  other  week  (i.e., every  2 weeks)  
Q3W  Every  3 weeks  
RBC Red blood  cell (count)  
RECIST  Response  Evaluation  Criteria  in Solid  Tumors  
RP2D  Recommend  Phase 2 Dose  
SAE Serious  adverse event  
SC Subcutaneous(ly)  
SD Stable  Disease  
SDTM  Study  Data  Tabulation Model  
SIA Systemic  immune activation  
SOC  System  organ class  
SOD  Sum of Diameters  
T1DM  Type 1 diabetes  mellitus  
T3 Triiodothyronine  
Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  27 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
Abbreviation/Acronym  Definition  
T4 Thyroxine  
TEAE Treatment -emergent  adverse event  
TGF Transforming growth factor  
TIL Tumor -infiltrating  lymphocyte  
TKI Tyrosine kinase inhibitor  
TMTB  Total  Measured Tumor  Burden  
TSH Thyroid stimulating  hormone  
TTR Time  to response  
ULN Upper  limit of normal  
US United States  
V-type Variable -type 
WBC  White  blood  cell (count)  
WoCBP  Women  of Child  Bearing  Potential  
Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  28 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
3.OBJECTIVES 
 
3.1 Primary  
The primary  study  objectives  are: 
 
Phase 1b (Dose Determination Cohort) : To determine the dose -limiting  toxicities  (DLT)  and 
maximum  tolerated  dose  (MTD) or recommended Phase 2 dose  (RP2D) of entinostat  (SNDX - 
275) given in combination with atezolizumab. 
Phase 2 (Expansion Cohort) : To pe r form an evaluation of the efficacy of entinostat at the 
RP2D in combination with atezolizumab in patients  with aTNBC,  as determined by the duration 
of progression -free survival (PFS) based on the local investigator’s assessment of progressive 
disease using Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) . 
3.2 Secondary  
Secondary  study  objectives  are: 
 
Efficacy : In Phase  2, to evaluate the efficacy  of entinostat  in combination with atezolizumab in 
patients with aTNBC, as determined by:  
• PFS based on immune -related RECIST  (irRECIST)  
• Overall  response rate (ORR)  (i.e., complete response [CR] or partial  response [PR]) 
based on RECIST 1.1 and irRECIST 
• Clinical benefit  rate (CBR)  (i.e. CR or PR or stable disease  [SD] for at least  24 weeks) 
based on RECIST 1.1 and irRECIST 
• Overall  survival (OS) 
In patients  with best overall  response of CR or PR: 
 
• Duration of response (DOR)  
• Time  to response  (TTR)  
Safety: To ev aluate  safety  and tolerability  of entinostat  in combination  with atezolizumab,  as 
measured by clinical adverse events (AEs) and laboratory parameters.  
Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  29 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
3.3 Exploratory 
The exploratory  study  objectives  are to: 
 
•  
 
 
•  
 
•  
 
•  
•  
 
•  
 
•  
 
•  
 
•  
•  
 
•  
 

Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  30 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
4. ENDPOINTS  
 
4.1 Efficacy 
The primary  efficacy  endpoint  is: 
• PFS,  as determined  by the local investigator  using RECIST  1.1 
Secondary endpoints:  
• PFS determined by the local investigator  using irRECIST  
• ORR (CR or PR) by RECIST  1.1 and irRECIST  
• CBR (CR, PR, or SD for at least  24 weeks)  by RECIST  1.1 and irRECIST  
• OS 
In patients  who experience a response  to treatment  (i.e., CR or PR): 
• DOR  
• TTR 
4.2 Safety 
Safety  endpoints  are: 
 
• Determination of DLT,  MTD  and RP2D  
• AEs 
• Clinical laboratory  parameters,  Vital Signs,  Physical  Exam  
4.3 Exploratory 
Exploratory  endpoints  include:  
•  
•  
•  
•  
•  
•  
 
•  
•  
•  
•  
•  

Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  31 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
5. BACKGROUND  AND RATIONALE  
 
Triple negative breast cancer (TNBC) represents 15- 20% of newly diagnosed breast cancer 
cases, and is associated  with a younger  age and advanced stage  at diagnosis,  increased  risk of 
visceral metastasis and poorer outcome. The five -year survival rate for women diagnosed with 
Stage IV TNBC is only 22% with limited  treatment  options.  Development  of novel  approaches  to 
improve the treatment outcome for TNBC patients remains a significant unmet challenge. 
Immuno- oncology is an  emerging field of cancer  medi cine that has focused on the development 
of therapeutic approaches designed to activate the immune system to find and destroy cancer 
cells. The immune system consists of two parts, the innate immune system and the adaptive 
immune system and both play a role in an immune mediated effective anti -tumor immune 
response. The innate immune system, composed of key cells such as natural killer (NK) and neutrophils,  is non-specific  and is designed  to rapidly  identify  and eliminate  immediate  threats  to 
the body, such as infections and other pathogens. The adaptive immune system, composed of 
B cells,  T cells and other  immune regulatory  cells, targets  specific  antigens  and provides  a long- 
term response, known as immunologic memory, to antigens it recognizes as foreign.  
Many tumors have the ability to evade both the innate and adaptive immune system through direct cellular interactions and recruitment of immune- suppressive cells to the area surrounding 
the tumor ( Wu 2015) . Cancer cells can express proteins on their cell surface known as check 
point proteins, such as PD -L1 and programmed cell death protein ligand 2, or PD- L2, that block 
the ability of immune cells known as cytotoxic T cells to kill cancer cells ( Mahoney 2015; 
Sharma  2015).  Antibodies  that block  PD-L1 or PD-L2 restore  the ability  of cytotoxic  T cells to kill 
cancer cells and have shown great clinical promise. Positive results notwithstanding, durable responses have been observed in only a relatively small population of patients, with overall response rates below 30% depending on tumor type; this suggests that additional strategies enhancing the anti- tumor immune response are needed to improve the survival of cancer 
patients ( Mahoney 2015 ; Sharma 2015 ). 

Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  32 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
Research to identify the basis for the limited efficacy of recently developed immune therapies 
has provided investigators  with an appreciation for the role that specific  immune regulatory  cells, 
such as MDSCs and Tregs, have in dampening the cytotoxic T cell response ( Joyce 2015 ; 
Mahoney 2015 ; Sharma 2015). MDSCs and Tregs localize in the area surrounding the tumor 
and, together with the immune checkpoints, play a significant role in helping a tumor evade detection and elimination by the immune system ( Marvel 2015; Adeegbe).  
MDSCs are immature myeloid cells that are activated by disease or injury and are generally 
increased in cancer  patients.  The primary  function of MDSCs is  to suppress  an activated  T cell 
immune response through the production and secretion of enzymes that deplete key amino 
acids required for the growth and function of cytotoxic T cells ( Marvel 2015 ). High 
concentrations  of circulating  MDSCs  in various  cancers, including breast,  lung,  head and neck, 
correspond with a poor prognosis and limited response to cancer therapy ( Liu 2010; Najjar  
2013; Solito 2011 ; Weed 2014). Recent data further indicate that high concentrations of 
circulating MDSCs in melanoma patients are inversely correlated with clinical response to 
immune checkpoint inhibitors  suggesting that targeting MDSCs may offer new therapeutic 
opportunities for enhancing the anti -tumor response to immune checkpoint inhibitors ( Weber  
2015).  
Tregs  are a second  type of immune  suppressor  cell and are recruited  to sites of active  immune 
response in order to shut down the cytotoxic T cell response ( Adeegbe 2013; Zhang 2015).  
Unlike MDSCs, which are found in activated states in circulating blood, Tregs are recruited to the tumor microenvironment and activated by local signals from the cancer cell ( Adeegbe 2013 ; 
Zhang 2015). As with MDSCs, an increase in the concentration of activated Tregs correlates with poor prognosis  in a number  of tumor  types  including  breast,  colorectal,  and ovarian cancers 
(Freiser 2013; Zhang 2015). Tregs suppress cytotoxic T cell responses through the secretion of 
cytokines that inhibit the growth of cytotoxic T cells. In addition Tregs can cause other immune regulatory cells in the tumor microenvironment to secrete immune suppressive enzymes  
(Freiser 2013; Zhang 2015). Inhibiting Tregs may therefore relieve immune suppression in a  
way similar and potentially complementary to that of other immune -targeted approaches.  

Product:  Entinostat  
Protocol  Number: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  33 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
Separate preclinical studies have demonstrated that entinostat is a dual inhibitor of immune 
suppressor  cells and targets  both MDSCs  and Tregs.  Figure 5-1 below  shows  that entinostat 
reduces the growth of MDSCs at  concentrations that spare the growth of cytotoxic T cells.  
Approximately  half of the MDSCs  are stopped  from growing  at 200 nM of entinostat,  which  is 35 
times less than the concentration of entinostat  that stops half of the cytotoxic T cells from 
growing ( Kim 2014).  
Investigators have previously demonstrated FOXP3, a protein involved in Treg function, is an indicator of Treg immune suppressor activity. Figure 5 -2 below shows that entinostat reduces 
the expression  of FOXP3  protein in Tregs,  when  administered  in an animal  cancer  model,  thus 
demonstrating entinostat’s ability to inhibit Treg immune suppressor activity ( Shen 2012 ). 
 
 
 
 
Figure 5-1 ( Kim 2014) Figure 5-2 ( Shen 2012) 
 
 
In order to  determine whether the effects observed in preclinical research studies can also be 
observed  in cancer  patients  treated with entinostat,  an analysis  was conducted  on immune  cells 
in blood samples collected from a subset of patients treated in ENCORE 301, a  Phase 2b 
clinical trial in advanced HR+ breast cancer patients. As shown in Figure 5- 3 below, in these 
peripheral blood samples, a statistically significant reduction in the concentration of circulating 
MDSCs was observed in patients treated with the combination of entinostat and exemestane, a hormone therapy, but not in patients treated with the combination of placebo and exemestane.  

Product:  Entinostat  
Protocol  Number: SNDX -275-0602 (TRIO025) 
Date:  11 Sep 2018  Page  34 of 141 
Figure  5-3 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
   
 
     
 
     
 
  
 
Data  on file 
 
 
Data  Supporting  Entinostat  in Combination  with Immune  Checkpoint  Inhibitors. 
 
 
Preclinical. In or der to determine whether  entinostat  could be combined effectively  with immune 
checkpoint inhibitors, entinostat was tested in combination with anti -PD-1 and anti -cytotoxic T - 
lymphocyte -associated protein 4, or CTLA4, directed antibodies in immune -resistant animal 
models. As shown in Figure 5 -4 below, the elimination of both primary and metastatic tumors 
was observed in a 4T1 mouse triple negative metastatic breast cancer model that was treated 
with entinostat toge ther with dual PD -1/CTLA4 checkpoint inhibition. In this experiment, it was 
observed that entinostat reduced the number and activity of MDSCs, rather than attacking and destroying replicating cells like standard chemotherapy drugs. The significant anti -tumor effect 
of entinostat combine with immune checkpoint blockade in the 4T1 TNBC mouse model supports the clinical testing of entinostat combined with atezolizumab in TNBC.  

Product:  Entinostat  
Protocol  Number: SNDX -275-0602 (TRIO025) 
Date:  11 Sep 2018  Page  35 of 141 
Figure  5-4 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
 
 
 
 
Source:  (Kim 2014) 
 
Clinical. In patients who  were treated in two unrelated clinical  trials, physicians at JHU observed 
preliminary evidence for the potential beneficial effects of combining entinostat with a PD -1 or 
PDL-1 inhibitor. In a heavily pre- treated metastatic NSCLC population, patients given the 
combination of entinostat  and azacitidine,  an approved agent , achieved few objective responses 
and only a modest 3% overall response rate (Juergens 2011). However, investigators observed 
that patients who received the combination of entinostat and azacitidine and subsequently received immune checkpoint therapy demonstrated a higher response rate than expected for this patient population. Figure 5 -5 below illustrates that all five patients who received either 
nivolumab, an approved anti -PD-1, or an investigational PDL- 1 inhibitor as their next therapy 
derived durable  clinical benefit.  Three of the patients had durable responses and two had 
durable stable disease. This enhanced response rate was better than the 15% response to nivolumab alone observed in a similar advanced NSCLC population and led investigators to hypothesize that the prior effect of the combination of entinostat and azacitidine therapy was 
“priming” the tumors to the subsequent immune therapy (Wrangle 2013).  To confirm these 
findings and further explore the ability of the combination of azacitidine and entinostat to 
enhance the response of NSCLC patients to nivolumab, the investigators at JHU have initiated  
a follow -on randomized Phase 2 clinical trial, J1353.  

Product:  Entinostat  
Protocol  Number: SNDX -275-0602 (TRIO025) 
Date:  11 Sep 2018  Page  36 of 141 
Figure  5-4 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
 
 
 
Data  on file 
 
 
Based on these findings  it is hypothesized that entinostat  combined with a PD-1/PD -L1-blocking 
antibody, atezolizumab, will result in an improvement in PFS for the combination compared to 
atezolizumab alone.  
5.1 Study Treatment  
 
5.1.1  Entinostat  (SNDX -275) 
 
Deoxyribonucleic acid (DNA) within the cell nucleus combines with a class of proteins called 
histones to form chr omatin. Histones have amino terminal groups that are positively charged 
and are deacetylated  by HDACs.  The positive  charge tightly  binds  the histones  to the negatively 
charged DNA phosphodiester backbone. Gene transcription and expression are inhibited by such a condensed conformation of the DNA. Histone acetyltransferases acetylate the amino terminal ends and neutralize their positive charges, thus leading to a more open chromatin conformation, facilitating DNA transcription. 
Entinostat  (SNDX -275),  an orally available synthetic  pyridylcarbamate  licensed from Bayer 
Schering AG by Syndax Pharmaceuticals and previously named MS -275, inhibits histone  

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  37 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
deacetylases  (HDACs). Entinostat  promotes  hyperacetylation of nucleosomal  histones,  allowing 
transcriptional activation of a distinct set of genes. This ultimately leads to the inhibition of cell 
proliferation, induction of terminal differentiation, and/or apoptosis ( Hess -Stumpp, 2007 ). 
Altered activity  of HDACs  and inactivation of histone acetyltransferases  within  transformed cells 
are key events that affect chromatin remodeling. There is evidence that HDACs are associated with a wide range of tumors including melanomas, neuroblastomas, lymphomas, and lung, breast, prostate, ovarian, bladder, and colon cancers. In a number of in vitro models, HDAC 
inhibitors triggered growth arrest and induced cell differentiation or apoptosis. In acute promyelocytic leukemia, recruitment of HDACs by aberrant fus ion proteins repressed 
constitutive gene transcription and thus prevented promyelocytic differentiation.  
Entinostat also induced histone hyperacetylation and induced expression of various tumor 
suppressor genes. Various in vitro studies in a range of human  cancer cell lines have 
demonstrated  the antiproliferative  activity  of entinostat.  In vivo, entinostat  inhibited  the growth of 
a range  of human  tumor  xenograft  model,  including lung,  prostate,  breast,  pancreatic,  renal  cell, 
and glioblastoma.  
More recently, entinostat has been shown to modify the phenotype of cancer cells from a mesenchymal to an epithelial one, leading to a reduction in the metastatic potential of the 
cancer  cells (Shah,  2014 ). In addition,  there is a suggestion that entinostat  may have  longer 
term effects on cancer phenotypes, cancer stem cells (CSCs) or progenitor cell pool and potential sensitization to subsequent post -study treatments ( Juergens, 2011).  
5.1.1.1  Entinost at in Patients  with Solid  Tumors,  including breast  cancer  
To date, entinostat  has been investigated alone or in combination in >1000 patients with cancer 
in clinical studies.  In breast cancer, entinostat has been studied in a randomized phase 2 
clinical trial sponsored  by Syndax,  ENCORE  301, in patients  with ER+ metastatic  breast  cancer. 
ENCORE -301 was a placebo- controlled, double- blind trial of exemestane in combination with 
entinostat (EE) versus exemestane plus placebo (EP). The primary endpoint of PFS was met, with EE resulting in a median of 4.3 months and EP a median of 2.3 months. Overall survival,  
an exploratory endpoint, showed a survival benefit of approximately 8 months in favor of EE (28.1 months) versus EP (19.8 months), In 2014 the FDA granted Breakthrough Therapy designation for entinostat combined with exemestane in metastatic hormone receptor -positive 
breast cancer in post -menopausal women whose disease has progressed following non- 
steroidal aromatase inhibitor (AI) therapy based on these results. A phase 3 registration study,  

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  38 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
E2112, has been designed to confirm the ENCORE 301 results and is currently being 
conducted by ECOG -ACRIN  under  sponsorship from the NCI under  a Special  Protocol 
Assessment.  
In clinical trials to date, entinostat has been well tolerated at the doses and schedules investigated. The AEs reported most frequently included gastrointestinal (GI) disturbances, primarily nausea with or without vomiting and diarrhea; fatigue; and hematologic abnormalities, primarily anemia, thrombocytopenia, neutropenia, and leukopenia. Most of these events were Grade 1 or 2 in severity and non- serious. Grade 3 and 4 hematologic abnormalities are more 
commonly  seen in patients  with hematologic  malignancies  and are less common  in patients  with 
solid tumors.  
Additional information on the chemistry, pharmacology,  toxicology,  preclinical findings,  and 
clinical experience to date may be found in the Investigator’s Brochure (IB).  
 
5.1.2  Atezolizumab 
 
5.1.2.1  Background  
Atezolizumab (MPDL3280A) is a humanized immunoglobulin (Ig) G1 monoclonal antibody consisting of two heavy  chains  (448 amino  acids)  and two light chains  (214 amino  acids)  and is 
produced in Chinese hamster ovary cells.  Atezolizumab was engineered to eliminate Fc - 
effector function via a single amino acid substitution (asparagine to alanine) at position 298 in the heavy chain, which results in a non- glycosylated antibody that has m inimal binding to  
Fc receptors  and, consequently,  eliminates  detectable Fc-effector  function and depletion of cells 
expressing PD -L1. Atezolizumab targets human PD -L1 and inhibits its interaction with its 
receptor, PD -1. Atezolizumab also blocks the binding of PD -L1 to B7.1, an interaction that is 
reported to provide additional inhibitory signals to T cells.  
Atezolizumab is being investigated  as a potential  therapy  for solid tumors  and hematologic 
malignancies in humans.  
Refer  to the current  atezolizumab IB for detailed background information on this drug product.  
 
5.1.2.2  Pharmaceutical  and Therapeutic  Background  
The PD -1 receptor -ligand interaction is a major pathway hijacked by tumors to suppress 
immune  control  (Pedoeem  2014 ). The normal  function of PD-1, expressed  on the cell surface  of 
activated T cells under  healthy conditions, is to down- modulate unwanted or excessive immune  

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  39 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
responses, including autoimmune reactions. PD -1 (encoded by the gene Pdcd1) is an 
immunoglobulin (Ig) superfamily member related to CD28 and CTLA -4, which has been shown 
to negatively regulate antigen receptor signaling upon engagement of its ligands (PD -L1 and/or 
programmed  death  ligand-2 [PD-L2]). The structures  of murine  PD-1 alone  (Zhang  2004 ) and in 
complex with its ligands have been resolved ( Lazar -Molnar 2008 ; Lin 2008), and more recently 
the nuclear magnetic resonance- based structure of the human PD -1 extracellular region and 
analyses of its interactions with its ligands were also reported ( Cheng 2013). PD -1 and family 
members are type I transmembrane glycoproteins containing an Ig Variable-t ype (V -type) 
domain responsible for  ligand binding and a cytoplasmic tail  which is responsible for  the binding 
of signaling molecules. The cytoplasmic tail of PD -1 contains 2 tyrosine- based signaling motifs, 
an immunoreceptor tyrosine- based inhibition motif (ITIM) and an immunoreceptor tyrosine- 
based switch  motif  (ITSM). Following  T cell stimulation,  PD-1 recruits  the tyrosine phosphatases 
SHP-1 and SHP -2 to the ITSM motif within its  cytoplasmic tail, leading to the dephosphorylation 
of effector molecules, such as CD3ζ, PKCθ and ZAP70, which are involved in the CD3 T cell 
signaling cascade ( Sheppard 2004 ). The mechanism by which PD -1 down- modulates T cell 
responses is similar to,  but distinct from that of CTLA -4 (Ott 2013). PD -1 was shown to be 
expressed on activated lymphocytes, including peripheral CD4+ and CD8+ T cells, B cells, T 
regs and natural killer cells ( Yao 2014 ). Expression has also been shown during thymic 
development on CD4-CD8- (i.e., double -negative) T cells ( Nishimura 1996 ), as well as subsets 
of macrophages ( Huang 2009) and dendritic cell s (Pena- Cruz 2010). The ligands for PD -1 
(PD-L1 and PD-L2) are constitutively  expressed or can be induced in a variety  of cell types  (Keir 
 
 
2008).  PD-L1 is expressed at low levels  on various  non-hematopoietic  tissues,  most  notably  on 
vascular endothelium, whereas PD- L2 protein is only detectably expressed on antigen- 
presenting cells found in lymphoid tissue or chronic inflammatory environments ( Keir 2008 ). 
Both ligands are type I transmembrane receptors containing both Ig variable- and Ig constant - 
like domains in the extracellular region and short cytoplasmic regions with no known signaling motifs. Binding of either  PD-1 ligand to PD-1 inhibits  T cell activation  triggered through  the T cell 
receptor.  PD-L2 is thought to control immune T cell activation in lymphoid organs, whereas  
PD-L1 serves to dampen unwarranted T cell function in peripheral tissues. Although healthy 
organs express little (if any) PD -L1, a variety of cancers were demonstrated to express 
abundant  levels  of this T cell inhibitor  (Karim  2009 ; Taube  2012 ), wh
 ich, via its interaction  with 
the PD -1 receptor on tumor -specific T cells, plays a critical role in immune evasion by tumors  

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  40 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
(Sanmamed 2014).  As a consequence,  the PD-1/PD -L1 pathway  is an attractive target  for 
therapeutic intervention in cancer ( Topalian 2012 ). 
5.1.2.3  Atezolizumab  Non-Clinical  Studies Summary  
The nonclinical strategy of the atezolizumab program was to demonstrate in vitro and in vivo 
activity, to determine in vivo pharmacokinetic (PK) behavior, to demonstrate an acceptable safety  profile,  and to identify  a Phase  I starting  dose.  Comprehensive pharmacology,  PK, and 
toxicology evaluations were performed with atezolizumab. 
The safety,  pharmacokinetics,  and toxicokinetics  of atezolizumab were  investigated in mice  and 
cynomolgus monkeys to support intravenous (IV) adminis tration and to aid in projecting the 
appropriate  starting  dose  in humans.  Given  the similar  binding  of atezolizumab  for cynomolgus 
monkey and human PD -L1, the cynomolgus monkey was selected as the primary and relevant 
nonclinical model for understanding the safety, pharmacokinetics, and toxicokinetics of 
atezolizumab.  
Overall, the nonclinical pharmacokinetics and toxicokinetics observed for atezolizumab 
supported entry into clinical studies, including providing adequate safety factors for the 
proposed  Phase I starting  doses.  The results  of the toxicology  program  were  consistent  with the 
anticipated pharmacologic activity of downmodulating the PD -L1/PD -1 pathway; heightened 
immune responses and the potential to increase immune -associated inflammatory lesions were 
identified as possible safety risks in patients.  
Refer  to the Atezolizumab  Investigator’s  Brochure  (IB) for details  on the nonclinical  studies.  
 
5.1.2.4  Atezolizumab  Clinical  Studies  Summary  
Atezolizumab is currently being tested in multiple Phase I, II, and III studies, both as 
monotherapy  and in combination with several  anti-cancer  therapies  (see the Atezolizumab 
Investigator’s Brochure for study descriptions). The single- agent safety and efficacy data 
available to date are from the following studies: one Phase Ia (Study PCD4989g) and two Phase II studies (Studies GO28625 [FIR] and GO28753 [POPLAR]).  
Clinical benefit from atezolizumab monotherapy was observed in a broad range of  malignancies 
including non-small cell lung cancer  (NSCLC),  renal  cell carcinoma  (RCC),  melanoma,  urothelial 
bladder cancer (UBC), head and neck cancer, gastric cancer, breast cancer and sarcoma.  
Results  sugges t that PD-L1 expression in the tumor  microenvironment  is associated with an 
increased probability of clinical benefit with atezolizumab.  

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  41 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
         
Across all these  patients,  fatigue was the most  frequently  reported adverse  event.  Given  the 
mechanism of action of atezolizumab, events associated with inflammation and/or immune - 
mediated adverse events have been monitored closely during the clinical program.  These 
include potential dermatologic, hepatic, endocrine, gastrointestinal and respiratory events.  
In trials investigating atezolizumab both as a single agent and in combination with 
chemotherapy,  the incidence of adverse  events  in the treatment  arms  with combined use was 
consistent  with the known safety  profiles  of the individual  study  drugs.  Currently,  no maximum 
tolerated dose, no dose- limiting toxicities and no clear dose- related trends in the incidence of 
adverse events have been determined. 
Refer  to the Atezolizumab Investigator’s  Brochure  for additional details  on clinical studies.  
 
5.2 Study Rationale  
Treatment of TNBC represents a significant challenge due to the lack of clinically validated 
targets that are available for the other breast cancer subtypes. Preliminary data has indicated that treatment with immune checkpoint inhibitors targeting PD -1 such as pembrolizumab and 
PD-L1 such as atezolizumab results  in approximately  an 18-19% response  rate in women  with 
TNBC who also test positive for PD-L1 expression.  While  these  data are promising,  the benefit 
appears to be restricted to a relatively small fraction of the total TNBC patient population.  
Combination strategies to increase the clinical benefit of PD -1 / PD -L1 inhibitors in TNBC are 
the focus of intense research efforts. Preclinical testing in the 4T1 mouse model  of TNBC 
indicate that entinostat combined with immune checkpoint blockade results in complete inhibition  of primary  tumors  and metastases.  The mechanism  for this combined  anti-tumor  effect 
was determined to be entinostat’s ability to inhibit the growth an d function of MDSCs, an 
immune suppressor cell shown to block the anti -tumor T cell immune response. These data 
provide the basis for  clinical testing of entinostat  combined with atezolizumab in TNBC patients.  
5.3 Rationale for the Dose  Selection 
 
5.3.1  Entinostat  
 
Entinostat  has been  evaluated in vitro, in nonclinical  in vivo studies,  and in Phase  1 and 
2 studies  in patients  with various  solid tumors  and hematological malignancies  at doses  
between 2 and 12 mg/m2 and at dosing  frequencies  ranging  from once  daily to every  2 weeks. 
Increased histone acetylation was observed at the lowest dose evaluated with the effect persisting at least 48 hours post -dose. Pharmacokinetic (PK) studies of entinostat have  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  42 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
        
       
        
indicated a long half-life of entinostat,  ranging from 40 hours  to 120 hours.  Consistent  with this 
long half -life, entinostat concentrations were detectable 168 hours post -dose at doses of 2 to 
12 mg/m2. 
The MTD  for single  agent  entinostat  in non-hematologic  indications  was established as 4 mg/m2 
weekly  x 3 followed  by a 1 week  rest, or 10 mg/m2 every  other  week  continuously.  
 
PK analyses have demonstrated ~40% variability in the clearance of entinostat. However, when 
clearance was adjusted  for body  surface  area (BSA),  the inter-patient  variability  was similar.  In a 
linear regression analysis on factors that may contribute to this variability, ideal body weight, lean body mass, body weight, and body mass index, were not significant covariates. As a result of this analysis, fixed dosing is considered to be as accurate as dosing based on BSA ( Alao,  
2004).  
Entinostat  given  once  weekly  continuously  at a dose  of 5 mg (in combination with the aromatase 
inhibitor exemestane) in patients with locally advanced or metastatic breast cancer or given every other week continuously at a dose of 10 mg (in combination with erlotinib) in patients with stage  IIIB/IV  NSCLC, was  well tolerated.  The AE profile  at these  dose schedules  was consistent 
with previous clinical experience, with the most common AEs being fatigue and gastrointestinal disturbances, (nausea, vomiting, and diarrhea).  
Based on the clinical experience with entinostat, fixed dose of 5 mg given weekly has been selected as the starting dose  for this study,  with dose  initial de-escalation to 3 mg and secondly 
to 2 mg, if toxicity occurs with the combination treatment.  
 
5.3.2  Atezolizumab 
 
The fixed  dose  of 1200  mg (equivalent  to an average body  weight −based  dose of 15 mg/kg) 
was selected on the basis of  both nonclinical studies and available clinical data from Study 
PCD4989g as described below.  
The target exposure for atezolizumab was projected on the basis of nonclinical tissue distribution data in tumor -bearing mice,  target -receptor  occupancy  in the tumor, the observed 
atezolizumab interim pharmacokinetics in humans, and other factors.  The target trough 
concentration (C
trough) was projected to be 6 µg/mL on the basis of several assumptions, 
including:  1) 95% tumor -receptor  saturation  is needed for efficacy and 2) the tumor -interstitial 
concentration to plasma ratio is 0.30 based on tissue  distribution data in tumor -bearing mice.  

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  43 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
The atezolizumab dose is also informed by available clinical activity, safety, PK, and 
immunogenicity  data.  Anti-tumor  activity  (ATA)  has been observed across  doses  from 1 mg/kg 
to 20 mg/kg  administered q3w.  The MTD  of atezolizumab was not reached,  and no DLTs  have 
been observed at any dose in Study PCD4989g. Available preliminary PK data (0.03 −20 
mg/kg) from Study PCD4989g suggest that for doses ≥ 1 mg/kg q3w, overall atezolizumab 
exhibits pharmacokinetics that are both linear and consistent with typical IgG1 antibodies.  
Detectable  ATAs  were  observed in patients  at all dose levels  but were  associated with changes 
in pharmacokinetics  for some  patients  in only the lower  dose  cohorts  (0.3, 1, and 3 mg/kg).  It is 
unclear from currently available data in these lower dose cohorts whether administration of higher doses to patients with both detectable ATAs and reduced exposure would necessarily restore exposure to expected levels.  No clear relationship between the development of 
measurable ATAs and safety or efficacy has been observed.  Available data suggest that the 
development of detectable ATAs does not appear to have a significant impact on pharmacokinetics for doses from 10 to 20 mg/kg administered q3w in most  
patients.  Correspondingly,  patients  dosed at the 10-, 15-, and 20-mg/kg q3w dose levels  have 
maintained target trough concentrations of drug despite the detection of ATAs.  
Currently available PK and anti- treatment antibody data suggest that the 15- mg/kg 
atezolizumab q3w regimen (or  fixed -dose  equivalent)  would be sufficient to both maintain 
C
trough ≥ 6 µg/mL  and further  safeguard against  both interpatient  variability  and potential  effect  of 
ATAs that could lead to sub- therapeutic levels of atezolizumab relative to the 10- mg/kg  q3w 
regimen (or fixed -dose equivalent).  From inspection of available observed C trough data, a  
20 mg/kg atezolizumab q3w regimen  does  not appear  to be warranted  to maintain targeted 
Ctrough levels relative to the proposed 15- mg/kg q3w level.  
Simulations ( Bai et al. 2012) do not suggest any clinically meaningful differences in exposure 
following  fixed  dose  or dose  adjusted  for weight.  On the basis  of this analysis,  a fixed  dose  of 
1200 mg q3w is selected (equivalent to a body weight −based dose of 15 mg/kg q3w).  
Selection of an every -21-day dosing interval  is supported by this preliminary  pharmacokinetics 
evaluation and allows for a convenient integration with common therapeutic regimens.  
5.4 Hypothesis  
Phase 1b: The combination of atezolizumab  and entinostat  at a biologically  active dose will be 
suffic iently safe and well tolerated to warrant further investigation.  

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  44 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
Phase 2: Entinostat  at the dose  determined  in Phase  1b combined with atezolizumab will result 
in an improved Progression- Free Survival compared to atezolizumab alone.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  45 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
6. EXPERIMENTAL  PLAN  
 
6.1 Study Design 
Study SNDX -275-0602 (TRIO025) is a randomized, placebo- controlled, double- blind, 
multicenter  phase 2 study  evaluating the combination of atezolizumab with or without  entinostat  
in patients with aTNBC with a Phase 1b lead- in phase to determine the recommend phase 2 
dose of entinostat.  
 
 
Figure 6-1 Flowchart  of Dose  Determination  Advancement  
 
Entinostat  
Dose  DL T in: Action  DLT in: Outcome  
 
 
 
0 or 1 of 6 
 
0 or 1 of 3 Add 3 
 
5 mg ≥ 2 of 6 
 
≥ 2 of 3 
 
 
 
0 or 1 of 6 
 
0 or 1 of 3 Add 3 
 
3 mg ≥ 2 of 6 
 
≥ 2 of 3 
  
 
 
 
0 or 1 of 6 
 
0 or 1 of 3 Add 3 
 
2 mg ≥ 2 of 6 
 
≥ 2 of 3 Amend protocol  to 
study alternative 
dosing regimen  Recommended 
Phase 2 Dose   
Enroll at 2 mg Recommended 
Phase 2 Dose   
Enroll at 3 mg Recommended 
Phase 2 Dose  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  46 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
 
Phase  2: a TNBC  
Randomized,  double -blind  
Dose  Determination 
N = 6 -18 Entinostat + 
Atezolizumab 
N = 35  
Placebo + 
Atezolizumab  
N = 35  
 
Figure 6-2 Study  Schema 
 
 
 
Phase 1b sites will be notified  by TRIO regarding the availability  of slots in a given cohort, 
observation of DLTs and entinostat  dose levels, to assist with screening activity.  
Regardless of phase, patients will be screened for study eligibility within 21 days before 
enrollment.  Patients  who are determined to be eligible,  based on screening assessments,  will 
be enrolled in the study within 3 business days of starting study treatment on Cycle 1, Day 1 (C1D1).  
A cycle is 21 days  in length.  During  treatment,  patients  will attend study  center  visits  and study 
evaluations will be performed on C1D1, C1D8, and C1D15; D1 and D15 of C2; and on D1 of each cycle thereafter.  
Phase  1b: aTNBC  
open label  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  47 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
Fresh tumor  tissue core biopsy  (image- guided  if applicable)  will be collected during  the study  as 
follows.:  
• During  screening from all patients  on a mandatory basis.  Archival  tumor  tissue will also 
be collected when available.  
• On C2D15 (+ /-3 days) on an optional basis from patients in the Phase 1b Dose 
Determination Phase . All patients  in the Dose  Determination Phase  will be strongly 
encouraged to undergo an optional  biopsy  in order  to help understand dose -immune 
correlate effects.  
• On C2D15  (+/-3 days)  on a mandatory  basis  until 20 samples  are obtained  in the 
Phase 2 Expansion  Phase and on an optional  basis  for subsequent  patients  in this 
phase.  
• At the end of study  treatment  prior to the start of another  systemic therapy,  on an 
optional  basis  for all patients.  
• At disease progression  on an optional  basis  for all patients.  
If, based on an interim review of tumor tissue data from the initial patients in the Expansion 
Phase, such data are considered informative, tumor tissue samples will be collected on a mandatory  basis  from all subsequent  patients  on C2D15  (+/-3 days).  Alternatively,  if such data 
are not considered informative, subsequent samples will not be collected.  
Blood f
or  immune  correlates  is to be collected  pre-dose on each  of C1D1,  C2D1,  C2D15,  C3D1 
and at the end of treatment. Blood for protein lysine acetylation is to be collected pre -dose on 
C1D1 and C1D15.  Patients will have radiological disease assessments performed every  
6 w eeks  (+/-3 days) (Week  6, Week  12, etc.) beginning at C1D1,  during  study  treatment  through 
week 36 or until progressive disease. If progressive disease has not occurred by week 36, radiological assessments will then be done every 9 weeks (+/ -3 days) until  progressive disease. 
If a patient comes off study for reasons other than progressive disease, radiological assessments will continue at 6 week intervals until what would have been study week 36 and 
then switch to a 9 week interval, until progressive disease is radiologically documented.  
Disease will be assessed by computed tomography (CT), magnetic resonance imaging (MRI), 
and bone scans, as appropriate, and response will be assessed by the Investigator using irRECIST.  The same imaging  modality  should  be employed for all follow- up scans  as was used 
at baseline.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  48 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
Safety  will be assessed during the study  by documentation of AEs,  clinical laboratory  tests, 
physical  examination,  vital sign measurements,  ECGs,  and Eastern Cooperative  Oncology 
Group (ECOG) performance status.  
Within  7 days  of the last dose of study  treatment,  all patients  will complete an End of Treatment 
(EOT) visit, and a Safety Follow -up (F/U) visit will be required 30 days (+/ - 3 days) thereafter.  
After  completion  of the 30-day F/U visit, patients  who have  experienced  progressive disease  are 
to be contacted every 3 months thereafter for survival status and information regarding 
treatment regimens, until death or closure of the study by the Sponsor. Those patients who  
have not experienced progressive disease, will continue radiological disease assessments as 
noted above.  
Phase 1b (Dose Determination) : This study phase employs a classical 3+3 design, with the 
determination of DLT and the MTD or RP2D based on the combination of entinostat wit h 
atezolizumab in C1. Six patients will need to be treated in a dose level for it to be considered MTD  or the RP2D.The  recommended dose for Phase  2 investigation  will be the higher  of either 
2, 3 or 5 mg weekly PO that results in less than a 33% incidence of DLT.  The final 
determination of the optimal dose for further use will consider both acute and cumulative 
toxicities; the incidence of required dose delays, reductions, and discontinuations; and the overall facility of administration in clinical practice . 
The initial 3-6 patients  will receive entinostat  at a starting dose  of 5 mg (Dose  Group 1) on D1, 
D8, and D15 along with atezolizumab 1200  mg via intravenous  (IV) infusion  on D1 of each 21- 
day cycle.  
If the 5 mg dose exceeds the MTD, then a 3 mg dose of entinostat (Dose Group - 1) will be 
evaluated in the same manner. If the -1 dose level exceeds the MTD, then a 2 mg dose of 
entinostat (Dose Group -2) will be evaluated.  Based on evaluation of the safety  and tolerability 
data gathered  during the dose determination phase together  with data from other  clinical trials,  it 
may also be decided that accrual will take place at an alternate dose level or dosing schedule via a protocol amendment.  
Patients who experience a DLT will be allowed to remain on study if they meet the following 
criteria; (1) the investigator  believes  it is appropriate for patients  to remain  on study  (2) the event 
has resolved and no longer meets the definition of DLT and (3) the timeline for resolution falls 
within the guidelines for dose delays ( Section 9.10). 

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  49 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
Phase 2 (Expansion) : The efficacy and safety of entinostat  in combination with atezolizumab 
will be evaluated using the RP2D identified in the Dose Determination Phase. In this 
randomized, placebo- controlled, double -blind study phase, 70 patients will be randomized in a 
1:1 fashion  to atezolizumab + entinostat  versus atezolizumab + placebo.  The randomization  will 
be stratified by geographic location (US vs. rest of world).  
Patients  will follow the same  schedule of study  visits and assessments  as specified in the Dose 
Determination phase. The exception is the C2D15 tumor tissue core biopsy. While this was 
optional in the Dose Determination phase, it is mandatory in the Expansion Phase until 20 samples are obtained. If the data learned from those first 20 samples is deemed informative, this procedure may become mandatory for the remainder of the patients  enrolled in this phase.  
Following the enrollment and completion of Cycle 1 of the first 20 patients in this study phase, cumulative  study  safety  data for all study  patients  will be reviewed by a Data  Safety  Monitoring 
Board (DSMB). The development of serious adverse events will be assessed by the Medical 
Monitor  and DSMB  on a continuous  basis. At the first DSMB  meeting,  the DSMB  members  will 
confirm which SAEs they need to see real time or at time of DSMB meetings only. Unless the 
DSMB wishes to suspend enrollment during the review of the safety data for the first 20 patients, enrollment will continue during the data review process.  
6.2 Number  of Centers  
Up to approximately  50 international  study  centers  are planned to be recruited for participation 
in this study. Study centers that do not enroll at least 1 patient  within 3 months of study  center 
initiation may be subject to closure in consultation with the Sponsor.  
6.3 Number  of Patients 
Phase 1b Dose  Determination  Phase:  Up to 18 patients  may be enrolled.  In this phase,  up to 3 
doses of entinostat will be explored in a standard “3+3” Phase 1 dose finding scheme.  Six 
patients will need to be treated in a dose level for it to be considered MTD or the RP2D. 
Entinostat  dosing will start at 5 mg po weekly  and then decrease to 3 mg weekly  in the case that 
the 5 mg weekly  dose  leads  to ≥ 2 DLTs.  It will again be de-escalated  to 2 mg weekly  should the 
3 mg weekly dose lead to ≥ 2 DLTs. Each patient will be counted in only 1 dose cohort. Thus, 
the total number of patients to be enrolled in the Dose Determination Phase is dependent upon 
the observed safety profile, which will determine the number of patients per dose cohort, as well as the number of dose de- escalations required to achieve the MTD. 
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  50 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
Note:  The patients  who discontinued the study  for reasons  other  than study  drug related 
toxicities before completing Cycle 1 may be replaced.  
In the Phase 2 Expansion Phase, a total of 70 TNBC patients are planned to be enrolled for 
evaluation (35 patients per arm).  Note:  It is anticipated that the number of patients who will 
drop out of the study  without  PFS failure  beforehand will be low (expected  to not exceed 2– 3%). 
Depending on the actual number of such dropouts, the number of patients accrued may be increased by 6– 10 additional patients to accommodate for a higher- than-expected number of 
dropouts.  
6.4 Estimated  Study Duration 
The estimated  duration of study  enrollment  is approximately  15 months;  6 months  for the Phase 
1b and 9 months for the Phase 2. Patients may continue study treatment until unequivocal progressive disease, intolerable toxicity or meets one of the study withdrawal criteria (Protocol Section 11). Patients will be followed for overall survival until the Sponsor terminates the trial.  

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  51 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
7. PATIENT  ELIGIBILITY  
 
7.1 Inclusion Criteria  
Patients  meeting all of the following  criteria  are considered eligible  to participate in the study:  
 
1. Females  aged  18 years  or older  on the day written  informed consent  is given.  
2. Has histologically or cytologically confirmed triple negative breast adenocarcinoma that is 
either metasta tic (stage IV of the TNM classification) or locally recurrent and not amenable 
to local curative treatment. TNBC diagnosis should be based on local laboratory 
ER/PgR/HER- 2 tests and will be defined as HER2 negativity (IHC 0- 1 and/or ISH non - 
amplification)  and ER and PgR negativity (<1%). Disease must also be amenable to core 
biopsy  (image- guided  if applicable)  at enrollment  and for certain cohorts  as described in the 
protocol, at least once during study treatment.  
3. Evidence of measurable (according to RECIST  version 1.1) locally  recurrent  or metastatic 
disease based on imaging studies (e.g., CT, MRI) within 28 days before 
enrollment/randomization.  
4. Has received  at least  1, but no more  than 2, prior lines of systemic therapy  for locally 
recurrent and/or metastatic disease  
5. If patient  has a history  of treated asymptomatic  CNS  metastases  they are eligible,  provided 
they meet all of the following criteria:  
• Patient  has measurable disease outside CNS;  
• Patient  does  not have  metastases  to midbrain,  pons,  medulla or spinal  cord;  
• Patient  is not on corticosteroids  as therapy  for CNS  disease (anticonvulsants 
at a stable dose are allowed);  
• Patient  has not had whole -brain radiation within  6 weeks  prior to study 
enrollment;  
• Patient has stable CNS disease as demonstrated by at least 4 weeks of 
stability  between the last intervention scan  and the study  screening scan 
6. ECOG  performance  status  of 0 or 1. 
7. Has the following  laboratory  parameters  within  21 days  of enrollment:  
 
System  Laboratory  Value  
Hematological   
Absolute  neutrophil  count  (ANC)  ≥1.5×109/L 
Platelets  ≥100×109/L 
Hemoglobin  ≥9 g/dL or ≥5.6 mmol/L  
Renal  
Creatinine OR 
Measured or calculated1 creatinine clearance (CrCl)  
(glomerular  filtration  rate [GFR]  can also be used  in 
place of creatinine or CrCl)   
≤1.5×  the upper  limit of normal  (ULN)  OR 
≥60 mL/min  for patient  with creatinine levels  >1.5× 
institutional ULN  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  52 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
System  Laboratory  Value  
Hepatic   
 ≤1.5×ULN  OR 
Total  bilirubin  Direct  bilirubin  ≤ULN  for patients  with total bilirubin  
 levels  >1.5×ULN  
Aspartate  aminotransferase  (AST)  and alanine  ≤2.5×ULN  OR 
aminotransferase  (ALT)  ≤5×ULN  for patients  with liver metastases  
Coagulation   
International  Normalized  Ratio  (INR)  or Prothrombin  ≤1.5×ULN  unless  patient  is receiving  anticoagulant  
Time  (PT) therapy  as long as PT or PTT is within  therapeutic  range  
 of intended  use of anticoagulants  
Activated  Partial  Thromboplastin  Time  (aPTT)  ≤1.5×ULN  unless  patient  is receiving  anticoagulant  
 therapy  as long as PT or PTT is within  therapeutic  range  
 of intended  use of anticoagulants  
1 Creatinine  clearance should be calculated  per institutional  standard.  
 
8. If a female of childbearing potential, has a negative serum blood pregnancy test during 
screening and a negative  pregnancy  test (urine or serum)  within  3 days  prior to receiving the 
first dose of study drug. If the screening serum test is done within 3 days prior to receiving the first dose of study drug, a second test is not required. Note: Women of childbearing 
potential (WoCP) are any women between menarche and menopause who have not been 
permanently  or surgically  sterilized  and are capable of procreation.  Menopause is defined as 
any of the following:  
• Bilateral  oophorectomy,  
• Age ≥ 60, 
• Age <60 and amenorrheic  for ≥ 12 months  in the absence of an alternative 
medical cause and FSH and estradiol in postmenopausal ranges. .  
Permanent  sterilization  includes  hysterectomy  and/or  bilateral  oophorectomy  and/or  bilateral 
salpingectomy but excludes bilateral tubal occlusion. WoCP include women who have experienced menopause onset < 12 months prior to enrollment.  
9. If a female of childbearing potential, willing to use 2 methods of birth control or  willing to 
abstain from heterosexual  activity  for the course of the study  through  120 days  after the last 
dose of study drug.  
10. Experienced resolution of toxic effect(s)  of the most  recent  prior anti-cancer  therapy  to 
≤Grade 1 (except alopecia or neuropathy ). If patient underwent major surgery or radiation 
therapy  of >30 Gy, they must  have  recovered  from the toxicity  and/or  complications  from the 
intervention.  
11. Able to understand  and give written  informed consent  and comply  with study  procedures.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  53 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
7.2 Exclusion Criteria  
Patients  meeting any of the following  criteria  are not eligible  for study  participation:  
 
1. Diagnosis  of immunodeficiency  or receiving systemic steroid  therapy  or any other  form of 
immunosuppressive therapy  within  7 days  prior to the first dose  of study  drug.  The use of 
physiologic doses of corticosteroids may be approved after consultation with the Medical 
Monitor.  
2. Active autoimmune disease including active  diverticulitis,  symptomatic  peptic  ulcer  disease, 
colitis, or inf lammatory bowel disease that has required systemic treatment in past 2 years 
(i.e., with disease modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement 
therapy for adrenal  or pituitary  insufficiency)  is not considered  a form of systemic treatment.  
3. Previously treated with a PD -1/PD -L1-blocking antibody (i.e., atezolizumab, nivolumab, 
pembrolizumab)  or a histone deacetylase inhibitor  (i.e., vorinostat,  belinostat,  romidepsin, 
panobinostat)  
4. History or current evidence of any condition, therapy, or laboratory abnormality that might 
confound  the results  of the study,  interfere  with the patient’s  participation for the full duration 
of the study, or is not in the best interest of the patient to participate, in the opinion of the 
treating Investigator, including, but not limited to:  
• History  of immune deficiencies  or autoimmune  disease (see Appendix  3 for complete 
list) 
• Myocardial infarction or arterial thromboembolic events within 6 months prior to enrollment  or severe or unstable angina,  New York Heart  Association (NYHA)  Class  III 
(see Appendix I) or IV disease, or a QTc interval > 470 msec.  
• Uncontrolled hypertension or diabetes  mellitus.  
• Another  known malignancy  that is progressing or requires  active treatment  (excluding 
adequately treated basal cell carcinoma or cervical intraepithelial neoplasia [CIN]/cervical carcinoma in situ or melanoma in situ ). Prior history of other cancer is 
allowed, as long as  there is no active disease within the prior 5 years.  
• Active infection requiring systemic therapy.  
• Known active central  nervous  system (CNS)  metastases  and/or  carcinomatous 
meningitis. (see inclusion criterion 5)  
5. Any contraindication to oral agents  or significant  nausea and vomiting,  malabsorption,  or 
significant small bowel resection that, in the opinion of the investigator, would preclude adequate absorption.  
6. Received a live vaccine within 30 days of the first dose of treatment (inactivated forms of influenza vaccinations  can be given during influenza season only (approximately  October  to 
March in the Northern hemisphere and April to September in the Southern Hemisphere).  
7. Prior  anti-cancer  monoclonal  antibody  (mAb) within  4 weeks  prior to study  enrollment  or who 
has not recovered (i.e., ≤Grade 1 at enrollment) from AEs due to mAb agents administered 
more than 4 weeks earlier.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  54 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
8. Prior  chemotherapy  within  3 weeks,  targeted small  molecule therapy  or radiation therapy 
within 2 weeks prior to study enrollment or who has not recovered (i.e., ≤Grade 1 at 
enrollment) from AEs due to a previously administered agent. 
Note:  Patients  with ≤Grade  2 neuropathy  or ≤Grade  2 alopecia are an exception to this 
criterion and may qualify for the study. 
9. Receive d transfusion of blood products (including platelets or red blood cells) or 
administration of colony  stimulating  factors  (including granulocyte -colony  stimulating  factor 
[G-CSF], granulocyte macrophage- colony stimulating factor [GM -CSF], or recombinant 
erythropoietin) within 4 weeks prior to the first dose of treatment.  
10. Currently participating and receiving study therapy or has participated in a study of an 
investigational agent  and received study  therapy  or used an investigational  device within  4 
weeks of the first dose of study drug.  
11. Currently  receiving treatment  with any other  agent  listed  on the prohibited medication list 
(protocol section 9.12) 
12. If female,  is pregnant,  breastfeeding,  or expecting  to conceive  starting with the screening 
visit through 120 days after the last dose of study drug. 
13. Known history  of human  immunodeficiency  virus  (HIV)  (HIV 1/2 antibodies).  
14. Known active hepatitis B (e.g., hepatitis B surface antigen- reactive) or hepatitis C (e.g., 
hepatitis C virus ribonucleic acid [qualitative]). Patients with past hepatitis B virus (HBV) infection or resolved HBV infection (defined as the presence of hepatitis B core antibody 
[HBc  Ab] and absence of HBsAg)  are eligible.  HBV DNA  test must  be performed  in these 
patients prior to randomization. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.  
15. Allergy  to benzamide or inactive components  of entinostat.  
16. History  of allergies  to any active or inactive  ingredients  of atezolizumab.  
17. Known psychiatric  or substance abuse  disorders  that would  interfere with cooperation with 
the requirements of the study.  

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  55 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
8. PATIENT  ENROLLMENT  
 
Section 15.3 describes  documentation required prior to the commencement  of study  enrollment . 
 
The screening period for a particular patient commences on the date on which the patient signs 
the informed consent  form.  The consent  form must  be signed before  any study -specific  tests  are 
performed.  
In Phase 1b, after a patient has been screened and successfully fulfills all eligibility criteria, a site representative will send a registration/enrollment form to the appropriate TRIO representative.  A patient identification (ID) number will be provided to the site and the patient 
will be created in the electronic data capture (EDC) system. The site will then enter complete screening data. Once the screening data have been manually reviewed by TRIO, and the eligibility confirmed, the site will be informed via form, that the patient is eligible to be enrolled into the study  at a determined Entinostat  dose.  If the patient  is not eligible,  the site will again be 
informed, via form and asked to indicate screen failure into the EDC system. This patient ID must be used on all study documentation related to that patient.  
In the Phase  2 portion  of the study,  an automated  system will randomize  the patient  to one of 
the blinded study arms. Refer to the Study Manual for details on this procedure.  

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  56 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
9. TREATMENT  PROCEDURES  
 
9.1 Study Drugs 
The study  drugs  being studied in combination during this clinical trial are atezolizumab and 
entinostat. First Study treatment  is to be administered within 3 business days of 
enrollment/randomization into the study.  
The Investigator shall take responsibility for maintaining appropriate records and ensuring 
appropriate  supply,  storage,  handling,  distribution,  and usage of study  drug, in accordance with 
the protocol and any applicable laws and regulations.  
9.2 Entinostat  
 
9.2.1  Supply and Storage 
 
Entinostat  is a synthetic small molecule bearing the chemical name 3- Pyridylmethyl N -{4-[(2- 
aminophenyl)carbamoyl]benzyl}carbamate and the molecular formula C 21H20N4O3, with a 
molecular weight of 376.41. Entinostat is classified as an antineoplastic agent, specific ally 
functioning as an inhibitor of histone deacetylases that promotes hyperacetylation of nucleosomal histones,  allowing  transcriptional activation of a distinct  set of genes  that leads  to 
the inhibition of cell proliferation, induction of terminal differ entiation, and/or apoptosis. 
Entinostat/placebo is an oral drug  supplied by Syndax to the sites as pink to light red (1 mg) or 
yellow (5 mg) as polymorph B coated tablets. Each tablet contains mannitol, sodium starch glycolate, hydroxypropyl cellulose, potassium bicarbonate, and magnesium stearate as inert 
fillers.  The film coating consists  of hypromellose,  talc, titanium  dioxide,  and ferric  oxide pigments 
(red and yellow) as colorants.  
Entinostat/placebo is to be stored  at controlled room  temperature  (15ºC  to 25ºC  / 59ºF to 77ºF ) 
in a secure, locked storage area to which access is limited.  
Entinostat/placebo is to be protected from light. Entinostat/placebo is not to be exposed to 
extremes  of temperature  (greater  than 30ºC  / 86°F  or less than 5ºC / 41°F).  The pharmacist  will 
dispense the investigational  material  to the patient  at appropriate intervals  throughout  the study 
in childproof containers.  
Entinostat/placebo will be supplied to patients  in bottles  containing  enough pills for a 3-week 
cycle, plus an additional dose in case tablets are lost.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  57 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
Please refer to the Pharmacy  Manual  for complete details  regarding supply,  storage 
accountability and destruction Entinostat. 
 
9.2.2  Dosing and Administration 
 
All patients  will self-administer  entinostat/placebo  PO once  weekly  on study  days  1, 8 and 15 of 
each 21 day cycle. A new bottle of entinostat/placebo will be dispensed  on day 1 of each  cycle, 
regardless of the number of pills remaining in the bottle from the previous cycle. 
On study  days  on which  patients  receive both entinostat/placebo and atezolizumab, 
entinostat/placebo is to be taken prior to atezolizumab. 
Entinostat/placebo is to be taken on an empty  stomach,  at least  2 hours  after a meal  and at 
least 1 hour before the next meal.  
If an entinostat/placebo dose is missed, it may be taken up to 48 hours after the scheduled 
dosing time.  If it is not taken  within  the 48 hour window,  the dose should  not be taken  and will 
be counted as a missed dose. The patient should take the next scheduled dose per protocol. Missed doses should be noted as such on the patient drug diary and in the eCRF.  
If entinostat/placebo is vomited,  dosing should not be re-administered but instead the dose 
should be skipped.  
9.2.2.1  Phase 1b 
During the Phase 1b Dose Determination Phase,  all patients  will receive  atezolizumab 1200 mg 
IV on D1 of each 21 day cycle. They will also receive entinostat orally weekly on days 1, 8 and 15 of each cycle at either  5 mg, 3 mg or 2 mg. Both drugs  will be given in an open- label  fashion.  
Patients  who discontinue from the study  treatment  for reasons  other  than study  drug- related 
toxicity before completing C1 may be replaced (refer to section 9.4). 
9.2.2.2  Phase 2 
During the Phase 2 Dose Expansion Phase, all patients will receive atezolizumab 1200 mg IV on D1 of each  21 day cycle. They  will also receive the RP2D of entinostat  or matched placebo 
weekly on days 1, 8 and 15 or  each cycle. Entinostat/placebo will be given in double blind 
fashion.  
Any det
ected  cumulative  toxicity  may require  later dose reductions  and/or  other  changes  to the 
dosing schedule, as appropriate, including further refinement of the RP2D.  

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  58 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
9.3 Atezolizumab 
 
9.3.1  Supply and Storage 
 
Atezolizumab is a humanized monoclonal antibody  that blocks  the interaction between PD-1 
and its ligands, PD -L1 and PD -L2. Atezolizumab is an IgG4 kappa immunoglobulin with an 
approximate molecular weight of 149 kDa.  
Atezolizumab drug product  is provided in a single -use, 20-mL USP/PH.  Eur. Type  1 glass  vial 
as a colorless -to-slightly -yellow, sterile, preservative- free clear liquid solution intended for IV 
administration.  The vial is designed to deliver 20 mL (1200 mg) of atezolizumab solution but 
may contain more  than the stated  volume to enable delivery  of the entire 20-mL volume.  The 
atezolizumab drug product is formulated as 60 mg/mL of atezolizumab in 20 mM histidine 
acetate, 120 mM sucrose, 0.04% polysorbate 20, pH 5.8.  
Atezolizumab must be refrigerated at 2°C−8°C (36°F−46°F) upon receipt until use. Atezolizumab vials should not be used beyond the expiration date provided by the 
manufacturer.  No preservative is used  in the atezolizumab drug product;  therefore,  each  vial is 
intended for single use only. Vial contents should not be frozen or shaken and should be 
protected from direct s unlight.  
Atezolizumab is supplied by Syndax  to the sites and is given intravenously.  
 
9.3.2  Dosing and Administration 
 
The dose level of atezolizumab in this study  is 1200 mg administered by IV infusion q3w. 
 
Administration  of atezolizumab will be performed  in a setting with emergency  medical  facilities 
and staff who are trained to monitor for and respond to medical emergencies.  
The initial dose of atezolizumab will be delivered over 60 ( ± 15) minutes. If the first infusion is 
tolerated without  infusion -associated adverse events,  the second infusion may be delivered  over 
30 (± 10) minutes.  If the 30- minute infusion is well tolerated, all subsequent infusions may be 
delivered over 30 ( ± 10) minutes, otherwise it should be delivered over 60 (±15) minutes. The 
patient’s vital signs (heart rate, respiratory rate, blood pressure, and temperature) should be determined no more than 60 minutes before each atezolizumab infusion. Vital signs should also be obtained during or after the atezolizumab infusion if clinically indicated.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  59 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
No premedication will be allowed  for the first dose of atezolizumab.  Premedication may be 
administered for subsequent infusions at the discretion of the treating physician after 
consultation with the Medical Monitor.  
Any overdose  or incorrect  administration  of study  drug should  be noted on the Study  Drug 
Administration electronic  eCRF.  Adverse events  associated  with an overdose or incorrect 
administration of study drug should be recorded on the Adverse Event eCRF.  
Refer  to the Pharmacy  Manual  for complete details  regarding supply,  storage,  accountability, 
and destruction of Atezolizumab. 
9.4 Study Drug(s)  Accountability  
The lot number(s)  of the study  drugs  (entinostat  and atezolizumab)  received at the site are to be 
recorded on the Drug Accountability Log maintained by the pharmacist. Additional distribution and return information will also be recorded at the site.  
Patient  medication  instructions  and dosing  diaries  will be provided to the patient  for purposes  of 
recording entinostat/placebo self -administration.  
9.5 Entinostat  Compliance  
Treatment compliance to entinostat will be assessed at the end of each cycle. Patients will complete a diary to document their weekly intakes. They will be instructed to return all unused drugs (partially used and empty containers) and their diary at each visit. Site staff will perform accountability of the returned drug and will assess patient compliance.  Site staff must ensure 
that the patient  clearly  understands  the directions  for self-medication  and follows  the schedule.  
9.6 Dose- limiting  Toxicity  
In the Dose -Determination  Phase,  DLTs  will be assessed during the DLT assessment window, 
which is defined as the first cycle of treatment. The DLT assessment window (Cycle 1) is the time period between C1D1 until C2D1 (expected to be 21 days after C1D1). 
In addition,  the total dose of entinostat  received  over the first two cycles has to be evaluated  as 
it corresponds to one of the DLT criteria.  
A patient  will be considered DLT evaluable if she: 
 
• Incurs  an adverse  event  meeting DLT criteria  during Cycle  1 
Or 
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  60 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
• Completes  Cycle  1 and receives  the full dose of atezolizumab  and all doses  of entinostat 
during this cycle, without incurring a DLT. In case a patient would not begin Cycle 2 for 
reasons other than a DLT, she would be considered DLT evaluable if she receives all planned doses  of entinostat  and atezolizu mab during cycle 1 and completes  7 days  after 
C1D15 without incurring a DLT.  
Patients  who are not considered DLT evaluable may be replaced  to complete a cohort.  
 
DLT is defined as the occurrence  of any of the following  events  within  the DLT Assessment  
window  that are considered by the Investigator to be at least possibly related to study drug: 
• Grade  5 events  
• Grade  ≥ 4 neutropenia (ANC  < 500/ µL) lasting  ≥ 7 days 
• Grade  ≥ 3 febrile  neutropenia  
• Grade ≥ 4 thrombocytopenia lasting  > 48 hours  
• Grade ≥ 4 anemia 
• Grade  ≥ 4 rash (cont’d  on next page)  
• Grade  ≥ 3 symptomatic  hepatic  toxicities  that do not resolve  to Grade ≤ 2 within  
48 hour s  or Grade ≥ 3 asymptomatic  hepatic  toxicities  that do not resolve  to Grade ≤ 1 
within 3 weeks of onset with the following exception: 
o For patients  with Grade  2 AST,  ALT,  and/or  alkaline  phosphatase  abnormality  at 
enrollment, an increase to >  10 × the upper limit of normal (ULN) that does not 
resolve to Grade  ≤ 2 within  48 hours (if symptomatic) or that does not resolve to 
Grade  ≤ 1 within 3 weeks of onset (if asymptomatic) will be considered a DLT.  
• Grade ≥ 3 non-hematologic,  non-hepatic  organ  toxicity, with the following  exceptions:  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  61 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
o Grade  3 immune- related  adverse  event  that resolves  to Grade  ≤ 1 within  3 weeks 
of its onset  
o Grade 3 nausea  or vomiting  that resolves  to Grade  ≤ 1 within  72 hours  of 
appropriate supportive therapy  
o Grade  ≥ 3 fatigue that resolves  to Grade ≤ 2 within  7 days 
o Grade  3 arthralgia that can be adequately  managed with supportive care or that 
resolves to Grade ≤  2 within 7 days  
o Grade  3 fever  (in the absence of any clinically  significant  source of fever)  that 
resolves to Grade ≤  2 within 7 days with supportive care  
o Grade ≥ 3 laboratory  abnormality  that is asymptomatic  and deemed by the 
investigator not to be clinically significant  
o Grade 3 autoimmune thyroiditis  or other  endocrine abnormality  that can be 
managed by endocrine therapy or hormonal replacement  
o Grade  3 tumor  flare defined as local pain,  irritation,  or rash localized  at sites of 
known or suspected tumor  
o Grade  3 infusion reaction that resolves  within  6 hours  to Grade ≤ 1 
• Inability  to receive all 3 doses  of entinostat  during the first cycle  
In addition,  the inability  to receive  greater  than 60% of the planned entinostat  dose  during  the 
first 2 cycles, will also be considered a DLT.  
All DLTs will be reported on the AE eCRF in the EDC system within 24 hours.  All DLTs will be 
considered adverse events  of special  interest  for this protocol  and will be reported  to TRIO  in an 
expedited manner. Please see Protocol Section 1 2.4 and also refer to the Adverse Event 
Reporting Procedures in the Study Manual. 
Patients who experience a DLT will be allowed to remain on study if they meet the following 
criteria: (1) the investigator  believes  it is appropriate for patients  to remain  on study  (2) the event 
has resolved and no longer meets the definition of DLT and (3) the timeline for resolution falls 
within the guidelines for dose delays ( Section 9.10). 
9.7 Maximum  Tolerated  Dose  
MTD  is defined as the highest  dose  level at which  <33%  of 6 patients  experience DLT. 
 
9.8 Recommended  Phase 2 Dose  
The RP2D will be equal to or less than the preliminary MTD. The RP2D will be determined in 
discussion with the Sponsor, Medical Monitor, and Dose Determination Phase Investigators. Additionally,  observations  related  to immune  correlates,  and any cumulative toxicity  observed 
after multiple cycles may be included in the rationale supporting the RP2D.  

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  62 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
9.9 Treatment  Duration  
The duration of treatment for this study is expected to be 1 year. Patients may remain on study 
until unequivocal progressive disease, unacceptable toxicity, or another treatment withdrawal criteria is met per Protocol Section 11. Study patients with evidence of radiological progressive 
disease who meet the criteria set forth in Protocol Section 10.3.2 for “Treatment After Initial 
Radiological  Progression”,  should continue treatment  and be followed  according to irRECIST  as 
described in section 10.3.2 . Any questions should be directed to the Medical Monitor.  
If a patient  permanently  discontinues  either  study  drug (entinostat/placebo  or atezolizumab),  the 
patient will be taken off study treatment and followed for progressive disease per protocol guidelines, or overall survival should progressive disease have been previously determined on 
study.  Patients will receive standard of care outside the auspices of this study at the 
Investigator’s discretion.  
After  discontinuation of study  treatment,  patients  will complete an EOT visit within  7 days  (+/- 3 
days) after the last study drug dose and a Safety F/U visit 30 days (+/ - 3 days) th ereafter.  
After completion of the 30- day
  Safety F/U visit, patients who have not  experienced PD are to 
continue to undergo radiological assessments every 6 weeks until study week 36, and then 
every  9 weeks  thereafter  until progressive disease.  The purpose of the post-treatment  follow- up 
is to ascertain the duration of PFS for all patients in the study.  
After they experience PD, surviving patients are to be contacted every 3 -m onths for 
documentation of subsequent  therapies  and survival until closure of the study  or patient  death, 
whichever should occur first.  
9.10 Dose Interruptions  and Modifications 
Although entinostat and atezolizumab have distinct toxicity profiles, they do share some AEs 
such as fatigue and nausea. There is also the possibility that 1 agent may potentiate the other 
and hence  drug causality  will not always  be clear.  In the event  of uncertainty,  dose  reductions  or 
delays will follow the most conservative approach (i.e., delays and/or dose reductions for both drugs) until resolution of the event, or the patient is taken off study. However, if the toxicit y is 
clearly associated with only one of the study drugs, then the other study drug may be continued at the discretion of the study investigator in consultation with the Medical Monitor, until  
resolution of the event or the patient is taken off study.  

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  63 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
Note:  If a patient  permanently  discontinues  either  study  drug (entinostat/placebo or 
atezolizumab), the patient will be taken off study treatment  
No dose reductions  will be performed for atezolizumab.  
 
Guidance for entinostat  delays and or dose reductions can be found in Protocol Section 9.10.1 . 
All dose modifications  should be based  on the AE requiring the greatest  modification  and should 
be properly documented in source documents. Investigators may take a more conservative 
approach than the guidelines outlined in the protocol on the basis of clinical judgment that is in 
the best interest of the subject. Such instances should be reported to the Medical Monitor.  
Expected AEs for each agent  are summarized  in Section 12. 
 
9.10.1  Entinostat  
 
In Phase 1b, dose delays, but not dose reductions will be allowed for entinostat during Cycle 1.  
If a dose  reduction is required during Cycle  1, the patient  will be taken  off study.  Dose  delays  for 
reasons other than toxicities definitely or possibly related to entinostat should be avoided as much as possible during Cycle 1.  
In P
hase  2, both dose  delays  and dose  reductions  will be allowed  as described below.  Once  the 
entinostat  dose is reduced, it cannot be re -escalated.  
9.10.1.1  Non-hematologic  Toxicity  at Least  Possibly Related to Entinostat  
The rules outlined in Table 9- 1 are to be followed for the management of non- hematologic 
toxicities that are definitely or possibly due to entinostat alone, with toxicities graded by the Investigator  according to the NCI, CTCAE,  version  4.03.  Note:  No dose  reduction is allowed 
during the first study treatment cycle in phase 1b.  

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  64 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
        
1  
Table  9-1 Non-hematologic  Toxicity:  Dose Modifications  for Entinostat  
 
Toxicity  Dose modifications  
 
Grade 4 Administer  symptomatic  remedies/  start prophylaxis.  
Hold1 dose P until recovery  to Grade 1 or baseline  under  the following  directions.  
1. If recovered within  4 weeks  of onset  (ie: ≤3 missed  doses)  , resume 
study drug as follows:  
• If receiving  5 mg, restart  study  drug at  3 mg 
• If receiving  3 mg, restart  study  drug at  2 mg 
• If receiving 2 mg, discontinue study  treatment  
2. If dose is held for 4 consecutive  weeks,  permanently  discontinue study 
drug.  
Grade 3 Administer  symptomatic  remedies/  start prophylaxis.  
Hold1 dose P until recovery  to Grade 1 or baseline  under  the following  directions:  
1 If recovered by next scheduled  dose,  resume  study  drug at prior dose.  If 
not recovered by next scheduled dose, continue to hold the dose.  
2 If recovered within  2-4 weeks  (i.e. missed 3 or less doses)  resume  study 
drug as follows:  
• If receiving  5 mg, restart  study  drug at  3 mg. 
• If receiving  3 mg, restart  study  drug at  2 mg. 
• If receiving 2 mg, discontinue study  treatment.  
If dose is held for 4 consecutive  weeks,  permanently  discontinue study 
drug.  
Recurrence of the 
sam
e Grade 3 toxicity 
despite dose reduction  Administer  symptomatic  remedies  / start prophylaxis.  
If receiving  2 mg, permanently  discontinue study  drug.  Otherwise,  hold
1 dose 
until recovery to Grade 1 or baseline.  
1. If recovered within  the next 2 scheduled doses,  resume  study  drug as 
follows:  
• If receiving  5 mg, restart  study  drug at  3 mg 
• If receiving  3 mg, restart  study  drug at  2 mg 
2. If the same ≥Grade  3 event  recurs  (i.e., 3 occurrence)  despite entinostat 
dose reduction to 2 mg, as described above, discontinue study drug.  
 
 
≤Grade 2 Administer  symptomatic  remedies  / start prophylaxis.  
Dosing  of study  drug may be interrupted at  the Investigator’s  discretion,  in 
consultation with the Medical Monitor.  
• If dose is held for 4 consecutive  weeks,  permanently  discontinue study 
drug.1 
• If toxicity  resolves,  resume entinostat  at the original  dose.  
P P  If greater  than 50% of doses  are missed  during any 6 week  period,  discontinue from study  drug treatment.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  65 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
   
9.10.1.2  Hematologic Toxicity  at Least  Possibly Related  to Entinostat  
The guidelines in Table 9- 2 will be followed for determining the timing of cycles based on 
hematologic  status  at the time of planned dosing.  Note:  No dose  reduction is allowed  during the 
first study treatment cycle during phase 1b.  
Table  9-2 Hematologic  Toxicity:  Dose Modification  for Entinostat  
 
Toxici ty P Dose modifications  
 
≥Grade 3 neutropenia,  
≥Grade 3 uncomplicated 
thrombocytopenia, or 
Grade 2 complicated thrombocytopenia 
 
 
 
  
 
 
 
Recurrence of the same  
hematologic  toxicity  Administer  symptomatic  remedies/  start prophylaxis.  
Hold dose1 until recovery  to Grade 1 or study  baseline  using the following 
directions:  
1. If recovered by next scheduled  dose,  resume  study  drug at prior dose.  If 
not recovered by next scheduled dose, hold the dose.  
2. If recovered within  the next  2-4 weeks  (i.e. missed  3 or less doses) 
resume study drug as follows:  
• If receiving  5 mg, restart  study  drug at  3 mg. 
• If receiving  3 mg, restart  study  drug at  2 mg. 
• If receiving  2 mg, permanently  discontinue  study  drug.  
3. If not recovered  within  4 weeks  (i.e. 4 doses  missed),  permanently 
discontinue study drug.  
Administer symptomatic remedies/ start prophylaxis. If receiving 2 mg, 
permanently  discontinue study  drug.  Otherwise,  hold1 dose until recovery  to 
Grade 1 or baseline.  
1. If recovered within  the next 2 scheduled doses,  resume  study  drug as 
follows:  
• If receiving  5 mg, restart  study  drug at  3 mg 
• If receiving  3 mg, restart  study  drug at  2 mg 
2. If the same ≥Grade 3 event recurs (i.e., third occurrence) despite 
entinostat  dose reduction to 2 mg, as described  above,  discontinue study 
drug.  
 
 
 
1 If greater  than 50% of doses  are missed  during any 6 week  period,  discontinue from study  drug treatment.  
 
9.10.2  Atezolizumab 
 
There will be no dose reduction for atezolizumab  in this study.  
 
Patients  may temporarily  suspend  study  treatment  for up to 84 days  beyond the last dose  if they 
experience adverse events  that require  atezolizumab to be withheld.  If atezolizumab is 
withheld because of atezolizumab related adverse events for > 84 days beyond the last dose, 
then the patient  will be discontinued from study  treatment  and will be followed  up for safety 
and efficacy per protocol.  

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  66 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
If, in the judgment of the investigator, the patient is likely to derive clinical benefi t from 
atezolizumab after a hold of >  84 days, and entinostat has been administered per protocol 
during this time,  study  drug may be restarted only with the approval  of the Medical  Monitor.  
As discussed in Protocol  Section 9.12, systemic corticosteroids  should be used to treat immune 
mediated toxicities related to atezolizumab. If a patient must be tapered off steroids used to 
treat adverse events, atezolizumab may be held for additional time beyond 84 days from the 
last dose until steroids are discontinued or reduced to prednisone dose (or dose equivalent)  
≤ 10 mg/day.  The acceptable length of interruption  will depend on an agreement  between the 
investigator  and the Medical Monitor.  
Dose interruptions for reason(s) other than toxicity, such as surgical procedures, may be allowed  with Medical  Monitor  approval.  The acceptable length  of interruption will depend on 
agreement between the investigator and the Medical Monitor .  
9.11 Concomitant  Therapy 
All concomitant treatments and therapies, or medication, including all prescription, over -the- 
counter, herbal supplements, and IV medications and fluids, administered during the 30 days 
preceding the screening study  visit must  be reported in the electronic  case report  form (eCRF). 
If changes  occur during  the study  period,  documentation  of drug dosage,  frequency,  route,  and 
date should also be included on the eCRF. The generic name of the drug (or trade name for 
combination drugs) must be specified along with the route of administration, indication, and duration of treatment.  
Throughout the study, the Investigator may prescribe any concomitant medications or treatments deemed necessary to provide adequate supportive care, such  as potassium  and 
phosphorus  supplements  and antiemetics,  with the exception of those  listed  in Section 9.12. 
No premedication will be allowed for the first dose of atezolizumab.  Premedication may be 
administered for subsequent infusions at the discretion of the treating physician after consultation with the Medical  Monitor.  Patients  must  notify  the Investigator  of all concomitant 
medications taken through completion of the study (30 day follow -up safety  visit).  
Medications or vaccinations specifically prohibited in the exclusion criteria are not allowed 
during the ongoing study ( Section 9.12). If there is a clinical indication for any medication or 
vaccination specifically prohibited during the study, discontinuation from study drug will be 
required.  The Investigator  should  discuss any questions  regarding  this with the Medical  Monitor.  

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  67 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
The final decision on any supportive  therapy  or vaccination rests  with the Investigator  and/or  the 
patient's  primary  physician.  However,  the decision  to continue the patient  on study  drug requires 
the mutual agreement of the investigator, the Medical Monitor and the patient.  
9.12 Prohibited Medication 
The following  medications  are excluded while  the patient  is receiving study  treatment:  
• Any other  HDAC inhibitor,  including valproic  acid 
• DNA  methyltransferase inhibitors  
• Any additional investigational or commercial anticancer agents, such as chemotherapy, 
immunotherapy,  targeted  therapy,  biological  response modifiers,  or endocrine therapy,  will 
not be allowed, even if utilized as treatment of non- cancer indications.  
• Prophylactic  use of hematopoietic  colony  stimulating  factors  are not allowed  during the 
Phase 1b, but can be used per investigator discretion during other parts of the study.  
• Radiation therapy  
Note:  Radiation therapy  to a symptomatic  solitary  lesion  or to the brain may be considered 
on an exceptional case -by-case basis after consultation with the Medical Monitor. The 
radiation field cannot  encompass  a target  lesion.  Radiation to a target  lesion is considered 
progressive  disease and the subject  should be removed  from study  treatment.  The patient 
must have clear measurable disease outside the radiated field. Administration of palliative 
radiation therapy will be considered clinical progression.  
• Traditional  herbal  medicines;  these  therapies  are not fully studied and their use may result  in 
unanticipated drug- drug interactions that may cause or confound the assessment of toxicity  
• RANKL inhibitor (denosumab): patients who are receiving denosumab pri or to 
randomization must  be willing  and eligible  to receive a bisphosphonate instead while  on 
study  
• Immunomodulatory  agents,  including but not limited  to interferons  or IL-2, during the entire 
study; these agents could potentially increase the risk for autoimmune conditions when 
received in combination with atezolizumab  
• Immunosuppressive medications, including but not limited to cyclophosphamide, azathioprine,  methotrexate,  and thalidomide;  these agents  could potentially  alter the activity 
and the safety  of atezolizumab  
• Us
e  of steroids  to premedicate patients  for whom  CT scans  with contrast  are contraindicated 
(i.e., patients with contrast allergy or impaired renal clearance); in such  patients, MRIs of the 
chest, abdomen, and pelvis with a non- contrast CT scan of the chest must be performed  
• Any live, attenuated  vaccine (e.g.,  FluMist) while  the patient  is receiving atezolizumab and 
for a period of 90 days after the discontinuation of atezolizumab  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  68 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
Influenza vaccinations  (inactivated forms  only)  should be given during influenza season only 
(approximately October to March in the Northern hemisphere and April to September in the 
Southern Hemisphere).  
Systemic corticosteroids  and anti−TNF-α agents  may attenuate  potential  beneficial immunologic 
effects of treatment with atezolizumab. If feasible, alternatives to these agents should be considered. Systemic corticosteroids may be administered at the discretion of the treating 
physician in consultation with the Medical  Monitor  at doses  no greater  than 10 mg prednisone or 
for no longer than 7 consecutive days if at higher doses, to treat acute conditions other than 
immune- mediated toxicity  related to study drug.  The use of physiologic doses of corticosteroids  
for prolonged periods may be approved in consultation with the Medical Monitor. Inhaled steroids are allowed for management of asthma or other chronic disorders, as prescribed.  
Patients  should not receive other  immunomodulatory  agents  for 10 weeks  after the last dose  of 
atezolizumab.  
Patients who, in the assessment by the Investigator, require the use of any of the 
aforementioned treatments  for clinical management  should be removed  from the study,  unless 
as otherwise noted. Patients may receive other medications that the Investigator deems to be 
medically necessary.  
The exclusion criteria  (Section 7.2) describe other  medications  that are prohibited in this study.  
 
9.13 Medications  to be Avoided D uring the Study  
Concomitant  use of the drugs  below  with entinostat  should be avoided during the study:  
• Sensitive  substrates  of CYP enzymes  listed  in Appendix  2 
• Drugs  that are known  to inhibit  or induce P- gp (see Appendix  2) 
Should the use of these medications  be required,  the Medical  Monitor  must  be consulted for 
guidance.  
9.14 Management  for Atezolizumab -Specific  Adverse Events 
Toxicities  associated with, or possibly  associated  with atezolizumab treatment,  should be 
managed according to standard medical practice. Additional tests, such as autoimmune 
serology or biopsies, should be used to determine a possible immunogenic etiology.  
Although most immune -mediated adverse events observed with immunomodulatory agents 
have been mild and self-limiting,  such events  should be recognized early  and treated promptly  

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  69 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
to avoid potential major complications.  Discontinuation of atezolizumab may not have an 
immediate therapeutic effect and, in severe cases, immune- mediated toxicities may require 
acute management  with topical  corticosteroids,  systemic corticosteroids,  mycophenolate,  or 
TNF-α inhibitors.  
The investigator should consider the benefit -risk balance for a given patient prior to further 
administration of atezolizumab.  Atezolizumab should be permanently  discontinued in patients 
with life -threatening immune- mediated adverse events.  
For the management  of other  adverse events  associated with the atezolizumab not provided 
below, refer to the Atezolizumab IB.  
 
9.14.1  Pulmonary  Events  
 
Dyspnea,  cough,  fatigue,  hypoxia,  pneumonitis,  and pulmonary  infiltrates  have  been associated 
with the administration of atezolizumab..  Patients will be assessed for pulmonary signs and 
symptoms throughout the study and will also have CT scans of the chest performed at every 
tumor assessment.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  70 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
 Continue  atezolizumab  with close  monitoring 
Re-evaluate on serial imaging  
Consider  pulmonary  consultation  
Withhold  atezolizumab for up to 12 weeks  after event  onset.ª  
Pulmonary  and infectious  disease specialists  consultation and consider 
bronchoscopy or bronchoscopic alveolar lavage (BAL)  
Start treatment with 1 −2 mg/kg/day oral prednisone or equivalent 
When  improves  to Grade 0 or Grade 1, then taper  steroids  over ≥ 1 
month.Atezolizumab  may be resumed if the event  improves  to Grade 0 or Grade 1 b 
If event  does  not resolve  to Grade 1 or better  while  withholding atezolizumab, 
permanently discontinue atezolizumab and contact Medical Monitor c 
Treat  as Grades  3−4 for recurrent  events  
Permanently  discontinue atezolizumab and contact  Medical  Monitor  c 
Bronchoscopy/BAL  is recommended  
Start  treatment  with 1-2 mg/kg/day  oral prednisone  or equivalent  
Taper  steroids  over ≥ 1 month after symptoms  improve to Grade 0 or Grade 1 
If not improving  within  48 hoursafter  initiating  corticosteroids,  consider  adding an 
immunosuppressive agent  • 
Grades  3−4 • 
• 
• 
• 
• • 
• 
• 
• 
• 
 
• 
• 
 
• Grade  1 
 
 
 
Grade  2 Management  Severity   
All pulmonary events should be evaluated thoroughly for other commonly reported etiologies 
such as pneumonia/infection,  lymphangitic  carcinomatosis,  pulmonary  embolism,  heart  failure, 
chronic obstructive pulmonary disease, or pulmonary hypertension. by the following means:  
Measurement  of oxygen saturation (i.e., arterial  blood gas) 
Bronchoscopy with bronchoalveolar lavage and biopsy  
Pulmonary  function tests  (diffusion  capacity  of the lung for carbon monoxide [DL CO]) 
Pulmonary function testing with a pulmonary embolism protocol  
Table  9-3 Management  Guidelines for Pulmonary Events,  Including Pneumonitis  
 
 
a Atezolizumab may be withheld for a longer  period of time (i.e., > 12 weeks  after event  onset)  to allow 
for corticosteroids (if started) to be reduced to ≤  10 mg/day oral prednisone or equivalent.  The 
acceptable length of the extended period of time must be agreed upon by the investigator and the 
Medical Monitor.  
b If corticosteroids  have been  started,  they must  be tapered over ≥ 1 month to ≤ 10 mg/day  oral 
prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of  atezolizumab may be considered in patients  who are deriving  benefit  and have fully 
recovered from the immune -related event.  Patients can be re- challenged with atezolizumab only 
after approval has been documented by both the investigator (or an appropriate delegate) and the 
Medical Monitor.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  71 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
9.14.2  Hepatic  Events 
 
Immune- mediated hepatitis has been associated with the administration of atezolizumab. 
Eligible  patients  must  have  adequate liver function,  as manifested  by measurements  of total 
bilirubin and hepatic transaminases, and liver function will be monitored throughout study 
treatment.  
While in this study, patients who present with right upper -quadrant abdominal pain and/or 
unexplained nausea or vomiting  should have liver function tests  (LFTs)  performed immediately 
and reviewed before administration of the next dose of study drug. 
If LFTs increase, concurrent medications, viral hepatitis, and toxic or neoplastic etiologies 
should be considered  and addressed,  as appropriateImaging of the liver, gall bladder,  and 
biliary  tree should be performed  to rule out neoplastic  or other  causes  for increased  LFTs. 
Anti-nuclear antibody, perinuclear anti -neutrophil cytoplasmic antibody, anti -liver kidney 
microsomal antibodies,  and anti −smooth muscle antibody tests should be performed if an 
autoimmune etiology is considered. 
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  72 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
Table  9-4 Management  Guidelines  for Hepatic Events 
Severity  Management  
Grade 1 •  Continue atezolizumab  
• Continue LFT monitoring until values  resolve  to within  normal  limits  
Grade 2 All Events:  
• Monitor  LFTs  at least  twice  a week  until return  to baseline values  
Events  of > 5 days’  duration: 
• Withhold  atezolizumab  for up to 12 weeks  after event  onset.  a 
• Initiate  treatment  with 1−2 mg/kg/day  oral prednisone or equivalent.  
• If event  resolves  to Grade  0 or Grade 1, resume  atezolizumab  b 
• If corticosteroids  have  been  started,  they must  be tapered over ≥ 1 month  to 
≤ 10 mg/day  oral prednisone or equivalent  before  atezolizumab can be 
resumed.  
• If event does not resolve to Grade 0 or Grade 1 while withholding 
atezolizumab,  permanently  discontinue atezolizumab and contact  Medical 
Monitor  c 
• If persists >  5−7 days:  withhold therapy and start 60 mg prednisone or 
equivalent  per day;  when LFTs are ≤  Grade 1, taper  steroids over  ≥ 1 month, 
resume therapy  if the event  improves  to Grade 0 or Grade 1 within  12 weeks 
and systemic steroid dose is ≤  10mg oral prednisone equivalent per day.  
Grades  3−4 •  Permanently  discontinue  atezolizumab  and contact  Medical  Monitor.  c 
• Consider  gastrointestinal  (GI) specialist  consult  and liver biopsy  to establish 
etiology of hepatic injury  
• Start  1-2 mg/kg/day  oral prednisone or equivalent  
• If event  does  not improve within  48 hours  after initiation  of corticosteroids, 
consider adding an immunosuppressive agent  
• Taper  steroids  over ≥ 1 month,  when  symptoms  improve to Grade 0 or Grade 1 
a Atezolizumab may  be withheld  for a longer  period of  time (i.e., > 12 weeks  after event  onset)  to 
allow  for corticosteroids  (if started)  to be reduced to ≤ 10 mg/day  oral prednisone or equivalent. 
The acceptable length of the extended period of time must be agreed upon by the investigator 
and the Medical Monitor.  
b If corticosteroids  have been  started,  they must  be tapered over ≥ 1 month to ≤ 10 mg/day  oral 
prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and have 
fully recovered  from the immune- related  event.  Patients  can be rechallenged with  atezolizumab 
only after approval has been documented by both the investigator (or an appropriate delegate) 
and the Medical Monitor.  
 
 
9.14.3  Gastrointestinal  Events  
 
Immune- mediated  colitis  has been associated with the administration of atezolizumab.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  73 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
All events of diarrhea or colitis should be thoroughly evaluated for other more common 
etiologies.  If the event is of significant duration or magnitude or is associated with signs of 
system ic inflammation or acute phase reactants (e.g., increased C -reactive protein, platelet 
count,  or bandemia),  perform  sigmoidoscopy  (or colonoscopy,  if appropriate)  with colonic  biopsy 
with three to five specimens for standard paraffin block to check for inflammation and lymphocytic infiltrates for confirmation of the diagnosis of colitis.  
Perform  laboratory  tests  to rule out alternate etiology  (i.e., WBCs  and stool  calprotectin).  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  74 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
Table  9-5 Management  Guidelines  for Gastrointestinal  Events (Diarrhea/Colitis)  
Severity  Management  
Grade 1 •  Continue atezolizumab  
• Symptomatic  treatment  
• Endoscopy  is recommended if symptoms  persist  for greater  than 7 days 
• Close  monitoring  
Grade 2 • Withhold  atezolizumab for up to 12 weeks  after event  onset  a 
• Symptomatic  treatment  
• GI consultation  recommended  
• If persists  > 5 days  or recurs  start oral prednisone 1-2 mg/kg/day  or equivalent  
• Taper  steroids  over ≥ 1 month  when symptoms  improve  to Grade 0 or Grade  1 
• may be resumed if the event  improves  to Grade 0 or Grade  1b 
• If event does not resolve to Grade 0 or Grade 1 while withholding 
atezolizumab,  permanently  discontinue atezolizumab and contact  Medical 
Monitor  c 
Grade 3 • Withhold  atezolizumab for up to 12 weeks  after event  onset  a 
• GI referral  and confirmation  biopsy  
• Start treatment with IV steroids 1− 2 mg/kg/day methylprednisolone or 
equivalent  and convert  to 1-2 mg/kg/day  oral prednisone or equivalent  after 
improvement  
• When  improves  to Grade  0 or Grade  1, then taper  steroids  over ≥ 1 month.  
• may be resumed if event  improves  to Grade 0 or Grade  1b 
• If event  does  not resolve  to Grade 1 or better  while  withholding atezolizumab, 
permanently discontinue atezolizumab and contact Medical Monitor  c 
Grade 4 •  Permanently  discontinue  atezolizumab and contact  Medical  Monitor  c 
• GI referral  and confirmation  biopsy  
• Start treatment with IV steroids 1− 2 mg/kg/day methylprednisolone or 
equivalent  and convert  to 1-2 mg/kg/day  oral prednisone or equivalent  after 
improvement  
• When  patient’s  diarrhea or colitis  improves  to Grade 0 or Grade 1, then taper 
steroids over ≥  1 month  
• If not improving  within  48 hours  of initiating  corticosteroids,  consider  adding an 
a immunosuppressive agent  
IV = intravenous  
a Atezolizumab may be withheld for a longer  period of time (i.e., > 12 weeks  after event  onset)  to allow 
for corticosteroids (if initiated) to be reduced to ≤  10 mg/day oral prednisone or equivalent.  The 
acceptable length of the extended period of time must be agreed upon by the investigator and the 
Medical Monitor.  
b If corticosteroids have been initiated, they must be tapered over ≥  1 month to ≤  10 mg/day oral 
prednisone or equivalent before atezolizumab can be resumed.Resumption of atezolizumab may be 
considered in patients who are deriving benefit and have fully  recovered from the immune -related 
event.  Patients  can be rechallenged with atezolizumab only  after approval  has been  documented by 
both the investigator (or an appropriate delegate) and the Medical Monitor  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  75 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
9.14.4  .Endocrine Events 
 
Thyroid disorders,  adrenal  insufficiency,  diabetes  mellitus  and pituitary  disorders  have  been 
associated with the administration of atezolizumab.  
Patients with unexplained symptoms such as headache, fatigue, myalgias, impotence, mental 
status changes, or constipation should be investigated for the presence of thyroid, pituitary, or 
adrenal endocrinopathies. An endocrinologist should be consulted if an endocrinopathy is 
suspected.  Thyroid- stimulating hormone (TSH) and free triiodothyronine (T3) and thyroxine 
(T4) levels  should  be obtained to determine  whether  thyroid  abnormalities  are present.  Pituitary 
hormone levels and function tests (e.g. TSH, growth hormone, luteinizing hormone , follicle - 
stimulating hormone, testosterone, prolactin, adrenocorticotropic hormone [ACTH] levels and ACTH stimulation test) and magnetic resonance imaging (MRI) of the brain (with detailed pituitary sections) may help to differentiate primary adrenal insufficiency from primary pituitary 
insufficiency.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  76 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
Table  9-6 Management  Guidelines  for Endocrine  Events  
Severity/Event  Management  
Asymptomatic 
hypothyroidism  • Continue atezolizumab  
• Start  thyroid  replacement  hormone 
• Monitor  TSH weekly  
• Withhold  atezolizumab.  
• Start  thyroid  replacement  hormone 
• Monitor  TSH weekly  
• Consider  referral  to an endocrinologist.  
• Restart  atezolizumab  when symptoms  are controlled  andthyroid  function is 
improving  
If serum TSH ≥ 0.1 mU/L and < 0.5mU/L:  
• Continue atezolizumab.  
• Monitor  TSH every  4 weeks 
TSH < 0.1 mU/L:  
Follow  guidelines  for symptomatic  hyperthyroidism  
• Withhold  atezolizumab  
• Initiate  treatment  with anti-thyroid drug such  as methimazole or carbimazole as 
needed  
• Consider  referral  to an endocrinologist  
• Restart  atezolizumab  when symptoms  are controlled  by thyroid replacement  and 
thyroid function is improving 
• Permanently  discontinue atezolizumab and contact  Medical  Monitor  for 
life-threatening immune- related hyperthyroidism c  
Symptomatic hypothyroidism  
 
 
Asymptomatic 
hyperthyroidism  
 
 
Symptomatic hyperthyroidism  
Symptomatic  • Withhold  atezolizumab for up to 12 weeks  after event  onset  a 
• Refer  patient  to endocrinologist  
• Perform  appropriate imaging 
• Initiate  treatment  with 1−2 mg/kg/day  IV methylprednisolone or equivalent  and 
convert to 1− 2 mg/kg/day oral prednisone or equivalent upon improvement  
• If event  resolves  to Grade  0 or Grade 1 and patient  is stable on replacement 
therapy, resume atezolizumab b 
• If event does not resolve to Grade 0 or Grade 1 or patient is not stable on replacement  therapy  while  withholding atezolizumab,  permanently  discontinue 
atezolizumab and contact Medical Monitor  
c adrenal  
insufficiency, 
Grade 2− 4 
Hyperglycemia 
Grade 1 or 2  • Continue atezolizumab  
• Start  treatment  with insulin  if needed  
• Monitor  for glucose control  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  77 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
Table  9-6 Management  Guidelines  for Endocrine  Events  
Hyperglycemia,  • Withhold atezolizumab 
Grade 3 or 4  • Start  treatment  with insulin  
• Monitor  for glucose control  
• Resume  atezolizumab when  symptoms  resolve  and glucose levels  are stable  
Hypophysitis  • Withhold  atezolizumab for up to 12 weeks  after event  onset  a 
pan- • Refer  patient  to endocrinologist  
hypopituitarism),  • Perform brain MRI (pituitary  protocol) Grade 2-3 
• Start  treatment  with 1−2 mg/kg/day  IV methylprednisolone or equivalent  and 
convert  to 1−2 mg/kg/day  oral prednisone  or equivalent  upon improvement  a 
• Initiate  hormone replacement  therapy  if clinically  indicated  
• If event  resolves  to Grade 0 or Grade  1, resume atezolizumab b 
• If event does not resolve to Grade 0 or Grade 1 while withholding 
atezolizumab,  permanently  discontinue atezolizumab and contact  Medical 
Monitor  c 
• For recurrent  hypophysitis,  treat as a Grade 4 event  
Hypophysitis  • Permanently  discontinue  atezolizumab  and contact  Medical  Monitor  c 
(pan- • Refer  patient  to endocrinologist. hypopituitarism),  
Grade 4 • Perform  brain  MRI (pituitary  protocol)  
• Start  treatment  with 1−2 mg/kg/day  IV methylprednisolone or equivalent  and 
convert  to 1−2 mg/kg/day  oral prednisone or equivalent  upon  improvement  a 
• Initiate  hormone replacement  therapy  if clinically  indicated  
IV = intravenous;  TSH = thyroid stimulating hormone;  MRI = magnetic  resonance imaging;  
a Atezolizumab may be withheld for a longer  period of time (i.e., > 12 weeks  after event  onset)  to allow 
for corticosteroids (if initiated) to be reduced to ≤  10 mg/day oral prednisone or equivalent.  The 
acceptable length of the extended period of time must be agreed upon by the investigator and the 
Medical Monitor.  
b If corticosteroids  have been  initiated, they must  be tapered over ≥ 1 month to ≤ 10 mg/day  oral 
prednisone or equivalent before atezolizumab can be resumed.  
C Resumption of atezolizumab may be considered in patients who are deriving benefit and have fully 
recovered from the immune -related event.  Patients  can be rechallenged with atezolizumab only after 
approval  has been documented by both the investigator  (or an appropriate delegate)  and the Medical 
Monitor.  
 
 
9.14.5  Ocular  Events 
 
An ophthalmologist  should evaluate visual  complaints  (e.g.,  uveitis,  retinal  events ). 
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  78 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
 • Permanently  discontinue  atezolizumab  and contact  Medical  Monitor  c 
• Refer  patient  to ophthalmologist  
• Initiate  treatment  with 1−2 mg/kg/day  oral prednisone or equivalent  
• If event  resolves  to Grade  0 or Grade  1, taper  corticosteroids  over ≥ 1 month  Grade  3 or 
4 Continue  atezolizumab  
Evaluation  by an ophthalmologist  is strongly  recommended  
Treat  with topical  corticosteroid eye drops  and topical  immunosuppressive 
therapy  
If symptoms  persist,  treat as a Grade 2 event  
Withhold  atezolizumab for up to 12 weeks  after event  onset  a 
Patient  referral  to ophthalmologist  is strongly  recommended  
Start  treatment  with topical  corticosteroid eye drops  and topical 
immunosuppressive therapy  
• If event  resolves  to Grade 0 or Grade  1, resume atezolizumab b 
• If event  does  not resolve  to Grade 0 or Grade 1 or better  while  withholding 
atezolizumab, permanently discontinue atezolizumab  and contact  Medical 
Monitor  c • 
• 
• 
• Grade  2 • 
• 
• Grade  1 Management  Severity   
Table  9-7 Management  Guidelines  for Ocular  Events 
 
a Atezolizumab may be withheld for a longer  period of time (i.e., > 12 weeks  after event  onset)  to allow 
for corticosteroids (if initiated) to be reduced to ≤  10 mg/day oral prednisone or equivalent.  The 
acceptable length of the extended period of time must be agreed upon by the investigator and the 
Medical Monitor.  
b If corticosteroids  have been  initiated, they must  be tapered over ≥ 1 month to ≤ 10 mg/day  oral 
prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and have fully 
recovered from the immune -related event.  Patients  can be rechallenged with atezolizumab only after 
approval  has been documented by both the investigator  (or an appropriate delegate)  and the Medical 
Monitor.  
 
9.14.6  Immune- Related  Myocarditis  
Immune- related myocarditis has been associated with the administration of atezolizumab. 
Immune- related myocarditis should be suspected in any patient presenting with signs or 
symptoms suggestive of myocarditis, including, but not limited to, dyspnea, chest pain, 
palpitations,  fatigue,  decreased exercise tolerance,  or syncope.  Immune -related myocarditis 
needs to be  distinguished from myocarditis resulting from infection (commonly viral, e.g.  in a 
patient who reports a recent history of gastrointestinal illness), ischemic events, underlying 
arrhythmias, exacerbation of pre -existing cardiac conditions, or progression of malignancy.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  79 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
All patients with possible myocarditis should be urgently evaluated by performing cardiac 
enzyme assessment, an ECG, a chest X -ray, an echocardiogram, and a cardiac MRI as 
appropriate per institutional guidelines. A cardiologist should be consulted. An endomyocardial 
biopsy  may be considered to enable a definitive  diagnosis  and appropriate treatment, if clinically 
indicated.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  80 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
Table  9-8 Management  Guidelines  for Immune- Related Myocarditis  
 
Severity  Management  
Grade 1 • Refer  patient  to cardiologist  
• Start  treatment  as per institutional guidelines  
Grade 2 • Withhold  atezolizumab for up to 12 weeks  after event  onset  a 
and contact  Medical  Monitor  
• Refer  patient  to cardiologist  
• Initiate treatment as per institutional guidelines and consider 
antiarrhythmic  drugs,  temporary  pacemaker,  ECMO,  or VAD as 
appropriate  
• Consider  treatment  with 1−2 mg/kg/day  IV methylprednisolone 
or equivalent  and convert  to 1−2 mg/kg/day  oral prednisone or 
equivalent upon improvement a 
• If event  resolves  to Grade 0 or Grade  1, resume atezolizumab b 
• If event  does  not resolve  to Grade 0 or Grade 1 while 
withholding atezolizumab, permanently discontinue atezolizumab and contact Medical Monitor  
c 
Grade 3-4 • Permanently  discontinue atezolizumab and contact  Medical 
Monitor  c 
• Refer  patient  to cardiologist  
• Initiate treatment as per institutional guidelines and consider antiarrhythmic  drugs,  temporary  pacemaker,  ECMO,  or VAD as 
appropriate  
• Initiate  treatment  with 1−2 mg/kg/day  IV methylprednisolone or 
equivalent and convert to 1 −2 mg/kg/day oral prednisone or 
equivalent upon improvement  
a,b 
• If event does not improve within 48 hours after initiating corticosteroids,  consider  adding an immunosuppressive agent  
• If event  resolves  to Grade 0 or Grade 1, taper  corticosteroids 
over ≥ 1 month  
ECMO  = extracorporeal  membrane oxygenation;  VAD = ventricular  assist  device; 
IV = intravenous.  
a Atezolizumab may be withheld for a longer period of time (i.e., >  12 weeks after event onset) to 
allow  for corticosteroids  (if initiated)  to be reduced to ≤ 10 mg/day  oral prednisone or  equivalent. 
The acceptable length of the extended period of time must be agreed upon by the investigator 
and the Medical Monitor.  
b If corticosteroids  have been  initiated,  they must  be tapered over ≥ 1 month to ≤ 10 mg/day  oral 
prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and have 
fully recovered  from the immune- related  event.  Patients  can be rechallenged with  atezolizumab 
only after approval has been documented by both the investigator (or an appropriate delegate) and the Medical Monitor.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  81 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
9.14.7  Pancreatic  Events 
 
Symptoms of abdominal pain associated with elevations of amylase and lipase, suggestive of 
pancreatitis,  have  been associated with the administration  of other  immuno- modulatory  agents. 
The differential diagnosis of acute abdominal pain should include pancreatitis.  Appropriate 
work -up should include an evaluation for ductal obstruction, as well as serum amylase and 
lipase tests.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  82 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
Table  9-9 Management  Guidelines  for Pancreatitis  
 
Pancreatic 
Event   
Severity   
Management  
Amylase and 
/or lipase 
elevation  Grade 2 
 
 
 
 
Grades  3 and 4 
 
 
 
 
 
 
 
 
 
 
 
 
Grade 2 or 3 • Continue atezolizumab  
• Monitor  amylase/lipase weekly  
• Consider  oral prednisone  10 mg daily or equivalent  for prolonged 
elevation (e.g., more than 3 weeks)  
• Withhold  atezolizumab for up to 12 weeks  after event  onset  a 
• Consult  a gastroenterologist  
• Monitor  amylase/lipase every  other  day 
• Consider  oral prednisone  1-2 mg/kg/day  or equivalent  if no 
improvement  
• Atezolizumab  may be resumed  if the event  resolves  to Grade 0 or 
Grade 1 b 
• If event  does  not resolve to Grade 0 or Grade 1 while  withholding 
atezolizumab,  permanently  discontinue atezolizumab and contact 
Medical Monitor  c 
• Permanently  discontinue  atezolizumab for recurrent  events  and 
notify the Medical Monitor c 
• Withhold  atezolizumab for up to 12 weeks  after event  onset  a 
• Consult  a gastroenterologist  
• Start treatment with 1- 2 mg/kg/day IV methylprednisone or 
equivalent  and convert  to 1-2 mg/kg/day  oral prednisone or 
equivalent when symptoms improve  
• Atezolizumab  may be resumed if  the event  improves  to Grade 0 or 
Grade 1 If event does not resolve to Grade 1 or better while 
withholding atezolizumab, permanently discontinue atezolizumab 
and contact Medical Monitor c 
• Permanently  discontinue  atezolizumab for recurrent  events  and 
notify the Medical Monitor c  
Amylase and 
/or lipase 
elevation  
 
 
 
 
 
Immune- related 
pancreatitis  
Immune- related 
pancreatitis  Grade 4 • Permanently  discontinue  atezolizumab and contact  Medical 
Monitor 
c 
• Refer  patient  to gastrointestinal  specialist  
• Start  treatment  with 1−2 mg/kg/day  IV methylprednisolone or 
equivalent and convert to 1 −2 mg/kg/day oral prednisone or 
equivalent upon improvement  
• If event does not improve within 48 hours after initiating 
corticosteroids,  consider  adding  an immunosuppressive agent  
• If event  resolves  to Grade 0 or Grade 1, taper  corticosteroids 
over ≥  1 month.  
IV = intravenous;  
a Atezolizumab may be withheld for a longer  period of time (i.e., > 12 weeks  after event 
onset) to allow for corticosteroids (if initiated) to be reduced to ≤  10 mg/day oral 
prednisone or  equivalent.  The acceptable length of the extended period  of time must 
be agreed upon by the investigator and the Medical Monitor.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  83 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
b If corticosteroids  have been  initiated,  they must  be tapered over ≥ 1 month to ≤ 10 
mg/day oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit 
and have fully recovered from the immune- related event.  Patients can be rechallenged 
with atezolizumab only after approval  has been documented by both the investigator  (or 
an appropriate delegate) and the Medical Monitor.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  84 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
 Reduce  infusion  rate to half the rate being  given  at the time of event  onset  
After  the event  has resolved,  the investigator  should wait  for 30 minutes  while 
delivering the infusion at the reduced rate  
If tolerated,  the infusion  rate may then be increased to the original  rate 
Interrupt  atezolizumab infusion  
Administer  aggressive symptomatic  treatment  (e.g.,  oral or IV antihistamine, 
anti-pyretic, glucocorticoids, epinephrine, bronchodilators, oxygen)  
After  symptoms  have resolved to baseline,  resume  infusion at half the rate 
being given at the time of event onset  
o For subsequent infusions, consider administration of oral 
premedication with antihistamine,  anti-pyretics,  and/or  analgesics 
and monitor closely for IRRs  
Stop infusion  
Administer  aggressive symptomatic  treatment  (e.g.,  oral or IV antihistamine, 
anti-pyretic, glucocorticoids, epinephrine, bronchodilators, oxygen)  
• Permanently  discontinue  atezolizumab  and contact  Medical  Monitor  a Grades  3−4 • 
• • 
• 
• 
 
• Grade  2 • 
• Grade  1 Management  Severity   
9.14.8  Infusion-Related  Events  
 
No premedication is indicated for the administration of atezolizumab in Cycle 1.  Patients who 
experience an infusion- related reaction with Cycle  1 of atezolizumab may receive premedication 
with antihistamines or antipyretics/analgesics (e.g., acetaminophen) for subsequent infusions.  
Metamizole  (dipyrone)  is prohibited in treating atezolizumab associated infusion -related 
reactions, due to its potential for causing agranulocytosis. 
 
 
Table  9-10 Management  Guidelines  for Infusion- Related Reactions 
 
IRR = infusion- related  reactions;  IV = intravenous.  
a Resumption of atezolizumab may be considered in patients who are deriving benefit and have fully 
recovered from the immune -related event.  Patients  can be rechallenged with atezolizumab only after 
approval  has been documented by both the inve stigator  (or an appropriate delegate)  and the Medical 
Monitor.  
Table  9-11 Management  Guidelines  for Pancreatitis  
 
Pancreatic 
Event   
Severity  Management  
Amylase and 
/or lipase 
elevation  Grade 2 • Continue atezolizumab  
• Monitor  amylase/lipase weekly  
• Consider  oral prednisone  10 mg daily or equivalent  for prolonged 
elevation (e.g., more than 3 weeks)  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  85 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
Amylase  and Grades  3 and 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
Grade 2 or 3 • Withhold  atezolizumab for up to 12 weeks  after event  onset  a 
• Consult  a gastroenterologist  
• Monitor  amylase/lipase every  other  day 
• Consider  oral prednisone  1-2 mg/kg/day  or equivalent  if no 
improvement  
• When lab abnormalities return to Grade 0 or Grade 1, then taper 
steroids  over ≥ 1 monthAtezolizumab  may be resumed  if the event 
resolves to Grade 0 or Grade 1 b 
• If event  does  not resolve to Grade 0 or Grade 1 while  withholding 
atezolizumab,  permanently  discontinue atezolizumab and contact 
Medical Monitor  c 
• Permanently  discontinue  atezolizumab for recurrent  events  and 
notify the Medical Monitor c 
• Withhold  atezolizumab for up to 12 weeks  after event  onset  a 
• Consult  a gastroenterologist  
• Start treatment with 1- 2 mg/kg/day IV methylprednisone or 
equivalent  and convert  to 1-2 mg/kg/day  oral prednisone or 
equivalent when symptoms improve  
• Atezolizumab  may be resumed if  the event  improves  to Grade 0 or 
Grade 1 If event does not resolve to Grade 1 or better while 
withholding atezolizumab, permanently discontinue atezolizumab 
and contact Medical Monitor c 
• Permanently  discontinue  atezolizumab for recurrent  events  and 
notify the Medical Monitor c /or lipase  
elevation  
 
 
 
 
 
Immune - 
related  
pancreatitis  
Immune- related 
pancreatitis  Grade 4 • Permanently  discontinue  atezolizumab and contact  Medical 
Monitor 
c 
• Refer  patient  to gastrointestinal  specialist  
• Start  treatment  with 1−2 mg/kg/day  IV methylprednisolone or 
equivalent and convert to 1 −2 mg/kg/day oral prednisone or 
equivalent upon improvement  
• If event does not improve within 48 hours after initiating 
corticosteroids,  consider  adding  an immunosuppressive agent  
• If event  resolves  to Grade 0 or Grade 1, taper  corticosteroids 
over ≥  1 month.  
IV = intravenous;  
a Atezolizumab may be withheld for a longer  period of time (i.e., > 12 weeks  after event 
onset) to allow for corticosteroids (if initiated) to be reduced to ≤  10 mg/day oral 
prednisone or  equivalent.  The acceptable length of the extended period  of time must 
be agreed upon by the investigator and the Medical Monitor.  
b If corticosteroids  have been  initiated,  they must  be tapered over ≥ 1 month to ≤ 10 
mg/day oral prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit 
and have fully recovered from the immune- related event.  Patients can be rechallenged 
with atezolizumab only after approval  has been documented by both the investigator  (or 
an appropriate delegate) and the Medical Monitor.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  86 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
 Continue  atezolizumab  
Consider  topical  corticosteroids  and/or  other  symptomatic  therapy  (e.g., 
antihistamines)  
Continue atezolizumab 
Consider  dermatologist  referral  
Administer  topical  corticosteroids  
Consider  higher  potency  topical  corticosteroids  if event  does  not improve  
Withhold  atezolizumab for up to 12 weeks  after event  onset  a 
Consult  a dermatologist  
Start treatment with oral prednisone 10 mg/day or equivalent.  If event 
unresolved after 48−72 hours,  administer  oral prednisone 1-2 mg/kg/day  or 
equivalent  
Restart  atezolizumab if event  resolves  to Grade 0 or Grade 1 b 
If event  does  not resolve  to Grade 0 or Grade 1 while  withholding atezolizumab, 
permanently discontinue atezolizumab and contact Medical Monitor c 
Grade  4 • Permanently  discontinue  atezolizumab  and contact  Medical  Monitor  c • 
• • 
• 
• 
• 
• 
• 
• Grade  3 Grade  1 • 
• 
 
Grade  2 Management  Severity   
 
9.14.9  Dermatologic  Events 
 
Treatment -emergent  rash has been associated  with atezolizumab.  The majority  of cases  of 
rash were mild in severity and self -limited, with or without pruritus. A dermatologist should 
evaluate persistent and/or severe rash or pruritus.  A biopsy should be considered unless 
contraindicated.  
Table  9-12 Management  Guidelines  for Immune -Mediated Dermatologic  Events 
 
a Atezolizumab may be withheld for a longer  period of time (i.e., > 12 weeks  after event  onset)  to allow 
for corticosteroids (if initiated) to be reduced to ≤  10 mg/day oral prednisone or equivalent.  The 
acceptable length of the extended period of time must be agreed upon by the investigator and the 
Medical Monitor.  
b If corticosteroids  have been  initiated,  they must  be tapered over ≥ 1 month to ≤ 10 mg/day  oral 
prednisone or equivalent before atezolizumab can be resumed.  
C Resumption of atezolizumab may be considered in patients who are deriving benefit and have fully 
recovered from the immune -related event.  Patients  can be rechallenged with atezolizumab only after 
approval  has been documented by both the investigator  (or an appropriate delegate)  and the Medical 
Monitor.  
 
9.14.10  Neurological  Disorders  
 
Myasthenia gravis and Guillain- Barré syndrome have been observed with single agent 
atezolizumab.  Patients  may present  with signs  and symptoms of sensory  and/or  motor  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  87 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
neuropathy.  Diagnostic  work -up is essential  for an accurate characterization to differentiate 
between alternate etiologies.  
Table  9-13 Management  Guidelines for Neurologic  Disorders 
 
Neurologic 
Disorder   
Severity   
Management  
Myasthenia 
Gravis and 
Guillain -Barré 
syndrome   
 
 
 
 
All grades  • Permanently  discontinue atezolizumab and contact  the 
Medical Monitor c 
• Refer  patient  to a neurologist  
• Start  treatment  as per institutional guidelines  
Consider  initiation  of 1-2 mg/kg/day  oral of IV prednisone or 
equivalent  
Immune - Grade  1 • Continue atezolizumab.  
• Investigate etiology  
 
 
• Withhold  atezolizumab for up to 12 weeks  after event 
onset a 
• Investigate etiology  
• Treatment  should  be as per institutional  guidelines  
• If event  resolves  to Grade 0 or Grade 1, resume 
atezolizumab b 
• If event  does  not resolve  to Grade 0 or Grade 1 while 
withholding atezolizumab, permanently discontinue 
atezolizumab and contact Medical Monitor c 
• Permanently  discontinue atezolizumab and contact  the 
Medical Monitor c 
• Start  treatment  as per institutional guidelines  
 
• related   
neuropathy   
Immune- 
related neuropathy   
Grade 2 
 
 
 
Immune- related neuropathy   
 
 
Grades  3−4 
IV = intravenous  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  88 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
a Atezolizumab may be withheld for a longer  period of time (i.e., > 12 weeks  after event  onset)  to allow 
for corticosteroids (if initiated) to be reduced to ≤  10 mg/day oral prednisone or equivalent.  The 
acceptable length of the extended period of time must be agreed upon by the investigator and the 
Medical Monitor.  
b If corticosteroids  have been  initiated,  they must  be tapered over ≥ 1 month to ≤ 10 mg/day  oral 
prednisone or equivalent before atezolizumab can be resumed.  
c Resumption of atezolizumab may be considered in patients who are deriving benefit and have fully 
recovered from the immune -related event.  Patients  can be rechallenged with atezolizumab only after 
approval  has been documented by both the investigator  (or an appropriate delegate)  and the Medical 
Monitor.  
9.14.11  Immune- Related  Meningoencephalitis  
Immune- related meningoencephalitis is an identified risk associated with the administration of 
atezolizumab.  Immune -related meningoencephalitis should be suspected in any patient 
present ing with signs or symptoms suggestive of meningitis or encephalitis, including, but not 
limited  to, headache,  neck  pain,  confusion,  seizure,  motor  or sensory  dysfunction,  and altered or 
depressed level of consciousness. Encephalopathy from metabolic or electrolyte imbalances 
needs to be distinguished from potential meningoencephalitis resulting from infection (bacterial, 
viral, or fungal) or progression of malignancy, or secondary to a paraneoplastic process.  
All patients being considered for meningoencephalitis should be urgently evaluated with a CT 
scan and/or MRI scan of the brain to evaluate for metastasis, inflammation, or edema. If 
deemed safe by the treating physician, a lumbar puncture should be performed and a neurologist  should  be consulted.  Patients  with signs  and symptoms  of meningoencephalitis,  in 
the absence of an identified alternate etiology,  should be treated  according  to the guidelines  in 
Table 9- 13. 
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  89 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
Table  9-14 Management  Guidelines  for Immune- Related Meningoencephalitis 
 
Event  Management  
Immune- related 
meningoencephalitis, 
all grades  • Permanently  discontinue atezolizumab and contact 
Medical Monitor a 
• Refer  patient  to neurologist  
• Initiate treatment with 1− 2 mg/kg/day IV 
methylprednisolone or equivalent and convert to 
1−2 mg/kg/day  oral prednisone or equivalent  upon 
improvement  
• If event  does  not improve  within  48 hours  after 
initiating corticosteroids, consider adding an 
immunosuppressive agent  
• If event  resolves  to Grade  1 or better,  taper 
corticosteroids over ≥  1 month  
IV = intravenous.  
a Resumption  of atezolizumab  may be considered in  patients  who are deriving benefit  
and have fully recovered from the immune- related event.  Patients can be 
rechallenged with atezolizumab only after approval has been documented by both the investigator (or an appropriate delegate) and the Medical Monitor.  
 
 
 
9.14.12  Systemic  Immune  Activation  
 
Systemic immune activation  (SIA)  is a rare condition characterized by an excessive immune 
response. Given the mechanism of action of atezolizumab, SIA is considered a potential  
risk when  given in combination with other  immunomodulating agents.  SIA should be included in 
the differential diagnosis for patients who, in the absence of an alternative etiology, develop a 
sepsis -like syndrome after administration of atezolizumab, and the initial evaluation should 
include the following:  
• CBC with peripheral smear  
• PT, PTT,  fibrinogen,  and D- dimer  
• Ferritin  
• Triglycerides  
• AST,  ALT,  and total bilirubin  
• LDH 
• Complete neurologic  and abdominal examination (assess for 
hepatosplenomegaly)  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  90 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
9.15 Diet/Activity/Other  Considerations 
 
9.15.1  Diet 
 
Patients  should maintain a normal  diet unless  modifications  are required  to manage an AE such 
as diarrhea, nausea, or vomiting.  
 
9.15.2  Contraception  
 
Women of childbearing potential  must  agreement  to remain  abstinent  (refrain  from heterosexual 
intercourse) or use 2 contraceptive methods that result in a failure rate of < 1% per year during 
the treatment period and for at least 120 days after the last dose of study treatment.  
A woman is considered to be of childbearing potential if she is between menarche and 
menopause  and has not been permanently  or surgically  sterilized  and is capable of procreation. 
Permanent sterilization includes hysterectomy and/or bilateral oophorectomy and/or bilateral 
salpingectomy but excludes bilateral tubal occlusion. This definition also includes women who have experienced menopause onset < 12 months prior to enrollment.  
Examples  of single  contraceptive methods  with a failure  rate of < 1% per year include bilateral 
tubal ligation, male sterilization, and copper intrauterine devices.  
The reliability  of sexual  abstinence should be evaluated in relation  to the duration of the clinical 
trial and the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, 
ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.  
Patients should be informed that taking the study dug may involve unknown risks to the fetus 
(unborn baby) if pregnancy were to occur during the study. In order to participate in the study 
they must adhere to the contraception requirement (described above)  for the duration of the 
study and for at least 120 days after the last dose of study treatment. If there is any question that a patient  will not reliably  comply  with the requirements  for contraception,  that patient  should 
not be entered into the study.  
 
9.15.3  Study Drug  Use in Pregnancy  
 
If a patient  inadvertently  becomes  pregnant  while  on study  drug,  the patient  will immediately  be 
removed from study treatment. The site will contact the patient at least monthly and document 
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  91 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
the patient’s status until the pregnancy has been completed or terminated. The outcome of the 
pregnancy  will be reported  to TRIO without  delay  and within  24 hours  if the outcome  is a serious 
adverse experience (e.g., death, abortion, congenital anomaly, or other disabling or life- threatening complication to the mother or newborn). The Investigator will make every effort to obtain permission  to follow the outcome  of the pregnancy  and report  the condition of the fetus  or 
newborn to the Sponsor. See Section 12.4.1 for information regarding reporting a pregnancy.  
 
9.15.4  Study Drug  Use in Nursing Women  
 
It is unknown whether  study  drug is excreted  in human milk. Since  many  drugs  are secreted  in 
human milk, and because of the potential for serious adverse reactions in the nursing infant, patients who are breast -feeding are not eligible for enrollment.  

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  92 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
10. STUDY  TESTS AND OBSERVATIONS  
 
After provision of written informed consent, patients will be screened for study eligibility within 
21 days  before  study  enrollment.  Patients  who are determined  to be eligible  based  on screening 
assessments and who are enrolled, must begin treatment (C1D1) with  entinostat/placebo in 
combination with atezolizumab within 3 business days of the date of 
enrollment/randomization.  
A cycle is 21 days  in length.  Patients  will attend study  center  visits  and undergo study 
evaluations  on C1D1,  C1D8,  and C1D15;  D1 and D15 of C2; and on D1  of each cycle 
thereafter.  
Patients  will have radiological disease assessments during screening  and then during  treatment 
and follow -up every 6 weeks (+/ -3 days) (Week 6, Week 12, etc.) through week 36 and then 
every  9 weeks  (+/- 3 days)  thereafter  until unequivocal  progressive  disease.  This schedule is to 
be followed both during study treatment and following discontinuation of study treatment in the 
absence of progressive disease.  
After discontinuation of study treatment, patients will complete an EOT visit within 7 days (+/ - 3 
days) after the last study  drug dose and a Safety Follow- up visit 30 days (+/ - 3 days) thereafter. 
After completion of the 30- day Safety F/U visit, patients who have not experienced PD are to 
continue to undergo  radiological assessments every  6 weeks  through  week  36 and then every  9 
weeks thereafter until unequivocal progressive disease. The purpose of the post -treatment 
follow- up is to ascertain the duration of PFS for all patients in the study. After progressive 
disease, surviving patients are to be followed every 3 -months for documentation of subsequent 
therapy and survival until closure of the study or death.  
Protocol -required  tests,  observations,  and procedures  are summarized  in Table 1-1 . 

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  93 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
10.1 Screening Assessments 
All patients  must  provide written  informed consent  before the performance  of any study -related 
procedures.  
 
10.1.1  Demographics  
 
Patient  demographics,  including  age, race,  and ethnicity,  are to be documented during 
screening.  
 
10.1.2  Medical  History  
 
A complete medical  history  is to be documented during screening and updated prior to 
administration of the first study drug dose.  
The medical history is to include cancer history, including date of and stage at diagnosis, 
method of diagnosis, and all previous treatments, including radiation therapy, and response to such treatment.  It should  also include  any medical  condition that might  complicate the patient’s 
disease or affect the treatment outcome.  
 
10.1.3  Pregnancy Testing  
 
For females of child- bearing potential, a serum pregnancy test is required and must be 
performed  during  screening and a urine  test within  3 days  before  the first study  drug dose  if the 
serum test is performed more than 3 days before the first study drug dose. Results must be available and confirmed to be negative prior to study drug administration. Pregnancy testing is to be repeated during the study any time  pregnancy is suspected.  
10.2 Safety  Assessments  
 
10.2.1  Physical  Examination 
 
A complete physical examination will be conducted for all patients during screening; at enrollment; and at the EOT (within 7 days post -last dose) and Safety F/U (30 days (+/ -3 days) 
thereafter)  visits.  If the screening complete  physical  examination  was performed  within  7 days  of 
enrollment, then a symptom -directed physical examination may be performed at C1D1. 
Symptom -directed  physical  examinations  will be performed  for all patients  on D1, D8, and D15 
of C1; D1 and D15 of C2; and on D1 of each subsequent cycle. 
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  94 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
10.2.2  Electrocardiograms 
 
All patients will undergo a 12- lead ECG during screening; pre- dose (i.e., before entinostat and 
atezolizumab) on C3D1, and then every 3 cycles thereafter. A 12- lead ECG also is to be 
repeated  as clinically  indicated  during treatment  and again at the EOT visit (within  7 days  post- 
last dose).  
ECGs  will be recorded after the patient  has rested  in a supine position for at least  10 minutes  in 
each case.  The Investigator or designated physician will review the paper copies of each of the 
timed 12 -lead ECGs when they are collected.  
 
10.2.3  Vital  Signs  
 
Vital signs, including systolic and diastolic blood pressure (mmHg), pulse (beats per  minut e), 
respiration rate (breaths  per minute),  and temperature,  are to be measured  during screening, 
on D1 of each treatment cycle, at the EOT (7 days post -last dose) and the Safety F/U visits.  
Measurements  are to be made after the patient  has been  resting in a supine position  for a 
minimum of 5 minutes.  
Blood pressure and pulse will be measured using a blood pressure recording device with an 
appropriately sized cuff. The units ( °F or ° C) and mode of temperature recording will be 
documented  (e.g.,  oral, axillary);  the same  units  and mode  should  be used  for a patient  across 
all measurements. Height will be collected at the screening visit only.  
 
10.2.4  Weight  
 
Weight  is to be measured  during screening,  on D1 of each  treatment  cycle, at the EOT and the 
Safety F/U visits.  
 
10.2.5  ECOG  Performance  Status  
 
ECOG  performance  status  is to be assessed during screening,  on D1 of each  treatment  cycle, 
and at the EOT and Safety F/U visits. It should also be measured if there is any indication of 
fluid retention.  
The ECOG  performance  status  scale,  with corresponding Karnofsky  performance status  score 
equivalents, is presented in Table 10- 1. 

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  95 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
Table 10 -1 Eastern Cooperative Oncology Group  Performance Status  Scale,  with 
Equivalent Karnofsky Performance Status Scores 
 
ECOG1 Karnofsky2 
Score  Criterion  % Criterion  
0 Normal  activity 100 
 
90 
 
80 
 
70 
 
60 
 
50 
 
40 
 
30 
 
 
20 
10 
 
0 Normal;  no complaints;  no evidence of 
disease  
Able to carry  on normal  activity;  minor 
signs or symptoms of disease 
Normal  activity  with effort;  some signs 
or symptoms of disease  
Cares  for self; unable to carry  on 
normal activity or do active work  
Requires  occasional  assistance  but is 
able to  care for  most  of his/her  needs  
Requires  considerable assistance  and 
frequent medical care  
Disabled,  requires  special  care and 
assistance  
Severely  disabled;  hospitalization is 
indicated though death is not 
imminent  
Very sick; hospitalization  is necessary  
Moribund;  fatal processes  progressing 
rapidly  
Dead   
1  
Symptoms  but ambulatory  
 
2  
In bed <50%  of time 
 
3  
In bed >50%  of time 
 
 
4  
 
100%  bedridden  
 
5  
Dead  
1 Oken  MM, Creech  RH, Tormey  DC, Horton J, Davis  TE, McFadden  ET, Carbone PP. Toxicity  and response criteria 
of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649- 655. 
2 Mor V, Laliberte  L, Morris  JN, Wiemann  M. The Karnofsky  Performance Status  Scale:  an examination of its 
reliability and validity in a research setting. Cancer. 1984;53:2002-2007.  
 
10.2.6  Clinical  Laboratory Tests 
 
Blood samples for hematology and clinical chemistries are to be collected during screening, on 
D1, D8 and D15 of C1; on D1 and D15 of C2; on D1 of each  subsequent  treatment  cycle; and at 
the EOT visit. If screening hematology and clinical chemistry tests are performed within 7 days of enrollment, they need not be repeated at C1D1 unless clinically indicated.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  96 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
The following  analytes  are to be measured:  
 
Hematology 
 
White blood cell count (WBC) with differential   Hemoglobin 
Red blood cell count (RBC)  Hematocrit  
Platelet count  Coagulation studies,  including PT or INR and 
aPTT (screening only)  
 
Clinical  Chemistries  
 
ALT AST 
 
Alkaline  phosphatase  Albumin  
 
Total  bilirubin  Blood urea nitrogen (BUN)  
 
Calcium  Creatinine  
 
Sodium  Potassium  
 
Chloride  Bicarbonate  
 
Glucose Lactic  dehydrogenase  
 
Phosphorus  Total  Protein 
 
Uric acid  Magnesium  and TSH (screening only,  unless 
clinically indicated)  
 
In addition to the scheduled assessments, clinical laboratory evaluations are to be repeated as 
necessary  during  treatment  at a schedule determined by the Investigator,  based on the patient’s 
clinical status. 
Laboratory  abnormalities  that are considered  by the Investigator  to be clinically  significant  for a 
particular patient are to be reported as AEs.  
 
10.2.7  Adverse Events  
 
AEs, as defined in Section 12.2.1, are to be documented from the time of informed consent 
through  30 days  post-last dose,  with the exception of AESIs  with atezolizumab,  which  must  be 

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  97 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
documented  through  90 days  following  cessation  of treatment,  or 30 days  after the initiation  of a 
new anticancer therapy, whichever is earlier. 
10.3 Efficacy  Assessments  
With the exception of OS, all efficacy endpoints in this trial (including the primary endpoint in 
Phase 2) are linked  to the tumor  response  assessments  and therefore  the importance  of timely 
and complete  disease assessments in this study  cannot  be understated.  Failure  to perform  any 
of the required disease assessments will result in the inability to determine disease status for 
that time point.  Frequent  off schedule or incomplete disease assessments  have the potential  to 
weaken the conclus ion of this clinical trial.  
The schedule of tumor burden assessments should be fixed according to the calendar, 
regardless of treatment interruptions. Tumor burden assessments will be performed until 
progressive  disease  as per RECIST  1.1 and irRECIST  regardless  of the discontinuation  of study 
treatment or the start of a subsequent anticancer therapy. Patients with radiographic  
progression only, as defined by RECIST 1.1 should continue on study treatment until 
unequivocal progressive disease is determined as defined by irRECIST, at the discretion of the investigator.  
The same  method of assessment  and the same  technique used  for study  screening (CT scan  or 
MRI)  to characterize each lesion  must be used  at each subsequent  post-screening assessment. 
Post-screening scans and the corresponding overall tumor assessment (according to RECIST 
and irRECIST) should be done at the next visit after the scans are performed and prior to indicating the subsequent cycle, to rule out progressive disease that would warrant study treatment discontinuation.  
 
10.3.1  Tumor  Measurements and Disease Response  Assessment  
 
10.3.1.1  Tumor  Measurement  and Assessment  
Initial tumor imaging at screening must be performed within 28 days prior to initial study drug dosing (C1D1).  (Scans  performed  as part of routine clinical management  are acceptable for use 
as initial tumor imaging if they are of diagnostic quality and performed within 28 days prior to C1D1 and can be assessed by the central imaging vendor.)  Patients will have radiological 
disease assessments performed every 6 weeks (+/ -3 days) (Week 6, Week 12, etc.) during 
study treatment through week 36 or until progressive disease.  If progressive disease has not  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  98 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
occurred by week 36, radiological assessments will be then be done every 9 weeks (+/ -3 days) 
until progressive disease. If a patient comes off study for reasons other than progressive 
disease, radiological assessments will continue on this same study schedule until progressive disease is unequivocally  documented.  Images  should be kept to the calendar  schedule and not 
be delayed for delays in cycles or study drug administration. Disease response in target and non-target lesions will be assessed locally by the Investigator using RECIST 1.1 and irRECIST. 
Measurable Disease 
 
To be eligible for study participation, all patients must have documented measurable disease per RECIST  1.1 that has been radiologically  documented  within  28 days  prior to initiating  study 
drug treatment, defined as follows:  
At least  1 measurable lesion:  
• ≥10 mm in longest  diameter  on an axial image  by CT scan or MRI with ≤ 5 mm 
reconstruction interval 
o If slice thickness  is greater  than 5 mm, longest  diameter  must  be at least  2 times 
the thickness  
 
• ≥20 mm longest  diameter  by chest  X-ray (if clearly  defined and surrounded by aerated 
lung); CT is preferred, even without contrast.  
 
• Lymph nodes  ≥ 15 mm in short  axis on CT scan (CT slice thickness  of ≤ 5 mm) 
 
If there is only 1 measurable lesion  and it is located  in previously  irradiated  field,  it must  have 
demonstrated progression according to RECIST 1.1.  
 
Non- measurable  Lesions  
 
Non-measurable lesions  are defined per RECIST  1.1 as the following  and should be captured 
and followed accordingly and within the eCRF according the eCRF guidelines.  
• Masses  < 10 mm 
• Lymph nodes  ≥10 to <15 mm in short  axis 
• Leptomeningeal  disease  
• Ascites, pleural  or pericardial  effusion 
• Inflammatory  breast  disease (cont’d on next page)  
• Lymphangitic  involvement  of skin or lung 
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  99 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
• Abdominal mases  or organomegaly  identified by physical  exam  which  cannot  be 
measured by reproducible imaging techniques  
• Blastic  bone lesions  
• Both benign and equivocal  (“cannot  exclude”)  findings  should not be included 
 
Target  versus non-target  
 
• Target:  all measurable lesions  up to a maximum  of 2 lesions  per organ  and 5 lesions  in 
total, representative of all involved organs, are to be identified as target lesions and 
measured and recorded at screening. Target lesions are to be selected on the basis of 
their size (i.e., those with the longest diameter) and suitability for accurate repeated measurement. The sum of the diameters for all target lesions is to be calculated and recorded on the eCRF as the sum of the longest diameters. 
• Non-target:  all other lesions not classified as target lesions (or sites of disease) are to 
be identif ied as non-target  lesions  and are to be recorded on the eCRF. Measurement  of 
non-target lesions is not required.  
10.3.1.2  Scan Procedures  
Contrast -enhanced CT scans of chest, abdomen, and, as clinically indicated, pelvis are 
preferred for evaluation of disease  status for this study;  however,  a contrast -enhanced MRI can 
also be performed  if a patient  has or develops  allergy  to iodinated contrast  agents.  The imaging 
modality used at screening should continue for all images during study participation, unless 
clinically contra -indicated.  
Positron emission tomography (PET) alone will not be acceptable as part of the imaging to be performed for this study. If PET is performed, the Investigator should not remove any patient based on PET alone,  as there can be false  positives.  If he/she thinks  a patient  has progressed 
via PET, it must be confirmed with a CT/MRI.  
If a combined 18F -deoxyglucose (FDG) PET- CT scan is performed, the CT portion of that 
examination should not be substituted for the dedicated CT examinations required by this protocol  for tumor  measurements  unless  the study  center  can document  that the CT performed 
as part of the FDG PET -CT is of identical diagnostic quality to a diagnostic CT (with IV and oral 
contrast).  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  100 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
CT Scan Procedures 
Study  centers  must  acquire and submit  CT scans  according to the parameters  below:  
 
• Use consistent scan parameters (spacing, thickness, field of view, etc.) for all 
assessments. Any alternate  imaging or parameter  variation from the protocol  should be 
noted.  
• If a patient  develops  hypersensitivity  to the iodinated contrast  medium  while  on study,  it 
is acceptable to perform chest CT scans without contrast. In addition, a contrast - 
enhanced MRI scan according to the  parameters described  in the MRI section must  be 
performed for the remainder of the required anatomy.  
• The patient  should be given oral contras t (as either  positive [e.g., barium  or Gastrografin] 
or negative [e.g., water or saline] contrast media, according to site standard of care)  
prior to the examination to allow for sufficient bowel opacification.  
• Non-ionic iodinated IV contrast  with a minimu m of 320 mg iodine/mL should be used  for 
this study.  Contrast  agent  volume should be according to the package insert.  The same 
contrast agent with the same concentration should be used throughout the study.  
MRI Scan Procedures 
• If IV contrast  is medically  contraindicated  during the study,  a dynamic  contrast -enhanced 
MRI is an acceptable alternative to CT scans of the abdomen and pelvis.  
• MRI must be performed using either 1.5T or 3.0T scanner. A change in scanner field 
strength  is not allowed  for an individual  patient  while  on study  (e.g.,  if a patient  has a C2 
MRI scan at 3.0T, all subsequent scans must be performed at 3.0T).  
• MRI scans should use optimized parameters to decrease motion artifact and maximize 
signal -to-noise ratio and resolution.  Breath -hold imaging,  fast-scanning techniques,  and 
gadolinium should be used to maximize lesion identification. Note: A non- contrast CT 
scan of the chest or digital chest X- ray must be acquired in addition to the MRI of the 
abdomen and, as applicable, pelvis.  
• The patient  must  undergo scanning with approved extracellular  contrast  media only 
(e.g., Magnevist, Dataram, Omniscan).  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  101 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
• The same equipment, field strength, sequences, scanning parameters, positioning, 
angulation, timing, field of view, and slice thickness should be utilized for all 
examinations  acquired  both pre- and post-contrast  for a given  patient  over the course  of 
the study.  
10.3.1.3  Disease Response Assessment  Criteria  
Patients will have radiological disease assessments performed every 6 weeks (+/ -3 days) 
(Week 6, Week 12, etc.) during study treatment through week 36 or until unequivocal 
progressive disease.  If progressive disease has not occurred by week 36, radiological 
assessments will be then be done every  9 weeks (+/ -3 days) until unequivocal progressive 
disease.  Images  should be kept to the calendar  schedule and not be delayed for missed study 
drug administration.  
Partial  or complete  response  should be confirmed  by a repeat  tumor  imaging  assessment  not 
less than 4 weeks from the date the response was first documented.  The tumor imaging for 
confirmation of response  may be performed at the earliest 4  weeks after  the first indication of 
response, or at the next scheduled scan if on a 6 week  schedule, whichever is clinically 
indicated.  
In subjects who discontinue study therapy without doc umented unequivocal progressive 
disease, every effort should be made to continue monitoring their disease status by tumor imaging every  6 weeks  until (1) unequivocal  progressive disease (2) death,  or (3) the end of the 
study, whichever occurs  first. All scans will be submitted (electronically whenever possible) to a 
central core radiologic laboratory within 3 days of being performed, where they will immediatel y 
be reviewed for readability. The lab will contact the site should any issues or questions arise.  
Disease progression is determined locally, not by the central core radiologic lab.  S
 cans from 
patients  who were  determined by the Investigator  to have  a response  to treatment  (CR or PR) 
will be reviewed by the core radiologic laboratory to confirm response The lab will collect and hold all scans should the sponsor decide to have them read to confirm PFS outcomes.  
Scans  from non-responders  may also be reviewed  by the core radiologic  laboratory  at the 
direction of the Sponsor.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  102 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
10.3.2  Treatment  after  Initial  Radiologic Progression  
 
Immune related RECIST (irRECIST) (Appendix 4) will be utilized to account for the unique 
tumor response characterist ics seen with atezolizumab treatment.  Immunotherapeutic agents 
such as atezolizumab may produce antitumor effects by potentiating endogenous cancer - 
specific immune responses. The response patterns seen with such an approach may extend beyond the typical  time course of responses  seen  with cytotoxic agents,  and a clinical response 
may manifest after an initial increase in tumor burden or even the appearance of new lesions.  
Patients with a first radiological evidence of progressive disease, should continue on study 
treatment, at the discretion of the investigator,  until confirmed progressive disease is 
determined per irRECIST  in a subsequent  scan. Therefore,  the following  process  for assessing 
radiological progressive disease will be used in this study:  
1. If radiologic imaging demonstrates initial evidence for PD, tumor assessment should be 
repeated at the earliest of 4 weeks, or preferably on the study schedule of 6 weeks, in order to confirm PD.  Treatment on -study may be continued while awaiting radiologic 
confirmation of progression. This clinical decision should be based on the patient’s overall  clinical condition,  including performance status,  clinical symptoms, and laboratory 
data.  
2. Specifically,  it is recommended that patients  continue to receive study  drug while  waiting 
for confirmation of PD if they are clinically stable as defined by:  
• Absence of signs  and symptoms  indicating PD. 
• No decline in ECOG  performance status.  
• Absence of rapid PD. 
• Absence of progressive tumor  at critical anatomical  sites (e.g.,  cord compression) 
requiring urgent alternative medical intervention.  
As per irRECIST, if repeat imaging does not show irPD, then PD by irRECIST will not have been confirmed  and treatment  may be continued.  If repeat  imaging confirms  irPD, PD will have 
been confirmed and the patient will be discontinued from study treatment.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  103 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
Table  10-2 Imaging and Treatment  After  1st Radiologic Evidence of PD 
 
 Clinically  Stable  Clinically  Unstable  
Imaging  Treatment  Imaging  Treatment  
1st radiologic  Repeat  imaging  at May continue  Repeat  imaging  at Discontinue  
evidence  of PD next scheduled  study  drug at the next scheduled  treatment  
 time point  to Investigator’s  time point  to  
 confirm  PD discretion  while  confirm  PD per  
  awaiting  physician   
  confirmatory  scan discretion  only  
  by site   
Repeat scan 
confirms  irPD No additional 
imaging  required  Discontinue 
treatment  No additional 
imaging  required  N/A 
Repeat  scan Continue  regularly  Continue  study  Continue  regularly  May restart  study  
shows  SD, PR or scheduled  drug at the scheduled  drug if condition  
CR (per imaging  Investigator’s  imaging  has improved  
irRECIST)  assessments  discretion  assessments  and/or  clinically  
    stable per 
    Investigator’s  
    discretion  
NOTE: If a subject has  confirmed radiographic progression (i.e. 2 scans  at least 4 weeks apart 
demonstrating progressive disease),  but the subject  is achieving a clinically  meaningful  benefit, 
and there is no further increase in the tumor burden at the confirmatory tumor imaging, an 
exception to continue treatment may be considered following consultation with the Medical 
Monitor. In this case, if treatment is continued, tumor imaging should continue to be performed 
following the study required intervals per Table 1-1 . 
When feasible,  patients  should not be discontinued until PD is confirmed.  However,  patients  that 
are deemed clinically unstable are not required to have repeat imaging for confirmation of PD 
and should come off study treatment.  
 
 
10.4 Protein Lysine  Acetylation and Immune  Correlates 
Based on preclinical studies it is suggested that entinostat may specifically target a population  
of MDSCs and thus improve the response to PD1 or PDL1 antibody treatment. The Sponsor 
plans to evaluate populations of MDSC and other myeloid cells in peripheral blood and tumor tissues  of the patients  (if available)  and also to evaluate the basic  T-cell function in patients,  with 
the expectation that if  MDSC level is decreased the response to antigens would be improved.  
 
10.4.1  Blood 
 
Thirty  (30) mL of blood  for immune  correlates  is to be collected  pre-dose  on C1D1,  C2D1, 
C2D15, C3D1 and at EOT for analysis at the Wistar Institute. Five (5) mL of blood will be collected pre -dose on C1D1, C2D1, C2D15 and at EOT for immune correlate analysis at  

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  104 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
Serametrix  Laboratory.  Blood is to be collected  and prepared  according to the instructions 
provided in the Laboratory Study Manual. 
Sixteen (16) mL of blood for protein lysine  acetylation is to be collected  pre-dose on C1D1  and 
C1D15, for analysis at the National Cancer Institute in the United States. 
The following  are immune  correlate analyses  that may be performed on the collected samples:  
 
• MDSCs,  PNM -MDSCs,  Monocytes,  DCs, Neutrophils,  B cells 
• Protein lysine  acetylation  in PBMCs  
• Peripheral  T-cell activation  and Treg panels,  Proliferation (Ki-67) 
• Functional/proliferation assay with PBMCs  using  CD3/CD28,  ConA  and tetanus  toxoid 
• Plasma  analysis  for chemokine/cytokines  (IL18,  CXCL10,  CXCL9,  IL6, CRP)  
• Antibody  to tumor  Antigen using peptide array  
• Whole exome  sequencing for Germline  identification 
Refer  to the Study  Laboratory  Manuals  for Covance and Serametix  for instructions  on sample 
collection and shipment.  
 
10.4.2  Tumor  Tissue  
 
Fresh tumor  tissue core biopsy  samples  will be collected during the study  as follows:  
 
• During  screening from all patients  on a mandatory basis.  
• On C2D15  (+/-3 days)  on an optional  basis  from patients  in the Dose  Determination 
Phase. Patients will be encouraged to provide an optional biopsy in order to help 
understand dose- immune correlate effects.  
• On C2D15 (+/ -3 days) on a mandatory basis until 20 samples are obtained in the 
Phase 2 portion of the study  and on an optional  basis  for subsequent  patients  in this 
Phase 2 Expansion.  
• At the time of progressive disease on an optional  basis  for all patients  
• At the end of study  treatment  prior to the start of another  systemic therapy,  on an 
optional  basis  for all patients  
Note:  Archival  tissue should also be collected at time of screening when available.  
If, based  on an interim  review  of tumor  tissue data from the initial patients  in Phase 2, such data 
are considered informative, then tumor tissue samples will be c ollected on a mandatory basis 
from all subsequent patients in the study. Alternatively, if such data are not considered 
informative, these samples will not be collected from subsequent patients.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  105 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
Tissue samples will be sent to a central laboratory facility for preparation and distribution to 
other  central  laboratories  for analysis.  In addition to protein lysine  acetylation testing,  pre and 
post treatment tissue samples will also be analyzed for the following:  
• PD-L1 expression level 
• MDSCs  – CD33+,  S100A9+  
• Macrophage  – CD163+  or CD68+  
• Neutrophil  – Neutrophil  elastase+  
• CD8/Ki -76 
• Dendritic  cells – DC-SIGN  (CD209)  
• MHC class I  
• FoxP3,  CD4,  CD8,  granzyme B positive  cells  
• Gene expression – nanostring 
• Whole exome  sequencing and RNAseq  
Refer  to the Study  Laboratory  Manual  for instructions  on sample collection  and shipment.  
 
 
10.5 Pharmacokinetics 
 
10.5.1  Entinostat  
 
Blood samples  for determination of entinostat  levels  will be collected at the following  time points:  
 
• Pre-dose  C1D1  
• 2-4 hours  post dose  C1D1  (1 sample)  
• C1D8  (1 sample,  anytime post dose)  
• C1D15  (1 sample,  anytime post dose)  
• Pre-dose  C2D1  
On each sample  collection  day, the time and date of entinostat  administration,  the start and stop 
time of atezolizumab administration, and the time and date of PK sample collection should be 
recorded in the eCRF.  
Refer  to the Study  Laboratory  Manual  for instructions  on sample collection  and shipment.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  106 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
10.5.2  Atezolizumab 
 
Blood samples  for determination of atezolizumab  levels  and anti-atezolizumab antibodies  will be 
collected at the following time points:  
• Pre-dose on C1D1  
• C1D1  30 minutes  (+/- 10 minutes)  post infusion (for atezolizumab  level only)  
• Pre-dose on C2D1  
• Pre-dose on C4D1.  
• End of Treatment  
• Day 120 after coming  off study  treatment  if patient  is still being followed  as per the 
protocol.  
On each sample  collection  day, the time and date of entinostat  administration,  the start and stop 
time of atezolizumab administration, and the time and date of sample collection should be 
recorded in the eCRF.  
Refer  to the Study  Laboratory  Manual  for instructions  on sample collection  and shipment.  
 
10.6 TRegs and Ki67 
Six (6) mL of blood will be collected from all study  patients  in the United  States  for analysis  of T 
regulatory cells and cell proliferation pre- dose on C1D1, C2D1, C3D1 and EOT.  
 
Refer  to the Study  Laboratory  Manual  for instructions  on sample collection  and shipment.  
 
10.7 Atezolizumab Plasma Biomarker  
Six (6) mL of blood will be collected  from all study  patients  for analysis  of plasma  biomarkers 
pre-dose on C1D1, C2D1, C2D15, C3D1 and EOT.  
Refer  to the Study  Laboratory  Manual  for instructions  on sample collection  and shipment.  
 
10.8 Atezolizumab Serum  Biomarker  
Three and one-hal f (3.5) mL of blood will be collected from all study  patients  for the analysis  of 
serum biomarkers pre -dose on  C1D1, C2D1, C2D15, C3D1 and EOT.  
 
Refer  to the Study  Laboratory  Manual  for instructions  on sample collection  and shipment.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  107 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
 
11. DISCONTINUATION AND  REPLACEMENT  OF PATIENTS 
 
Patients  have  the right to withdraw  fully or partially  from the study  at any time and for any 
reason without prejudice to their future medical care by the physician or  at the institution.  
Withdrawal of full consent for a study means that the patient does not wish to receive further 
investigational treatment and does not wish to, or is unable to, continue further study 
participation. Withdrawal of partial consent means that the patient does not wish to take 
investigational product any longer but is still willing to collaborate in providing further data by continuing on study (e.g., participate in all subsequent study visits or procedures or follow -up 
contact).  Any patient  may withdraw  full or partial  consent  to participate  in the study  at any time 
during the study. The level of study withdrawal is to be noted in the source documentation.  
In the event  of discontinuation of all treatment  or full withdrawal  from the study,  the Investigator 
will c omplete the End of Study form and indicate the date and the appropriate reason. To the 
greatest extent possible, the Investigator will attempt to complete protocol -required follow -up 
tests.  
During  the Phase  1b Dose  Determination  Phase,  patients  who discontinue  the study  for reasons 
other than study drug- related toxicity before completing C1 may be replaced.  
Reasons  for permanently  discontinuing  study  therapy  and/or  observation might  include:  
 
• ineligibility  
• withdrawal  of consent  
• administrative  decisio n by the Investigator  or Syndax  
• pregnancy  
• significant  protocol  deviation or patient  noncompliance 
• unacceptable toxicity  
• confirmed  progressive disease 
• the investigator  believes  it is no longer  in the patient’s  best interest  to continue study 
therapy  
During  the Phase  2, the number  of patients  may be increased  by 6-10 additional  patients  to 
accommodate for a higher than expected number of drop outs without PFS.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  108 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
12. ADVERSE EVENTS,  DATA  REPORTING,  AND RECORDING  
 
12.1 Study Drugs 
 
12.1.1  Entinostat  
 
Commonly encountered AEs across clinical studies of entinostat monotherapy in patients with 
solid tumors included hypoalbuminemia, fatigue, nausea, hypophosphatemia, anemia, and 
thrombocytopenia. Incidence and severity were dose- and schedule-d ependent. In a Phase 2, 
randomized,  placebo- controlled study  in patients  with breast  cancer,  in which  patients  received 
exemestane+entinostat  or exemestane+placebo,  treatment -emergent  adverse events  (TEAEs) 
occurring at a ≥10% higher incidence in entinosta t-treated patients versus placebo- treated 
patients included fatigue (48% vs 26%), nausea (40% vs 15%), neutropenia (30% vs 0%),  
peripheral edema  and vomiting  (both  21% vs 5%), thrombocytopenia  (19%  vs 6%), pain (16% 
vs 6%), and dyspepsia and leukopenia (both  14% vs 3%). The only Grade  3 or 4 AE occurring 
at a >10% incidence for entinostat vs placebo was neutropenia (14% vs 0%). In a Phase 2 
study in patients with metastatic melanoma treated with entinostat monotherapy, the most 
common TEAEs we re nausea (39%), hypophosphatemia (29%), pain in extremity (21%), and 
back pain and diarrhea (each 18%) ( Hauschild 2008).  
Additional clinical experience is summarized  in the entinostat  IB. As stated  previously,  there  are 
no clinical data with entinostat in combination with atezolizumab. 
 
12.1.2  Atezolizumab 
 
Please refer to the current  Informed Consent  and the Investigator’s  Brochure for the current 
safety profile and information regarding atezolizumab.  
12.2 Adverse  Event  Definitions 
 
12.2.1  Adverse Events  
 
An AE is defined in the International Council for  Harmonisation (ICH) Guideline for Good 
Clinical Practice as “any untoward medical occurrence in a patient or clinical investigation 
subject  administered a pharmaceutical  product  and which  does  not necessarily  have a causal 
relationship with this treatment” ( ICH E6:1.2 ). 

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  109 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
Worsening of a pre-existing  medical  condition,  (i.e., diabetes,  migraine headaches,  gout)  should 
be considered an AE if there is either an increase in severity, frequency, or duration of the 
condition or an association with significantly worse outcomes.  
Interventions  for pretreatment  conditions  (i.e., elective  cosmetic  surgery)  or medical  procedures 
that were planned before study enrollment are not considered AEs.  
PD should not be recorded  as an AE. If PD occurs, record  the date first documented  in the EOT 
visit eCRF. Also record all methods of assessment, i.e., 1 target/non -target lesion, tumor 
response assessment, and/or clinical disease assessment. Indicate if the patient starts new 
treatment.  
In the case of death,  record “Fatal”  for only the event  causing death.  AEs that are ongoing at the 
end of the study or time of death are to be noted as “not recovered/not resolved.” Classification 
of AEs is to be done by the Investigator in accordance with the NCI CTCAE, version 4.03. The 
Death eCRF must also be completed.  
The Investigator is responsible for reviewing laboratory test results and determining whether an abnormal value in an individual patient represents a significant change from baseline. In general, abnormal laboratory findings without clinical significance (based on the Investigator’s judgment)  should not be recorded as AEs;  however,  laboratory  value changes  requiring therapy 
or adjustment in prior therapy are considered AEs.  
 
12.2.2  Suspected Adverse  Reaction 
 
A suspected adverse  reaction is any AE for which  there  is a reasonable possibility  that the drug 
caused the adverse event. For the purposes of regulatory safety reporting, ‘reasonable 
possibility’ means there is evidence to suggest a causal relationship between the drug and the 
AE. A suspected adverse reaction implies a lesser degree of certainty about causality than adverse react ion, which means any AE caused by a drug.  
 
12.2.3  Unexpected Adverse Event  
 
An unexpected AE or suspected adverse reaction is considered “unexpected” if it  is not listed  in 
the Investigator  Brochure or is not listed  at the specificity  or severity that has been observed;  or, 
if an Investigator Brochure is not required or available, is not consistent with the risk  information 
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  110 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
described in the General  Investigational Plan or elsewhere in the current  application,  as 
amended.  
 
12.2.4  Serious  Adverse  Events 
 
An AE or suspected  adverse reaction is considered “serious”  if, in the view of either  the 
Investigator or Sponsor, it results in any of the following outcomes:  
• is fatal 
• is life-threatening (i.e., places  the patient  at immediate  risk of death)  
• requires  in-patient  hospitalization or prolongation of existing  hospitalization  
• results  in persistent  or significant  disability/incapacity  
• is a congenital  anomaly/birth defect  
• is a significant  medical  hazard,  such as new malignancy  
A hospitalization meeting the regulatory definition for “serious” is any in- patient hospital 
admission that includes a minimum of an overnight stay in a health care facility. Any AE that 
does  not meet  one of the definitions  of serious  (i.e., emergency  room  visit, out-patient  surgery, 
or requires urgent investigation) may be considered by the Investigator to meet the “other 
significant medical hazard” criterion for classification as a serious adverse event (SAE).  
12.3 Reporting  Procedures for All Adverse  Events 
 
The Investigator is responsible for ensuring that all AEs (as defined in Section 12.2) observed 
by the Investigator  or reported  by patients  are properly  captured  in the patients’  medical  records 
and reported in the Adverse Event eCRF.  
The following  AE attributes  must  be assigned  by the Investigator:  event  description (with  detail 
appropriate to the event); seriousness; dates of onset and resolution; severity; assessment of 
relatedness to entinostat and to atezolizumab; and the action taken. The Investigator may be asked to provide follow -up information, discharge summaries, and extracts from medical 
records.  
If applicable,  the study  drug relationship  will be assessed by means  of the question:  “Is there  a 
reasonable possibility that the event may have been caused by the combination of entinostat  

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  111 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
with atezolizumab?”  The causal  relation  between  an AE and the study  drug will be determined 
by the Investigator on the basis of his or her clinical judgment and the following definitions:  
 
• Related: event  can be fully explained by administration of the study  drugs  
 
• Possibly related : event  may be explained by administration  of the study  drugs,  or by 
the patient’s clinical state or other agents/therapies  
 
• Unlikely related: event  is most  likely  to be explained by the patient’s  clinical state  or 
other agents/therapies  
 
• Not related : event  can be fully explained by the patient’s  clinical state  or other 
agents/therapies  
 
When assessing the relationship between administration of the study drug and the AE, the 
following should be considered: follows a temporal sequence from administration of investigational product is a known response to the investigational product based on clinical or 
preclinical data could not be explained by the known characteristics of the patient’s clinical 
state, environmental or toxic factors,  or other therapy administered to the  patient disappears or 
decreases  upon cessation or reduction of dose of investigational product  reappears  or worsens 
when investigational product is reinstated. 
 
Whenever  possible,  the CTCAE,  version 4.03,  should be used  for assessing the severity  of AEs 
(https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010- 06- 
14_QuickReference_8.5x11.pdf).  
 
For AEs that are not adequately  addressed  in the NCI CTCAE,  the standard severity grading 
scale may be used ( Table 12-1 ). 

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  112 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
Table  12-1 Standard Severity Grading Scale 
 
Grade  Standard  Adverse  Event  Severity  Scoring  System  
 
1 Mild: Aware  of sign or symptom,  but easily  tolerated.  
 
2 Moderate:  Discomfort  enough  to cause interference  with usual  activity.  
 
3 Severe:  Incapacitating  with inability  to work  or do usual  activity.  
 
4 Life-Threatening:   Refers  to an event  in which  the patient  was, in the view of 
the Investigator,  at risk of death  at the time of the event. 
(This category is not to be used for an event that 
hypothetically might have caused death if it were more severe.)  
 
5 Fatal:  Event  resulted  in death.  
 
  
 
It will be left to the Investigator’s clinical judgment to determine whether an AE is related and of 
sufficient severity to require the patient’s removal from treatment or from the study. A patient 
may also voluntarily withdraw from treatment due to what he/she perceives as an intolerable AE. If either  of these  situations  arises, the patient  should be strongly  encouraged to undergo  an 
end-of-study assessment and be under medical supervision until symptoms cease or the 
condition becomes stable.  
12.4 Serious  Adverse  Event  Reporting  Procedures 
SAEs will be collected and recorded throughout the study period, beginning with the signing of the informed  consent  form through  90 days  after the last dose  of study  drug,  or after the end of 
the study  if thought  to be related to entinostat  or the combination.  All SAEs  must  be reported  to 
Syndax  or its represent ative  within  24 hours  of discovery  or notification  of the event.  Initial  SAE 
information and all amendments or additions must be recorded on a Serious Adverse Event Report Form and provided to Syndax or its representative. The SAE reporting procedure is provided in the Study Manual.  
For all deaths, available autopsy reports and relevant medical reports should be provided to 
Syndax  or its representative.  If a patient  is permanently  withdrawn  from the study  because  of an 
SAE, this information must be included in the initial or follow -up Serious Adverse Event Report 
Form as well as  the EOS eCRF.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  113 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
The Investigator  should notify  the IRB or EC of SAEs  occurring at the site and other  AE reports 
received from Syndax, in accordance with local procedures and statutes.  
 
12.4.1  Pregnancy and Lactation Reporting Procedures 
 
Although pregnancy  and lactation are not considered AEs,  it is the  responsibility  of Investigators 
or their designees to report any pregnancy or lactation in a patient (spontaneously reported to 
them) that occurs during the study or within 120 days of last dose of study drugor 30 days 
following cessation of treatment if the patient initiates new anticancer therapy, whichever is 
earlier. All patients who become pregnant must be followed to the completion/termination of the 
pregnancy.  Pregnancy  outcomes  of spontaneous  abortion,  missed abortion,  benign hydatidiform 
mole, blighted ovum, fetal death, intrauterine death, miscarriage, and stillbirth must be reported as SAEs (Important Medical Events). Such events must be reported within 24 hours to the Sponsor either by electronic media or paper. Sponsor Contact information can be found in the Study Manual.  
If the pregnancy  continues  to term,  the outcome  (health of infant)  must  also be reported.  
 
Please refer to the Study  Manual  for further  details  on the pregnancy  reporting procedure  and 
associated report form.  
12.4.2  Definition of an Overdose and Reporting of Overdose to the Sponsor  
 
For this study, a study drug overdose will be defined as any amount over the specified dose of 1,200 mg dose for atezolizumab and  >15 mg for entinostat. No specific information is available 
on the treatment of overdose of Atezolizumab or entinostat. If such an event occurs, TRIO should be immediately  notified  and the patient  observed  closely  for signs  of toxicity.  Any toxicity 
that occurs as a result of the overdose will be captured on the AE eCRF within 24 hours of site awareness. Appropriate supportive treatment should be provided if clinically indicated. An overdose will not be considered an SAE unless the outcome of the SAE meets seriousness criteria as defined in Section 12.2.4 Serious Adverse Events . 
 
12.4.3  Adverse  Events of Special  Interest  with Atezolizumab 
 
Selected non- serious and SAEs are also known as AESI, Adverse Events of Special Interest. 
As noted in Section  9.6, DLTs  will also be captured as AESI.  AESI  must  be recorded as such in 

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  114 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
the AE eCRF,  completing the same  fields  as for Serious  Adverse  Events,  and reported  within  24 
hours  to the Sponsor.  Such  events  must  be documented  through  90 days  following  cessation of 
treatment, or 30 days after the initiation of a new anticancer therapy, whichever is earlier.  
Sponsor  Contact  information  can be found in the Study  Manual.  
 
Toxicities  associated or possibly  associated with atezolizumab treatment  should be managed 
according to standard medical practice.  Additional tests, such as autoimmune serology or 
biopsies, should be used to determine a possible immunogenic etiology.  
Although most immune -mediated adverse events observed with immunomodulatory agents 
have been mild and self-limiting,  such events  should be recognized early  and treated promptly 
to avoid potential major complications.  Discontinuation of atezolizumab may not have an 
immediate therapeutic effect and, in severe cases, immune- mediated toxicities may require 
acute management with topical corticosteroids, systemic corticosteroi ds, mycophenolate, or 
TNF-α inhibitors.  
The investigator should consider the benefit -risk balance for a given patient prior to further 
administration of atezolizumab.  Atezolizumab should be permanently  discontinued in patients 
with life -threatening immune- mediated adverse events.  
For the management  of other  adverse events  associated  with the atezolizumab not 
provided below,  refer to the Atezolizumab  IB. Patients should be assessed for possible 
AESIs prior to each dose of study medication. Laboratory results  should be evaluated and 
patients should be asked for signs and symptoms suggestive of an immune -related event. 
Patients who develop an AESI thought to be immune- related should have additional testing to 
rule out other causes. If laboratory results or symptoms indicate a possible immune -related 
AESI,  then additional testing should be performed  to rule out other  causes. If no other  cause is 
found, then it is assumed to be immune -related.  
The following  conditions  may be suggestive of an autoimmune disorder  and are considered 
AESI for this study:  
 Pneumonitis  
 Colitis  
 Endocrinopathies:  Diabetes  mellitus, Pancreatitis,  Adrenal  Insufficiency, 
Hyperthyroidism, and Hypophysitis  
 Vasculitis  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  115 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
 Cases  of potential  drug-induced liver injury  that include  AST or ALT >3x 
ULN in combination with bilirubin >2x ULN 
 Hepatitis  Transaminitis:  including AST/ALT  >10x  ULN 
 Systemic Lupus  Erythematosus  
 Neurologic  Disorders:  Guillain  Barre  Syndrome,  myasthenic  syndrome  or 
Myasthenia Gravis, and meningoencephalitis  
 Grade ≥2 Cardiac  Disorders  (e.g.,  Atrial  fibrillation,  Myocarditis, 
Pericarditis)  
 Events  suggestive of hypersensitivity,  infusion related reactions,  cytokine 
release syndrome, influenza like illness, SIRS, and systemic immune 
activation  
 Nephritis  
 Ocular  toxicities  (e.g.,  uveitis,  retinitis,  and optic  neuritis)  
 Myositis  
 Myopathies,  including rhabdomyolysis  
 Autoimmune  hemolytic  anemiaSevere  cutaneous  reactions  (e.g., 
Stevens -Johnson syndrome, dermatitis bullous, toxic epidermal 
necrolysis)  
 Suspected transmission of an infectious  agent  by the study  treatment,  as 
defined below:  
• Any organism, virus, or infectious particle (e.g., prion protein transmitting transmissible spongiform encephalopathy), pathogenic or non- pathogenic, is considered an infectious 
agent.  A transmission of an infectious  agent  may be suspected 
from clinical symptoms or laboratory findings that indicate an 
infection in a patient  exposed to a medicinal  product.  This term 
applies only when a contamination of study treatment is 
suspected.  
 
 
12.4.4  Follow -Up of Adverse Events 
 
The Investigator must continue to follow all SAEs and non- serious AEs considered to be 
possibly related or related to study drug (as defined in section 12.3 ) until resolution or the 
Investigator  assesses  them  as chronic  or stable.  This follow- up may extend  after the end of the 
study.  

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  116 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
12.4.5  Reporting  Safety  Information  
 
The Investigator must promptly report to his or her IRB/EC all unanticipated problems involving 
risks to patients.  This includes  death from any cause and all serious  adverse events  reasonably 
or possibly associated with the use of study drug according to IRB/EC procedures.  
 
12.4.6  Protocol  Deviations Due to an Emergency or Adverse Event  
 
Departures  from the protocol  will be determined as allowable  on a case- by-case basis  and only 
in the event of an emergency. The Investigator or other physician in attendance in such an emergency  must  contact  the Medical  Monitor  as soon as possible to discuss the circumstances 
of the emergency.  
The Medical  Monitor,  in conjunction with the Investigators,  will decide whether  the patient 
should continue to participate in the study. All protocol deviations and corresponding 
remediation plan will be tracked in the TRIO Clinical Trial Management System.  
Period of Observation:  
 
The table below  summarizes  the different  periods  of observation of AE, SAE,  AESI  with 
Atezolizumab and Pregnancy/Lactation. 
 
 
 
Type of 
Event  AE SAE AESI with 
Atezolizumab  Pregnancy/Lactation  
Reporting 
period  From  consent 
until 30 days 
after the end of the 
treatment  From consent until 90 days 
after the last dose of study 
treatment for all 
SAEs, and any 
time after the 
end of study for SAEs believed 
related to 
entinostat  or the 
combination  From consent 
until 90 days 
after the last dose of study 
treatment, or 
30 days aft er 
the initiation  of 
a new anticancer 
therapy, 
whichever is 
earlier  From consent until 120 days after the 
last dose of study treatment or 30 days 
following the 
discontinuation of the 
study treatment in case of the start of a new anticancer 
therapy  
Note: all patients becoming pregnant 
must  be followed  up 
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  117 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
    to the completion  / 
termination of the 
pregnancy.  
Reporting 
Timelines  to 
the Sponsor  Entered  into 
the clinical 
database on 
an ongoing 
basis  Within  24 hours  Within  24 
hours  Within  24 hours  
 
12.5 Safety  Monitoring  
The safety and tolerability of the investigational treatments will be monitored throughout the 
course of the study by the Investigator and the Medical Monitor. Additionally, an independent data safety  monitoring board (DSMB)  will be established for the Phase  2 portion of this study  to 
act in an advisory capacity to the Sponsor with respect to safeguarding the interests of trial patients and assessing the safety of the interventions administered during the trial.  
 
The safety and tolerability data that will be reviewed by the Medical Monitor and DSMB will include, but are not limited to, adverse events, laborator y test results, and patient 
discontinuations.  Additionally,  the development  of serious  adverse  events  will be assessed by 
the Medical  Monitor  and DSMB  on a continuous  basis. Note:  All serious  adverse  events  must 
be reported to the Sponsor within 24 hours of discovery or notification of the event.  No formal 
safety stopping rules are specified in the protocol.  However, if any significant safety issues  
arise, a decision to modify or terminate the trial will be made by the Sponsor in collaboration with the DSMB and the study’s Steering Committee.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  118 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
13. STATISTICAL  CONSIDERATIONS  
 
13.1 Sample Size Estimation  
 
13.1.1  Dose Determination Phase 
 
Three to 6 patients will be enrolled in each dose cohort based on a standard Phase 1 dose- 
finding scheme.  The total number  of patients  to be enrolled in the dose  determination phase is 
dependent upon the observed safety profile, which will determine the number of patients per 
dose cohort, as well as the number of dose adjustments required to achieve either the MTD or the recommended Phase 2 dose. Therefore between 6 and 18 patients will be included in the Dose Determination Phase 1 part.  Note: patients who discontinued the  study for reasons other 
than study drug related toxicities before completing cycle 1 may be replaced.  
A starting  sample  size of 3 evaluable patients  per dose cohort,  expanding  to 6 in the event  of a 
marginal  DLT rate (33%)  was deemed  to be a safe and conventional  approach in dose- finding. 
Assuming a true DLT rate of 5% or less, there would be a 3% chance that dose escalation would be halted in a given cohort (i.e., observing 2 or more patients with DLT).  If a true DLT 
rate of 50% is assumed, then there would be an 83% chance that dose escalation would be halted in a given cohort.  
 
13.1.2  Expansion Phase 
 
The Expansion Phase will evaluate the efficacy and safety of entinostat when administered at the recommended Phase 2 dose with atezolizumab in a randomized, double- blind, placebo- 
controlled setting.  Up to 70 eligible  patients  with metastatic  TNBC will be randomized  to receive 
atezolizumab with entinostat or placebo in a 1:1 allocation.  
The true median PFS for patients with aTNBC receiving atezolizumab monotherapy is expected to be approximately 4 months from the initiation of such treatment.  It is hypothesized that the 
combination of entinostat and atezolizumab will improve true median P FS by 3 months (i.e., 
from 4 to 7 months).  Under the exponential distribution, such an improvement in median PFS 
represents  a reduction of 43% for the true PFS failure  hazard rate or equivalently,  a hazard ratio 
of 0.57.  Inferential comparisons will be performed using a stratified log- rank test, stratifying on 
the randomization stratification factor of geographic location.  Total information of 60 PFS 
failures, defined as documented progressive disease by RECIST 1.1 or death due to any cause  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  119 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
without  documented progressive disease beforehand,  is estimated  to provide 80% power  to 
detect a 43% reduction in the PFS failure hazard rate with 1 -sided significance level of 0.1 
(SEQDESIGN procedure, SAS version 9.2).  
Assuming approximately 9 months of accrual and an additional 9 months of follow -up, total 
accrual of 70 patients (approximately 35 per treatment arm) is projected to result in 60 PFS 
failures within approximately 18 months of the first patient randomization.  Patients who 
discontinue study  treatment  for reasons  not due to documented progressive disease by RECIST  
1.1 will continue to undergo disease assessments  until the earlier  of documented progressive 
disease, death, or withdrawal of consent/lost to  follow- up. It is anticipated that the number of 
patients who will drop out of the study without PFS failure beforehand will be low (2– 3%). 
Depending on the actual number of such dropouts, the number of patients accrued may be increased by  6–10 additional patients to accommodate for a higher -than-expected number of 
dropouts.  
13.2 Phase 2 Interim  Efficacy Analyses 
The sample size and number  of PFS failures  were  adjusted using  the O’Brien  
 
-Fleming group sequential procedure to account for 1 planned interim analysis of PFS after 45 
events  (75%  information).  It is projected that 75% and 100%  of total information will be reported 
at approximately 12 and 18 months, respectively. 
The interim  analysis  will be performed  to support  the Sponsor’s  product  development  plans  and 
ongoing resourcing activities. Although  there  are no plans  to terminate  the study  early  because 
of early evidence of superior efficacy for the combination treatment, the significance levels at 
the interim analysis and final analysis will be adjusted to maintain control of the overall type I 
error rate for multiple testing of PFS ( O’Brien 1979).  

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  120 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
13.3 Populations  for Analysis 
The Ful l  Analysis  Set (FAS)  will serve as the primary  population  for the analysis  of PFS and 
other  efficacy- related endpoints  in the Phase 2 portion of the study.  The FAS will include  all 
patients who undergo randomization, irrespective of the actual receipt of study treatment.  
Patients  will  be grouped  for analysis  according  to the treatment  arm to which  they were 
randomized.  
The Pe r -protocol  Analysis  Set is for various  supportive  analyses  that may be performed;  this 
excludes patients with important deviations that may substantially affect the results of the 
primary efficacy analyses. The final determination on protocol violations, and thereby the composition of the per-protocol  set, will be made  prior to locking  the clinical database  will be 
documented in a separate memo.  
The Safety Analysis Set  wi
 ll be used for the analysis of safety data  in both the Phase 1b and 
Phase 2 portions  of the study.  The safety  population will consist of all patients  who receive  at 
least 1 dose of either entinostat or atezolizumab.  At least 1 laboratory or other safety -related 
assessment subsequent to at least 1 dose of entinostat and atezolizumab is required for inclusion in the analysis of a specific safety parameter.  To assess change from baseline, a 
baseline measurement is also required.  
A patient that experiences an AE meeting DLT criteria during Cycle 1 or who receives the full dos
e of atezolizumab  and all doses  of entinostat  during Cycle  1 without  experiencing a DLT,  is 
considered a DLT- evaluable patient.  
13.4 Study Endpoints 
The primary endpoint of the Phase 1b Dose Determination portion of the study is the recommended Phase 2 dose  as assessed by incidence of DLT and overall  tolerance.  
The endpoints  of the randomized Phase  2 Expansion portion of the study  are as follows:  
 
Primary  Efficacy  
 
• PFS,  as determined by the local investigator  using  RECIST  1.1 
Secondary Efficacy  
 
• PFS as determined  by irRECIST  
• ORR (CR or PR), by RECIST  1.1 and irRECIST  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  121 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
• CBR (CR, PR, or SD for at least  24 weeks)  
• OS 
• TTR and DOR  (in patients  who experience  a best overall  response  of CR or PR) 
Safety 
 
• AEs,  clinical laboratory  parameters,  vital signs,  physical exams  
Exploratory:  
 
•  
•  
 
•  
•  
•  
•  
•  
 
•  
•  
•  
•  
 
13.5 Statistical Methods 
 
13.5.1  General  
 
The statistical  analyses  performed  for this study  will be presented  by study  phase.  For the Dose 
Determination phase, tabulations will be provided by dose cohort and overall.  For the 
expansion phase, tabulations will be provided by treatment arm.  Some analyses may be 
performed based on both phases combined. 
The statistical analyses will be performed using SAS® version 9.2 or later (SAS Institute Inc, 
Cary NC).  Programming specifications will be prepared which describe the datasets and 
variables  created  for this study.  The datasets  will be prepared  using the most  recent  version  of 
CDISC’s Study Data Tabulation Model (SDTM) and Analysis Dataset Model (ADaM).  The 

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  122 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
source  SDTM  and ADaM  datasets  from which  a statistical analysis  is performed  (including 
interim reviews) will be archived with the Sponsor.  
 
13.5.2  Patient  Disposition 
 
The number  of patients  included in each  analysis  set will be summarized,  along with the reason 
for any exclusions.  Patients discontinuing from study treatment and/or withdrawing from study 
participation the primary reason for discontinuation will be summarized.  
 
13.5.3  Demographics  and Characteristics  
 
Descriptive  summaries  of demographic  and screening characteristics will be tabulated for each 
study phase.  
 
13.5.4  Extent  of Exposure 
 
The overall duration of study treatment administration and number of cycles initiated will be 
tabulated for each patient and summarized for each study phase.  For each patient, the 
cumulative doses administered (in mg) of both entinostat and atezolizumab will be calculated. These data will be further summarized for each dose cohort (or treatment arm) by calculating the mean,  standard  deviation,  median,  and range  of these  values.  The number  and proportion 
of patients  with one or more  dose  modifications  (i.e., reduction  or delay)  will be tabulated  along 
with the reason for modification.  
 
13.5.5  Efficacy  Analyses  
 
Efficacy analyses  will be conducted using  the Full Analysis  Set and, where  appropriate,  the Per- 
protocol Set.  With the exception of PFS, all hypothesis testing will be assessed using a one- 
sided significance level of 0.1.  The Lan- DeMets alpha spending function with an O’Brien- 
Fleming type boundary will be used to control the overall type I error for multiple testing of PFS. The boundary will be derived based on the actual number of PFS failures reported for each analysis.  
The primary efficacy endpoint is duration of PFS, defined as the number of months from randomiza tion to the earlier of progressive disease or death due to any cause. Disease 
assessments will continue until progressive  disease,  even  after the  originally  assigned study 
treatment  is discontinued.  For purposes  of analysis,  one month  is considered 30.4375 days.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  123 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
The duration of PFS will be summarized  descriptively  using the Kaplan- Meier  method  with 95% 
confidence intervals calculated using Greenwood’s formula.  Inferential comparisons between 
treatment arms will be made using the stratified log rank test, stratifying on the randomization 
stratification factor of geographic location. Estimation of the hazard ratio for treatment effect 
and its corresponding 95% confidence interval will be determined using a stratified Cox proportional hazards model, without any other covariate.  Homogeneity in the hazard ratios 
between randomization strata will be examined by Wald’s test. The corresponding results 
without stratification will be reported as supplemental analyses.  The adequacy of the Cox 
model will be evaluated, including an assessment of the proportional hazards assumption 
(Therneau 2000).  
 
For the interim  and primary  analyses,  PFS will be right-censored for patients  who meet  one or 
more of the following conditions:  
• Patients  with no screening or post-screening disease assessments  unless  death 
occurred prior to the first planned assessment (in which case the death will be 
considered a PFS event)  
• Patients  who initiate  subsequent  anticancer  therapy  in the absence  of documented 
progression  
• Patients  who die or have  progressive  disease  after missing  2 or more  consecutively 
scheduled disease assessment visits  
• Patients  who are last known  to be alive and progression- free on or before  the data cut- 
off date 
 
For such patients,  the progression or censoring date will be determined  based on described 
conventions  (FDA 2007).  Sensitivity  analyses  will be performed to assess  the impact  of the 
different censoring mechanisms and deviations from the planned schedule of disease 
assessments ( Bhattacharya 2009 ; Stone 2011 ). 
ORR will be estimated based on the crude proportion of patients in each treatment arm whose best overall  response during the course of study  treatment  is CR or PR. Tumor  response  will be 
assessed using irRECIST.  Approximate 95% confidence intervals will be calculated by 
treatment  arm for the true ORR.  The inferential  comparison of the observed ORRs  will be made 
using the Cochran- Mantel -Haenszel chi -square test, stratified by the randomization stratification 
factors. The corresponding results without stratification will be reported as supplemental 
analyses.  

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  124 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
DOR will be calculated for patients who achieve CR or PR.  For such patients, DOR is defined 
as the number  of months  from the start date of PR or CR (whichever  response  occurs first) and 
subsequently confirmed, to the first date that recurrent or progressive disease is documented. 
The date of progression or censoring for DOR will be determined using the conventions described for PFS.  DOR will be summar ized descriptively for each treatment arm using the 
Kaplan- Meier method.  Inferential comparisons between treatment arms for DOR are not 
planned.  
CBR will be estimated based on the crude proportion of patients in each treatment arm whose best overall response during the course of study treatment is CR, PR, or stable disease lasting for at least 24 weeks.  Stable disease will be measured from the start date of study treatment 
until the criteria  for progressive disease  is first met. The analysis  of CBR and its duration will be 
based on the methods described above for ORR and DOR, respectively.  
OS is defined as the number of months from randomization to the date of death (due to any cause).  Patients  who are alive or lost to follow- up as of a data analysis  cutoff date will be right- 
censored.  The censoring  date will be determined from the patients’  date of last contact  or data 
analysis cutoff date, whichever date occurs first.  The analysis of OS will be based on the 
methods described above for PFS.  
 
13.5.6  Safety  Analyses  
 
Safety will be assessed by clinical review of all relevant parameters including AEs, SAEs, 
laboratory values, vital signs, physical exam and ECG results. Unless specified otherwise, the 
safety  analyses  will be conducted  for the safety  population.  An interim  safety  analysis  is planned 
following the completion of Cycle 1 for the first 20 patients enrolled in the Phase 2 expansion phase and will utilize a Data Safety Monitoring Board. 
Summary tables and listings will be provided for  all reported Treatment Emergent Adverse 
Events  (TEAEs),  defined  as AEs that start on or after the first administration of study  treatment. 
The reported AE term will be assigned a standardized preferred term using the current version 
of the Medical Dictionary for Regulatory Activities (MedDRA).  
TEAEs  will be summarized  based  on the number  and percentage  of patients  experiencing the 
event by MedDRA system organ class (SOC) and preferred term (PT).  In the event a patient  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  125 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
experiences  repeat  episodes  of the same AE, then the event  with the highest  severity  grade  and 
strongest causal relationship to study treatment will be used for purposes of incidence 
tabulations.  
Tabular  summaries  will be provided for: 
 
• all TEAEs  
• TEAEs  by relationship to study  treatment  and maximum  severity grade 
• TEAEs  with action of study  treatment  delayed/interrupted or dose reduced 
• TEAEs  with action of study  treatment  discontinued 
• SAEs  
 
For the escalation  phase,  the observed DLT rate in each  dose  cohort  will be calculated  by the 
crude proportion of patients who experienced DLT with a 2- sided 95% exact binomial CI.  
All deaths that occur on study (defined as during treatment or within 30 days of treatment discontinuation)  will be reported  in a patient  listing,  which  will include the primary  cause of death 
and the number of days between the date of the last dose of study drug and death.  
Hematology  and serum  chemistries  will be summarized  in a descriptive manner  by calculating 
the mean, standard deviation, median, and range as follows:  
• baseline value  
• minimum  post baseline value  
• maximum  post baseline value  
• average post baseline value  
• last post baseline value 
 
Laboratory values will be assigned toxicity grades when available using the NCI Common 
Terminology Criteria for Adverse Events (CTCAE) version 4.03.  Directional shifts in laboratory 
toxicity grades (comparing baseline grade with worst post -baseline grade) will be analyzed 
using standard shift tables, presenting number and proportion of patients and their maximum 
grade shift.  For analytes without a toxicity grading scale, the shift table will present directional 
shifts  from baseline  to above or below  the laboratory  standard normal  range using the maximum 
increase and/or decrease observed throughout the course of treatment/observation.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  126 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
Vital signs  will be summarized in a descriptive  manner  by calculating  the mean,  standard 
deviation, median, and range in the same manner described for laboratory values.  
ECG results will be listed and summarized in terms of the number and percentage of patients 
with abnormal  and normal  findings,  as reported by the Investigator,  at the time points  assessed 
(screening and EOT).  
Prior  and concomitant  medications  will be coded  to generic  term using the current  version  of the 
World Health Organization Drug Dictionary and will be tabulated and listed by patient.  
 
13.5.7  Pharmacokinetic  and Antidrug  Antibody  Analyses 
 
A population PK analysis will be used to describe the PK of entinostat. The effects of patient 
factors  (e.g.,  demographics,  clinical chemistries,  disease)  on entinostat  PK will be evaluated.  In 
addition, the relationship between entinostat  exposure parameters and indicators of safety will 
be assessed.  
Specific  details  for these  analyses  as well as analyses  of trough atezolizumab levels  and anti- 
atezolizumab antibodies will be provided in a separate analysis plan.  
 
13.5.8  Correlative Analyses 
 
Immune correlate values will be summarized in a descriptive manner.  For immune correlates 
measured  on a continuous  scale,  the number  of patients  with no missing  data,  mean,  either  the 
standard  error  or standard deviation,  median,  25th percentile (first quartile),  75th percentile (third 
quartile), minimum, and maximum values will be presented. For discrete data, the frequency 
and percent distribution will be presented.  The Wilcoxon signed rank test (for within- treatment 
comparisons) and Wilcoxon rank sum test (for between- treatment comparisons) will  be used to 
identify any systematic changes in biomarker levels from baseline.  Additionally, the correlation 
among the various  initial immune correlate  values  may be assessed by calculating Spearman’s 
correlation coefficient.  Analysis of covariance models may be used to explore the relationship 
between changes in immune correlates and selected measures of antineoplastic activity (e.g., maximum change from baseline in the sum of product diameters in measurable les ions).  The 
association among the various immune correlates and clinical outcomes (data permitting) may 
be explored using heat map and other data visualization techniques.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  127 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
14. REGULATORY  OBLIGATIONS  
 
This clinical study  was designed and shall be implemented  and reported  in accordance  with the 
protocol, the ICH Harmonized Tripartite Guidelines for Good Clinical Practice, with applicable 
local regulations  (including European Directives  2001/20/EC and 2005/28/EC  and the US Code 
of Federal Regulations Title 21), and with the ethical principles laid down in the Declaration of 
Helsinki.  
14.1 Informed  Consent  
A template informed consent form is provided for the Investigator to prepare the informed 
consent  document  to be used at his or her site. Updates to the template  will be communicated 
by letter from Syndax or designee to the Investigator. 
Before a patient’s participation in the clinical study, the Investigator is responsible for obtaining 
written informed consent from the patient or legally acceptable representative after adequate 
explanation of the aims, methods, anticipated benefits, and potential hazards of the study and before any protocol -specific  screening procedures  are conducted or any investigational  products 
are administered. The acquisition of informed consent should be documented in the patient’s medical records, and the informed consent form should be countersigned by the person who 
conducted the informed consent discussion (not necessarily an Investigator). The original  
signed informed consent form should be retained in accordance with institutional policy, and a copy of the signed consent form should be provided to the patient or legally acceptable representative.  
14.2 Institutional  Review  Board  (IRB)/Ethics  Committee  (EC) 
A copy of the protocol, proposed informed consent form, other written patient information, and 
any proposed adve rtising  material  must  be submitted to the IRB/EC  for written  approval.  A copy 
of the written approval of the protocol and informed consent form, in addition to other essential 
regulatory documents per Section 14.3, must be received by Syndax or designee before 
recruitment of patients into the study and shipment of study drug. 
The Investigator must submit and obtain approval from the IRB/EC for all subsequent protocol 
amendments  and changes  to the informed consent  document.  The Investigator  should notify  the 
IRB/EC of deviations from the protocol or SAEs occurring at the site and other AE reports received from Syndax, in accordance with local procedures. 

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  128 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
When required, the Investigator will be responsible for obtaining annual IRB/EC renewals 
throughout  the duration of the study. Copies  of the Investigator’s  submission and the IRB/EC 
continuance of approval must be sent to Syndax or its representative.  
14.3 Pre-study  Documentation Requirements  
The Investigator  is responsible for providing the following  documents  to Syndax  or its 
representative before study initiation can occur:  
• Signed and dated protocol  signature  page  (Investigator’s  Agreement).  
• Completed Food and Drug  Administration  form 1572 or equivalent  per local regulatory 
requirements.  
• Curricula  vitae  of Principal Investigator  and all sub-investigators  (updated within 
12 months).  
• Copy  of the IRB/EC  approval  of the protocol,  consent  form,  and patient  information 
sheet.  
• IRB/EC  composition or written  statement  that the board is in compliance with 
regulations.  
• Laboratory  normal  ranges  and documentation  of laboratory  certification  (or equivalent).  
• Signed Clinical Trial Agreement  between Syndax  or its representative and the 
authorized representative at the institution, or investigator if applicable.  
• Completed Financial  Disclosure  statements  for the Principal  Investigator  and all 
sub-investigators.  
14.4 Patient  Confidentiality  
The Investigator must ensure that the patient’s confidentiality is maintained. In the eCRFs or 
other study documentation submitted to Syndax or its representative, patients should be 
identified only by their initials  (unless  prohibited  by local regulatory  guidelines)  and a patient  ID 
number. Patient samples should be identified only by the patient ID number. Documents that 
are not for submission to Syndax or its representative (i.e., signed informed consent forms) should be kept in strict confidence by the Investigator. 
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  129 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
In compliance with federal guidelines and applicable local regulations, it is required that the 
Investigator  and institution  permit  authorized  representatives of  the company,  of the regulatory 
agency(s), and the IRB/EC direct access to review the patient’s original medical records for 
verification  of study -related procedures  and data.  Direct  access includes  examining,  analyzing, 
verifying, and reproducing any records and reports that are important to the evaluation of the study. The Investigator is obligated to inform and obtain the consent of the patient to permit named representatives to have access to his/her study -related records without violating the 
confidentiality of the patient.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  130 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
15. ADMINISTRATIVE  AND LEGAL  OBLIGATIONS  
 
15.1 Protocol  Amendments  and Study  Termination  
All protocol amendments will be implemented by Syndax  and must receive Health Authority 
(where required) and IRB/EC approval before implementation, except where necessary to 
eliminate  an immediate hazard to patients.  The Investigator  must  send a copy  of the approval 
letter from the IRB/EC, along with the revised Informed Consent form, to Syndax or its representative.  
Both Syndax  and the Investigator  reserve  the right to terminate  the study  according to the study 
contract. The Investigator should notify the IRB/EC in writing of the study’s completion or early termination and send a copy of the notification to Syndax or its representative.  
15.2 Study Documentation  and Archive  
The Investigator must maintain a list of appropriately qualified persons to whom he/she has delegated study  duties.  All persons  authorized  to make  entries  and/or  corrections  on eCRFs  will 
be included on the Syndax Delegation of Responsibility Form.  
Source documents  are original  documents,  data,  and records  from which  the patient’s  eCRF 
data are obtained. These include but are not limited to hospital records, clinical and office charts, laboratory and pharmacy records, diaries, microfiches, radiographs, and 
correspondence.  
The Investigator and study staff are responsible for maintaining a comprehensive and 
centralized filing system of study -related documentation,  available  for inspection and audit  at 
any time by representatives from Syndax and/or applicable regulatory authorities. Elements should include:  
• Patient  files containing informed  consent  forms  and patient  identification  list. 
• Study  files containing the Protocol  with all amendments,  Investigator’s  Brochure,  copies 
of pre -study documentation ( Section14.3), and all correspondence to and from the 
IRB/EC and Syndax.  
• Investigational Product  Accountability  Records  and all drug- related correspondence.  

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  131 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
In addition, all original source documents supporting entries  on the eCRFs must be maintained 
and be readily  available.  Source documents  should be retained by the investigator  according to 
ICH-E6 and local regulations or as indicated in the clinical study agreement, whichever is 
longer.  
No study  document  should be destroyed  without  prior written  agreement  between Syndax  and 
the Investigator. Should the Investigator wish to assign the study records to another party or 
move them to another location, he/she must notify Syndax in writing of the new responsible 
person and/or the new location.  
15.3 Study Monitoring and Data  Collection  
A study  monitor  will be responsible for contacting  and visiting  the Investigator  for the purpose of 
inspecting the facilities; verifying the eCRFs at regular intervals throughout the study to assess adherence to the protocol; ensuring completeness, accuracy, and consistency of the data; and 
ensuring adherence to local regulations on the conduct of clinical research. The monitor should 
have access to patient medical records and other study -related records needed to verify the 
entries on the eCRFs.  
The Investigator  agrees  to cooperate with the monitor  to ensure  that any problems  detected  in 
the course of  these monitoring visits, including delays in completing eCRFs, are resolved.  
In addition to routine monitoring and in accordance with United States 21 CFR Parts 312, 50, and 56, the ICH GCP and applicable local regulatory requirements, the study site may be selected for audit by a designee of Syndax or its representative and/or regulatory inspection by appropriate regulatory authorities. Inspection and audit of site facilities (i.e., pharmacy, drug storage  areas,  laboratories)  and review  of study -related r ecords  may occur to evaluate  the study 
conduct and compliance with the protocol and applicable regulatory requirements.  
Agreements between Syndax, the Institution and/or Principal Investigator regarding study payments,  insurance coverages  and publication p olicy are covered  in the clinical trial agreement 
and not in this protocol.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  132 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
16.REFERENCES  
 
Adeegbe DO, Nishikawa  H. Natural  and induced  T regulatory  cells in cancer.  Frontiers  in 
immunology 2013;4:190 . 
Alao JP, Lam EW, Ali S, Buluwela  L, Bordogna W, Lockey  P, et al. Histone  deacetylase inhibitor 
trichostatin A represses estrogen receptor alpha- dependent transcription and promotes 
proteasomal degradation of cyclin D1 in human breast carcinoma cell lines. Clin Cancer Res 
2004;10(23):8094- 104. 
Atkinson EN, Brown  BW. Confidence limits  for probability  of response in multi -stage  phase  II 
clinical trials. Biometrics 1985; 41: 741– 744. 
Bhattacharya S, Fyfe G, Gray  RJ, Sargent  DJ. Role of sensitivity  analyses  in assessing 
progression- free survival in late -stage oncology trials. J Clin Oncol. 2009;27:5958- 64. 
Chang WJ, Du Y, Zhao  X, Ma LY, Cao GW. Inflammation- related  factors  predicting prognosis  of 
gastric cancer. World J Gastroenterol 2014;20(16):4586 -96. 
Cheng X, Veverka V, Radhakrishnan A, Waters  LC, Muskett FW, Morgan  SH, et al. Structure 
and interactions of the human programmed cell death 1 receptor. J Biol Chem 2013;288(17):11771- 85. 
FDA. (2 007, May). Guidance for Industry Clinical Trial Endpoints for the Approval of Cancer 
Drugs and Biologics. Retrieved from Food and Drug Administration Web Site: https://www.fda.gov/downloads/drugs GuidanceComplianceRegulatoyInformation/Gui dance/U C 
M071590.pdf . 
 
Freiser  ME, Serafini  P, Weed DT. The immune  system and head and neck  squamous  cell 
carcinoma: from carcinogenesis to new therapeutic opportunities. Immunologic Research 2013;57(1- 3):52- 69. 
Hauschi ld A, Trefzer  U, Garbe  C, Kaehler  KC, Ugurel  S, Kiecker  F, et al. Multicenter  phase  II 
trial of the histone deacetylase inhibitor pyridylmethyl -N-{4-[(2-aminophenyl) -carbamoyl] - 
benzyl} -carbamate in pretreated metastatic melanoma. Melanoma Res 2008;18(4):274 -8. 

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  133 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
Hess -Stumpp  H, Bracker TU, Henderson  D, Politz  O. MS-275, a potent  orally  available inhibitor 
of histone deacetylases --the development of an anticancer agent. Int J Biochem Cell Biol 
2007;39(7- 8):1388- 405. 
Huang X, Venet F, Wang YL, Lepape A, Yuan Z, Chen Y, et al. PD -1 expression by 
macrophages  plays  a pathologic  role in altering  microbial  clearance  and the innate  inflammatory 
response to sepsis. Proc Natl Acad Sci U S A 2009;106(15):6303 -8. 
ICH. (1996). Guideline for Good Clinical Practice E6 (R1). Retrieved from 
https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guid elines/Efficacy/E6/E6_R1_G    
uideline.pdf  
Joyce JA, Fearon DT. T cell exclusion,  immune  privilege,  and the tumor  microenvironment. 
Science 2015;348(6230):74- 80. 
Juergens RA, Wrangle J, Vendetti FP, Murphy SC, Zhao M, Coleman B, et al. Combination 
epigenetic  therapy  has efficacy in patients  with refractory  advanced non-small  cell lung cancer. 
Cancer Discov 2011;1(7):598- 607. 
Karim  R, Jordanova  ES, Piersma  SJ, Kenter  GG, Chen L, Boer  JM, et al. Tumor -expressed B7- 
H1 and B7- DC in relation to PD- 1+ T-cell infiltration and survival of patients with cervical 
carcinoma. Clin Cancer Res 2009;15(20):6341-7 . 
Keir ME1,  Butte  MJ, Freeman  GJ, Sharpe  AH. PD-1 and its ligan ds in tolerance and immunity. 
Annu Rev Immunol 2008;26:677 -704. 
Kim K, Skora AD, Li Z, Liu Q, Tam AJ, Blosser RL, et al. Eradication of metastatic mouse 
cancers  resistant  to immune  checkpoint  blockade  by suppression of myeloid -derived cells.  Proc 
Natl Acad Sci U S A 2014;111(32):11774 -9. 
Lázár -Molnár  E, Yan Q, Cao E, Ramagopal  U, Nathenson  SG, Almo  SC. et al. Crystal structure 
of the complex between programmed death -1 (PD -1) and its ligand PD -L2. Proc Natl Acad Sci 
U S A 2008;105(30):10483-8 . 
Lin DY, Tanaka Y, Iwasaki M, Gittis AG, Su HP, Mikami B, et al. The PD -1/PD -L1 complex 
resembles  the antigen- binding Fv domains  of antibodies  and T cell receptors.  Proc Natl Acad 
Sci U S A 2008;105(8):3011- 6. 

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  134 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
Liu C, Wang Y, Wang C, Feng P, Ko H, Liu Y, et al. Population alterations of L- arginase- and 
inducible nitric oxide synthase- expressed CD11b+/CD14⁻ /CD15+/CD33+ myeloid -derived 
suppressor  cells and CD8+  T lymphocytes in patients  with advanced -stage  non-small  cell lung 
cancer. Journal of Cancer Research and Clinical Oncology 2010;136(1):35- 45. 
Mahoney  KM, Rennert  PD, Freeman GJ. Combination  cancer  immunotherapy  and new 
immunomodulatory targets. Nature reviews. Drug discovery 2015;14(8):561- 84. 
Marvel  D, Gabrilovich  DI. Myeloid -derived suppressor  cells in the tumor  microenvironment: 
expect the unexpected. Journal of Clinical Investigation 2015;125(9):3356- 64. 
Najjar  YG, Finke  JH. Clinical perspectives  on targeting of myeloid  derived suppressor  cells in 
the treatment of cancer. Frontiers in oncology 2013;3:49 . 
Nishimura  H, Agata  Y, Kawasaki  A, Sato M, Imamura  S, Minato  N, et al. Developmentally 
regulated expression of the PD- 1 protein on the surface of double- negative (CD4- CD8-) 
thymocytes. Int Immunol 1996;8(5):773 -80. 
O’Brien  P, Feliming  T, A Multiple  Testing Procedure for Clinical Trials.  Biometrics  1979; 
35(3):549- 556 
Ott PA, Hodi FS, Robert  C. CTLA -4 and PD-1/PD -L1 blockade:  new immunotherapeutic 
modalities with durable clinical benefit in melanoma patients. Clin Cancer Res 
2013;19(19):5300-9 . 
Pedoeem  A, Azoulay -Alfaguter  I, Strazza M, Silverman  GJ, Mor A. Programmed  death -1 
pathway in cancer and autoimmunity. Clin Immunol 2014;153(1):145 -52. 
Peña- Cruz  V, McDonough SM, Diaz-Griffero  F, Crum  CP, Carrasco RD, Freeman GJ. PD-1 on 
immature and PD -1 ligands on migratory human Langerhans cells regulate antigen- presenting 
cell activity. J Invest Dermatol 2010;130(9):2222- 30. 
Sanmamed  MF, Chen  L. Inducible expression of B7-H1 (PD-L1) and its selective role in tumor 
site immune modulation. Cancer J 2014;20(4):256 -61. 
Shah P, Gau Y, Sabnis G. Histone deacetylase inhibitor entinostat  reverses epithelial to 
mesenchymal  transition of breast  cancer  cells by reversing  the repression of E-cadherin.  Breast 
Cancer Res Treat 2014;143(1):99- 111. 
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  135 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
Sharma P, Allison  JP. The future  of immune checkpoint  therapy.  Science 2015;348(6230):56- 
61. 
Shen Li, Ciesielski M, Ramakrishnan S, Miles KM, Ellis L, Sotomayor P, et al. Class I histone 
deacetylase inhibitor  entinostat  suppresses  regulatory  T cells and enhances  immunotherapies 
in renal and prostate cancer models. PLoS One 2012;7(1):e30815 . 
Sheppard KA, Fitz LJ, Lee JM, Benander  C, George JA, Wooters  J, et al. PD-1 inhibits  T-cell 
receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream 
signaling to PKCtheta. FEBS Lett, 2004;574(1 -3):37- 41. 
Solito  S, Falisi E, Diaz Montero  CM, Doni A, Pinton  L, Rosato  A, et al. A human promyelocytic- 
like population is  responsible for the immune suppression mediated by myeloid- derived 
suppressor cells. Blood 2011;118(8):2254 -65. 
Stone AM, Bushnell  W, Denne J, Sargent  DJ, Amit O, Chen C, et al. Research outcomes  and 
recommendations for the assessment of progression in cancer trials from a PhRMA working group. European Journal of Cancer. 2011;47:1763– 1771. 
Taube JM, Anders RA, Young GD, Xu H, Sharma R, McMiller TL, et al. Colocalization of 
inflammatory response with B7- h1 expression in human melanocytic lesions supports an  
adaptive resistance mechanism  of immune escape.  Sci Transl  Med 2012;4(127):127ra37. 
Therneau TM, Grambsch PM. Modeling survival data:  extending the Cox model.  New York: 
Springer Science & Business Media; 2000.  
Topalian SL, Drake  CG, Pardoll  DM. Targeting the PD-1/B7-H1(PD -L1) pathway  to activate anti- 
tumor immunity. Curr Opin Immunol 2012;24(2):207- 12. 
Uppaluri  R, Dunn  GP, Lewis,  JS, Jr. Focus  on TILs:  prognostic  significance  of tumor  infiltrating 
lymphocytes in head and neck cancers. Cancer Immun 2008;8:16 . 
Weber  JS, Gibney  GT, Yu B, Cheng  PY, Martinez  AJ, Kroeger  J, et al. Survival,  biomarker,  and 
toxicity analysis of nivolumab (NIVO) in patients  that progressed on ipilimumab (IPI). Journal of 
Clinical Oncology 2015;33:(suppl; abstr 9055). 
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  136 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
Weed DT, Vella JL, Reis IM, De la Fuente AC, Gomez C, Sargi Z, et al. Tadalafil reduces 
myeloid -derived suppressor cells and regulatory T cells and promotes tumor immunity in 
patients  with head and neck  squamous  cell carcinoma.  Clinical cancer  research 2015;21(1):39- 
48. 
Wrangle J, Wang  W, Koch  A, Easwaran  H, Mohammad  HP, Vendetti  F, et al. Alterations  of 
immune response of Non- Small Cell Lung Cancer with Azacytidine. Oncotarget 
2013;4(11):2067- 79. 
Wu A, Drake  V, Huang H, Chiu S, Zheng L. Reprogramming the tumor  microenvironment: 
tumor -induced immunosuppressive factors paralyze T cells. Oncoimmunology 
2015;4(7):e1016700. 
Yao S, Chen L. PD-1 as an immune modulatory  receptor.  Cancer  J 2014;20(4):262-4 . 
 
Zhang X, Kelaria S, Kerstetter J, Wang J. The functional and prognostic implications of 
regulatory  T cells in colorectal  carcinoma.  Journal  of Gastrointestinal  Oncology  2015;6(3):307- 
13. 
Zhang X, Schwartz  JC, Guo X, Bhatia  S, Cao E, Lorenz  M, et al. Structural  and functional 
analysis  of the costimulatory  receptor  programmed death- 1. Immunity  2004;20(3):337 -47. 
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  137 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
17. APPENDICES  
 
 
17.1 Appendix 1 New York  Heart  Association (NYHA)  Classification of Heart  Failure  
 
 
Class  Symptomatology  
I No symptoms.  Ordinary  physical  activity  such  as walking and climbing  stairs  does 
not cause fatigue or dyspnea.  
II Symptoms  with ordinary  physical  activity.  Walking  or climbing stairs  rapidly,  walking 
uphill, walking or stair climbing after meals, in cold weather, in wind or when under 
emotional stress causes undue fatigue or dyspnea.  
III Symptoms with less than ordinary  physical  activity.  Walking 1  to 2 blocks on the 
level and climbing  more than 1 flight  of stairs  in normal  conditions  causes  undue 
fatigue or dyspnea.  
IV Symptoms  at rest. Inability  to carry  on any physical  activity without  fatigue  or 
dyspnea.  
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  138 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
17.2 Appendix 2 Concomitant  Medications to be Avoided  
Examples  of sensitive in vivo CYP substrates  and CYP substrates  with narrow  therapeutic  range are 
summarized in Table 17-1 . 
Table  17-1: Examples of substrates  that may be affected  by entinostat  
 
 
CYP Enzymes  Substrates  with 
narrow  therapeutic  range1 
CYP1A2  Theophylline,  tizanidine  
CYP2C8  Paclitaxel  
CYP3A2 Alfentanil, astemizole3, 
cisapride,  cyclosporine, 
dihydroergotamine, 
ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, terfenadine  
1 CYP substrates with narrow therapeutic range refers to drugs whose exposure-response relationship indicates that 
small  increases  in their exposure  levels  by the concomitant  use of CYP inhibitors  may lead to serious  safety  concerns 
(e.g. Torsades de Pointes).  
2 Because  a number  of CYP3A substrates  (e.g. darunavir,  maraviroc) are also substrates  of P-gp,  the 
observed increase in exposure could be due to inhibition of both CYP3A and P -gp. 
3 Withdrawn from the United  States  market  because  of safety  reasons.  
  
Table  17-2 P- gp Inhibitors and Inducers 
 
 
Inhibitor  Inducer  
P-gp, MDR1  Amiodarone, azithromycin, captopril, carvedilol, clarithromycin, conivaptan, diltiazem, dronedarone,felodipine, lopinavir,quercetin,  ranolazine,  ticagrelor,  
ritonavir, cyclosporine, verapamil, erythromycin,  ketoconazole,  itraconazole, 
quinidine Avasimibe, carbamazepine, 
phenytoin,  rifampin,  St John’s 
Wort, tipranavir/ritonavir  

Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  139 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
17.3 Appendix  3: Pre-existing Autoimmune Diseases 
Subjects should be carefully questioned regarding their history of acquired or congenital 
immune deficiencies  or autoimmune disease.  Subjects  with any history  of immune deficiencies 
or autoimmune disease listed in the table below are excluded from participating in the study.  
Possible  exceptions  to this exclusion could  be subjects  with a medical  history  of such entities  as 
atopic disease or childhood arthralgias where the clinical suspicion of autoimmune disease is 
low. Patients with a history of autoimmune- related hypothyroidism on a stable dose of thyroid 
replacement hormone may be eligible for this study.  In addition, transient autoimmune 
manifestations of an acute infectious disease that resolved upon treatment of the infectious agent are not excluded (e.g., acute Lyme arthritis).  Contact the Medical Monitor regarding any 
uncertainty over autoimmune exclusions.  
 
Acute  disseminated  Dermatomyositis  Neuromyotonia  
encephalomyelitis  Dysautonomia  Opsoclonus  myoclonus  
Addison’s  disease  Epidermolysis  bullosa  acquista  syndrome  
Ankylosing  spondylitis  Gestational  pemphigoid  Optic neuritis  
Antiphospholipid  antibody  Giant  cell arteritis  Ord’s  thyroiditis  
syndrome  Goodpasture’s  syndrome  Pemphigus  
Aplastic  anemia  Graves’  disease  Pernicious  anemia  
Autoimmune  hemolytic  anemia  Guillain -Barré  syndrome  Polyarteritis nodusa  
Autoimmune  hepatitis  Hashimoto’s  disease  Polyarthritis  
Autoimmune  IgA nephropathy  Polyglandular  autoimmune  
hypoparathyroidism  Inflammatory  bowel  disease  syndrome  
Autoimmune  hypophysitis  Interstitial  cystitis  Primary  biliary  cirrhosis  
Autoimmune  myocarditis  Kawasaki’s  disease  Psoriasis  
Autoimmune  oophoritis  Lambert -Eaton  myasthenia  Reiter’s  syndrome  
Autoimmune  orchitis  syndrome  Rheumatoid  arthritis  
Autoimmune  Lupus  erythematosus  Sarcoidosis  
thrombocytopenic  Lyme  disease  - chronic  Scleroderma  
purpura  Meniere’s  syndrome  Sjögren’s  syndrome  
Behcet’s  disease  Mooren’s  ulcer  Stiff-Person  syndrome  
Bullous  pemphigold  Morphea  Takayasu’s  arteritis  
Chronic  inflammatory  Multiple  sclerosis  Ulcerative  colitis  
demyelinating  Myasthenia  gravis  Vogt-Kovanagi -Harada  
polyneuropathy   disease  
Chung -Strauss  syndrome   Wegener’s  granulomatosis  
Crohn’s  disease    
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  140 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
17.4 Appendix  4: Immune -related  Response Criteria  Derived from  RECIST  1.1 (irRECIST)  
 
Increasing clinical experience indicates  that traditional  response criteria  may not be sufficient  to 
fully characterize activity in this new era of targeted therapies and/or biologics.  This is 
particularly true for immunotherapeutic agents such as anti -CTLA -4 and anti -PD1\anti PDL1 
which exert the antitumor activity by augmenting activation and proliferation of T cells, thus 
leading to tumor infiltration by T cells and tumor regression rather than direct cytotoxic effects 
(Hoos 2010; Hodi 2008).  Clinical observatio ns of patients with advanced melanoma treated 
with ipilimumab, for example, suggested that conventional response assessment criteria such 
as RECIST and WHO criteria are not sufficient to fully characterize pattercccns of tumor 
response to immunotherapy  because tumors  treated with immunotherapeutic  agents  may show 
additional response patterns that are not described in these conventional criteria (Hoos 2010; Nishino 2014).  
 
Furthermore, the conventional tumor assessment criteria (RECIST and WHO criteria) have  
been reported  as not capturing the existence of a subset  of patients  who have  an OS similar  to 
those who have experienced CR or PR but were flagged as PD by WHO criteria (Hoos 2010; 
Nishino 2012).  
 
On these  grounds,  a tumor  assessment  system has been developed that incorporates  these 
delayed or flare -type responses into the RECIST 1.1 criteria (irRECIST; Nishino 2014). .  
 
Lesion measurability  and baseline selection  of lesions:  
 
The RECIST 1.1 definitions for measurable and non- measurable lesions apply. At baseline, all 
tumor lesions/lymph nodes will be categorized as measurable or non -measurable. For target 
lesions, a Total Measured Tumor Burden (TMTB) for all target lesions will be calculated and reported as the baseline TMTB  (similarly  to the Sum of Diameters  in RECIST  1.1). The baseline 
TMTB will be used as reference to further characterize any objective tumor response in the measurable dimension of the disease. 
 
New lesions:  
 
irRECIST  do not necessarily  score the appearance of new lesions as  progressive disease.  Also, 
new lesions  should be categorized as measurable or non-measurable (same  measurability  rules 
as RECIST 1.1. apply).  
 
In order  to be selected as new measurable  lesions  (≤ 2 lesions  per organ,  ≤ 5 lesions  total,  per 
timepoint), new lesions must meet criteria as defined for baseline target lesion selection and meet  the same  minimum  size requirements  of 10 mm in long diameter  and minimum  15 mm in 
short axis for new measurable lymph nodes. New measurable lesions shall be prioritized 
according to size, and the largest lesions shall be selected as new measured lesions.  
 
All new lesions  not selected as New Measurable lesions  are considered New Non-measurable 
lesions and are followed qualitatively. 
Product:  Entinostat  
Protocol  Numbe r: SNDX -275-0602  (TRIO025) 
Date:  11 Sep 2018  Page  141 of 141 
CONFIDENTIAL  SYNDAX  PHARMACEUTICALS   
  
 
Post baseline tumor  assessments:  
- TMTB:  At each  post-baseline assessment  the TMTB  is defined as the sum of: 
o Longest  diameters  of all non-nodal  target  lesions  
o Longest  diameters  of all NEW  non-nodal  measurable lesions  
o Short  axis of all nodal  target  lesions  
o Short  axis of all NEW  nodal  measurable lesions  
- Non-target  lesions/New  Non-measurable lesions:  the RECIST  1.1 definitions  for the 
assessment of non- target lesions apply (irCR; irNN, irPD).  
 
Overall  response at each time point:  
 
- Immune- related complete response (irCR): Complete disappearance of all lesions 
(whether  measurable  or not) and no new lesions.  All measurable lymph  nodes  also 
must have a reduction in short axis to <10 mm.  
- Immune- related partial response (irPR): Decrease of ≥ 30% in TMTB relative to 
baseline,  non-target  lesions  are irNN,  and no unequivocal  progression of new non- 
measurable lesions  
- Immune- related  stable disease (irSD):  Failure  to meet  criteria  for irCR or irPR in the 
absence of irPD.  
- Immune- related  progressive disease (irPD):  Minimum  20% increase  and minimum  5 mm 
absolute increase in TMTB compared to nadir, or irPD for non -target or new non- 
measurable lesions.  
- irNE (Not evaluable):  used  in exceptional  cases  where insufficient  data exists. 